Clinical trial NCT01482715
Conditions: Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Keywords: gBRCA ovarian cancer platinum sensitive PARP Inhibitor Rucaparib CO-338 PF 01367338 AG 14699 BRCA1 BRCA2 platinum sensitive ovarian cancer platinum sensitive gBRCA ovarian cancer gynecological cancer relapsed disease homologous recombination deficiency HRD
Sponsor: pharmaand GmbH
Start date: 2011-11-01; Completion date: 2019-05-01
Enrollment: 136 participants; Allocation: NON_RANDOMIZED; Intervention model: SEQUENTIAL

Brief summary:
Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors.

Part 2A (Completed Enrollment) and Part 2B (Completed Enrollment) - The purpose of the second part of the study is to determine the safety and clinical activity of the RP2D of oral rucaparib administered daily to patients with a known deleterious BRCA mutation (germline or somatic).

Part 3 (Completed Enrollment) - The purpose of the third part of the study is to further evaluate PK of higher dose strength tablets at the RP2D in patients with any advanced solid tumor, inclusive of lymphoma, with evidence of a BRCA mutation (germline or somatic).

Detailed description:
Rucaparib (CO-338; formerly known as PF 01367338 and AG 14699) is an orally available, small molecule inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination \[HR\] DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies.

An oral formulation is the focus of current development efforts. Rucaparib is currently being investigated as monotherapy in patients with cancer associated with BRCA1 or BRCA2 mutations. For this study, it is anticipated that rucaparib will promote cell death in the BRCA-deficient tumor cells of ovarian cancer patients with evidence of a germline mutation, thereby limiting tumor progression and providing therapeutic benefit.

Arms: arm 1: Rucaparib 40, 80, 160, 300, 500 mg QD and 240, 360, 480, 600, 840 mg BID, for continuous 21-day cycles. Patients in Part 1 were initially treated in a Dose-escalation Evaluation Period (Cycle 1) and could then continue to receive treatment in an optional Treatment-extension Period (Cycle 2 and beyond). arm 2: Rucaparib 600 mg BID for 21-day cycles. arm 3: Rucaparib 600 mg BID for 21-day cycles. arm 4: Rucaparib 600 mg BID for 21-day cycles. Patients also received a single administration of 600 mg rucaparib on both Day -7 and Day 1 for assessing the effect of food on PK.
Interventions: intervention 1: Rucaparib
Intervention descriptions: intervention 1: Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.

Protocol documents:
Prot_000.pdf: 
Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 1 of 133 
Confidential 
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy 
Study of Oral Rucaparib in Patients with gBRCA Mutation Ovarian Cancer 
or Other Solid Tumor 
Protocol Number: 
CO-338-010 
Investigational Product: 
Oral rucaparib (CO-338) 
Eudra CT Number: 
 
IND Number: 
 
Development Phase: 
Phase I/II 
Indication Studied: 
Locally advanced or metastatic solid tumors, including 
lymphoma, and germline BRCA (gBRCA) ovarian cancer 
Sponsor Name and Address: 
Clovis Oncology, Inc. 
5500 Flatiron Parkway, Suite 100  
Boulder, CO 80301  
U.S.A. 
 
 
 
Responsible Medical Officer: 
 
Compliance Statement: 
This study will be conducted in accordance with the ethical 
principles that have their origin in the Declaration of 
Helsinki, clinical research guidelines established by the Code 
of Federal Regulations (Title 21, CFR Parts 50, 56, and 312), 
and International Conference on Harmonization (ICH) Good 
Clinical Practice (GCP) Guidelines.  Essential study 
documents will be archived in accordance with applicable 
regulations. 
 
 
 
 
 
 
CONFIDENTIALITY STATEMENT 
The information in this document contains commercial information and trade secrets that are privileged or 
confidential and may not be disclosed unless such disclosure is required by applicable laws and regulations.  In any 
event, persons to whom the information is disclosed must be informed that the information is privileged or 
confidential and may not be further disclosed by them.  These restrictions on disclosure will apply equally to all 
future information supplied to you that is indicated as privileged or confidential. 




Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 3 of 133 
Confidential 
Protocol Acceptance Form 
Protocol: 
CO-338-010 
 
Title: 
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary 
Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Ovarian 
Cancer, or Other Solid Tumor 
 
Date: 
29 June 2016 
 
 
 
I have carefully read this protocol and agree that it contains all of the necessary information 
required to conduct this study.  I agree to conduct this study as described and according to the 
Declaration of Helsinki, ICH Guidelines for GCP, and all applicable regulatory requirements. 
 
 
 
  
Investigator’s Signature 
 Date 
 
 
 
  
Name (printed) 
  
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 4 of 133 
Confidential 
Table of Contents 
Description 
Page 
1 
SYNOPSIS ......................................................................................................................... 12 
2 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ............................... 27 
3 
INTRODUCTION............................................................................................................. 30 
3.1 
DNA Repair and Cancer Therapy ................................................................................. 30 
3.2 
Background ................................................................................................................... 30 
3.2.1 
Nonclinical Experience ........................................................................................... 31 
3.2.1.1 
Rucaparib Absorption, Distribution, Metabolism, and Excretion ............... 31 
3.2.1.2 
Multiple-Dose Toxicity Studies .................................................................. 32 
3.2.1.3 
Additional Observations .............................................................................. 33 
3.2.2 
Clinical Experience ................................................................................................. 34 
3.2.2.1 
Rucaparib Monotherapy .............................................................................. 34 
3.2.2.2 
Recommended Phase II Dose (RP2D) of Rucaparib Monotherapy ............ 37 
3.2.2.3 
Absorption, Distribution, Metabolism, and Elimination ............................. 37 
3.3 
Rationale for Study ....................................................................................................... 38 
4 
STUDY OBJECTIVES ..................................................................................................... 40 
4.1 
Objectives and Endpoints ............................................................................................. 40 
5 
STUDY DESIGN ............................................................................................................... 42 
5.1 
Overall Study Design and Plan ..................................................................................... 42 
5.1.1 
Screening Period ..................................................................................................... 42 
5.1.2 
Part 1 (Phase I Portion) ........................................................................................... 42 
5.1.3 
Part 2 (Phase II Portion in Patients with BRCA-Mutant Ovarian 
Cancer) .................................................................................................................... 44 
5.1.4 
Part 3 (Phase II PK Portion in Patients with any Advanced Solid 
Tumor) .................................................................................................................... 44 
5.1.5 
End-of-Treatment and Follow-Up (Part 1, Part 2, and Part 3) ................................ 45 
5.1.6 
End of Study ........................................................................................................... 45 
5.2 
Study Schema................................................................................................................ 45 
6 
STUDY POPULATION ................................................................................................... 49 
6.1 
Number of Patients and Sites ........................................................................................ 49 
6.2 
Inclusion Criteria .......................................................................................................... 49 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 5 of 133 
Confidential 
6.3 
Exclusion Criteria ......................................................................................................... 52 
6.4 
Patients or Partners of Patients of Reproductive Potential ........................................... 53 
6.5 
Waivers of Inclusion/Exclusion Criteria ....................................................................... 54 
7 
DESCRIPTION OF STUDY TREATMENTS AND DOSE 
MODIFICATIONS ........................................................................................................... 55 
7.1 
Description of Investigational Product ......................................................................... 55 
7.2 
Method of Assigning Patients to Treatment Groups..................................................... 55 
7.3 
Preparation and Administration of Protocol-Specified Treatment ............................... 55 
7.3.1 
Dietary Restrictions ................................................................................................ 56 
7.3.2 
Fed and Fasted Requirements for Food-Effect PK Analysis .................................. 56 
7.4 
Starting Dose and Dose Modifications of Protocol-Specified Treatment .................... 57 
7.4.1 
Part 1 (Phase I Portion) ........................................................................................... 57 
7.4.1.1 
Dose Escalation ........................................................................................... 57 
7.4.1.2 
Maximum Tolerated Dose ........................................................................... 59 
7.4.1.3 
Dose-Escalation Design .............................................................................. 59 
7.4.1.4 
Dose-Limiting Toxicity ............................................................................... 61 
7.4.1.5 
Definition of DLT-Evaluable Patient .......................................................... 61 
7.4.1.6 
In the Event of Toxicity at Lowest Dose Level .......................................... 61 
7.4.1.7 
Recommended Phase II Dose ...................................................................... 61 
7.4.1.8 
Dose Modification Criteria ......................................................................... 62 
7.4.1.8.1 
Management of Rucaparib Treatment-emergent ALT/AST 
Elevations ....................................................................................... 62 
7.4.1.9 
Intrapatient Dose Escalation ....................................................................... 63 
7.4.1.10 Criteria for Re-Treatment ............................................................................ 64 
7.4.2 
Part 2 and Part 3 (Phase II Portion) ........................................................................ 64 
7.4.2.1 
Starting Dose ............................................................................................... 64 
7.4.2.2 
Dose Modification Criteria ......................................................................... 64 
7.4.3 
In the Event of Torsade de Pointes ......................................................................... 65 
7.4.4 
Treatment Beyond Progression ............................................................................... 65 
7.5 
Accountability of Protocol-Specified Treatment .......................................................... 66 
7.6 
Blinding/Masking of Treatment .................................................................................... 66 
7.7 
Treatment Compliance .................................................................................................. 66 
8 
PRIOR AND CONCOMITANT THERAPIES.............................................................. 67 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 6 of 133 
Confidential 
8.1 
Anticancer or Experimental Therapy ............................................................................ 67 
8.2 
Hematopoietic Growth Factors and Blood Products .................................................... 67 
8.3 
Antiemetics ................................................................................................................... 67 
8.4 
CYP450 Isoenzyme Inhibitors and Inducers ................................................................ 68 
8.5 
Bisphosphonates ........................................................................................................... 68 
8.6 
Anticoagulants .............................................................................................................. 68 
8.7 
Other Concomitant Medications ................................................................................... 68 
9 
STUDY PROCEDURES .................................................................................................. 69 
9.1 
Schedule of Assessments .............................................................................................. 69 
9.2 
Screening Period (Parts 1-3) ......................................................................................... 80 
9.3 
Part 1 - Dose-Escalation Evaluation Period .................................................................. 81 
9.3.1 
Day -8 Prior to Cycle 1 (Food Effect PK Cohort Only) ......................................... 81 
9.3.2 
Day -7 Prior to Cycle 1 (Food Effect PK Cohort Only) ......................................... 81 
9.3.3 
Day -1 Prior to Cycle 1 ........................................................................................... 82 
9.3.4 
Day 1 of Cycle 1 ..................................................................................................... 82 
9.3.5 
Days 8, 15, and 22 of Cycle 1 ................................................................................. 83 
9.4 
Part 1 - Optional Treatment-Extension Period.............................................................. 84 
9.4.1 
Day 1 of Cycle 2 and Beyond ................................................................................. 84 
9.5 
Part 2 (Phase II Portion in OC Patients) ....................................................................... 85 
9.5.1 
Day 1 of Cycle 1 ..................................................................................................... 85 
9.5.2 
Day 15 of Cycle 1 ................................................................................................... 86 
9.5.3 
Day 1 of Cycle 2 and Beyond ................................................................................. 87 
9.6 
Part 3 (Phase II PK in Patients with Any Advanced Solid Tumor) .............................. 87 
9.6.1 
Day -7 Prior to Cycle 1 (single dose fed or fasted PK) .......................................... 88 
9.6.2 
Day 1 of Cycle 1 (single dose fasted or fed PK) ..................................................... 88 
9.6.3 
Day 15 of Cycle 1 ................................................................................................... 89 
9.6.4 
Day 1 of Cycle 2 and Beyond ................................................................................. 90 
9.7 
End-of-Treatment Visit (Parts 1-3) ............................................................................... 91 
9.8 
Follow-up Visit ............................................................................................................. 92 
9.9 
Long-term Follow-up .................................................................................................... 92 
9.10 
Methods of Data Collection .......................................................................................... 92 
9.10.1 Pharmacokinetic Evaluations .................................................................................. 92 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 7 of 133 
Confidential 
9.10.1.1 Pharmacokinetic Blood Sample Collection in Part 1 .................................. 92 
9.10.1.2 Pharmacokinetic Blood Sample Collection in Part 2 .................................. 93 
9.10.1.3 Pharmacokinetic Blood Sample Collection in Part 3 .................................. 93 
9.10.1.4 Pharmacokinetic Evaluations ...................................................................... 94 
9.10.2 AAG Measurement ................................................................................................. 94 
9.10.3 Tumor Tissue Samples ............................................................................................ 94 
9.10.4 Safety Evaluations .................................................................................................. 95 
9.10.4.1 Adverse Event Assessment ......................................................................... 95 
9.10.4.2 Clinical Laboratory Investigations .............................................................. 95 
9.10.4.3 Vital Signs ................................................................................................... 96 
9.10.4.4 12-Lead Electrocardiograms ....................................................................... 96 
9.10.4.5 Body Weight and Height ............................................................................. 97 
9.10.4.6 Physical Examinations ................................................................................ 97 
9.10.4.7 ECOG Performance Status .......................................................................... 97 
9.10.5 Efficacy Evaluations ............................................................................................... 97 
9.10.5.1 Tumor Assessments .................................................................................... 97 
9.10.5.2 Tumor Markers ............................................................................................ 98 
10 
ADVERSE EVENT MANAGEMENT ........................................................................... 99 
10.1 
Definition of an Adverse Event .................................................................................... 99 
10.2 
Definition of a Serious Adverse Event ......................................................................... 99 
10.3 
Definition of an Adverse Event of Special Interest (AESI) ........................................ 100 
10.4 
Events or Outcomes Not Qualifying as Serious Adverse Events ............................... 100 
10.5 
Clinical Laboratory Assessments and Other Abnormal Assessments as 
Adverse Events and Serious Adverse Events ............................................................. 100 
10.6 
Pregnancy or Drug Exposure During Pregnancy ........................................................ 101 
10.7 
Recording of Adverse Events, Serious Adverse Events, and Adverse 
Events of Special Interest............................................................................................ 101 
10.7.1 Intensity of Adverse Events .................................................................................. 101 
10.7.2 Relationship of Adverse Events to Investigational Medicinal 
Products................................................................................................................. 102 
10.7.3 Outcome and Action Taken .................................................................................. 102 
10.8 
Follow-Up of Adverse Events, Serious Adverse Events, and Adverse 
Events of Special Interest............................................................................................ 103 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 8 of 133 
Confidential 
10.9 
Regulatory Aspects of Adverse Event Reporting ....................................................... 103 
11 
STATISTICAL METHODS .......................................................................................... 104 
11.1 
Analysis Populations ................................................................................................... 104 
11.2 
Statistical Methods ...................................................................................................... 104 
11.2.1 General Considerations ......................................................................................... 104 
11.2.2 Patient Disposition ................................................................................................ 105 
11.2.3 Baseline Characteristics ........................................................................................ 105 
11.2.4 Efficacy Analyses ................................................................................................. 105 
11.2.4.1 Overall Response Rate - Primary Endpoint (Part 2) ................................. 105 
11.2.4.2 Secondary Analyses and Endpoints in Part 2 and 3 .................................. 105 
11.2.4.2.1 ORR per RECIST v 1.1 and Gynecologic Cancer Intergroup 
(GCIG) CA-125 Criteria (Part 2) ................................................. 105 
11.2.4.2.2 Tumor Marker (CA-125) Response Rate Based on GCIG 
CA-125 Criteria (Part 2) .............................................................. 105 
11.2.4.2.3 Progression-free Survival (PFS) (Part 2) ..................................... 106 
11.2.4.2.4 Duration of Response - Secondary Endpoint (Part 2) .................. 106 
11.2.4.2.5 Overall Survival (Part 2B) ........................................................... 106 
11.2.4.2.6 Evaluation of Antitumor Activity – Secondary Endpoint 
(Parts 1 and 3) .............................................................................. 106 
11.2.4.2.6.1 
Changes in Tumor Markers Applicable to Patient’s 
Tumor Type (Part 1 and 3) ................................................ 106 
11.2.4.3 Exploratory Endpoints in Part 2 ................................................................ 106 
11.2.4.3.1 Explore the Association Between Genomic Alterations 
Identified in Tumor Tissue and Clinical Outcome (Part 2) ......... 106 
11.2.5 Pharmacokinetic Analyses .................................................................................... 107 
11.2.6 Exploratory Analysis - Relationship Between PK and QTc ................................. 107 
11.2.7 Exploratory Analysis - Metabolite Profiling at the Recommended 
Phase 2 Dose ......................................................................................................... 107 
11.2.8 Safety Analyses ..................................................................................................... 107 
11.2.8.1 Extent of Exposure .................................................................................... 107 
11.2.8.2 Adverse Events .......................................................................................... 108 
11.2.8.3 Clinical Laboratory Evaluations ............................................................... 109 
11.2.8.4 Vital Sign Measurements .......................................................................... 109 
11.2.8.5 12-Lead Electrocardiograms ..................................................................... 110 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 9 of 133 
Confidential 
11.2.8.6 Other Safety Measurements ...................................................................... 110 
11.3 
Interim Analysis .......................................................................................................... 110 
11.4 
Sample Size Considerations ........................................................................................ 110 
11.4.1 Sample Size Justification for Part 2A ................................................................... 111 
11.4.2 Sample Size Justification for Part 2B ................................................................... 111 
11.4.3 Sample Size Justification for Part 3 ...................................................................... 112 
12 
PATIENT DISPOSITION.............................................................................................. 113 
12.1 
Patient Discontinuations ............................................................................................. 113 
12.2 
Study Stopping Rules .................................................................................................. 113 
13 
STUDY ADMINISTRATION ....................................................................................... 114 
13.1 
Regulatory and Ethical Considerations ....................................................................... 114 
13.1.1 Regulatory Authority Approvals ........................................................................... 114 
13.1.2 Independent Ethics Committee/Institutional Review Board................................. 114 
13.2 
Confidentiality of Information .................................................................................... 115 
13.3 
Patient Informed Consent ........................................................................................... 115 
13.4 
Study Monitoring ........................................................................................................ 116 
13.5 
Case Report Form ....................................................................................................... 116 
13.6 
Study Termination and Site Closure ........................................................................... 117 
13.7 
Modification of the Study Protocol............................................................................. 117 
13.8 
Retention of Study Documents ................................................................................... 117 
13.9 
Clinical Study Report .................................................................................................. 118 
13.10 Study Publication ........................................................................................................ 118 
13.11 Quality Assurance Audits ........................................................................................... 118 
14 
REFERENCES ................................................................................................................ 119 
15 
APPENDICES ................................................................................................................. 122 
Appendix A Response Evaluation Criteria in Solid Tumors Criteria ........................................ 123 
Appendix B Eastern Cooperative Oncology Group Performance Status Scale ......................... 128 
Appendix C Examples of Concomitant Medications that can Prolong the QT Interval ............ 129 
Appendix D Examples of CYP Substrates with Narrow Therapeutic Range ............................ 133 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 10 of 133 
Confidential 
List of Tables 
Description 
Page 
Table 1. 
Primary and Secondary Objectives and Endpoints .................................................... 40 
Table 2. 
Exploratory Objectives and Endpoints ...................................................................... 41 
Table 3. 
Comparison of Dose Levels when Switching to 200/300 mg Strength Tablets 
from 120 mg Tablets .................................................................................................. 56 
Table 4. 
Dose-Escalation Decision Rules ................................................................................ 57 
Table 5. 
Dose-Escalation Plan ................................................................................................. 59 
Table 6. 
Example Dose Reduction Steps ................................................................................. 63 
Table 7. 
Dose Reduction Steps in Part 2A (Phase II in Patients with OC) using 120 mg 
tablets ......................................................................................................................... 64 
Table 8. 
Dose Reduction Steps in Part 2A and Part 2B (Phase II in Patients with OC) 
and Part 3 (Phase II in Patients with any Advanced Solid Tumor) using 300 
and 200 mg tablets ..................................................................................................... 65 
Table 9. 
Schedule of Assessments - Part 1:  All Cohorts Except Food-Effect Evaluation ...... 70 
Table 10. Schedule of Assessments - Part 1:  Food-Effect Evaluation Cohort(s) Only ............ 72 
Table 11. Schedule of Assessments - Part 2A and 2B:  All Patients ......................................... 74 
Table 12. Schedule of Dosing, Electrocardiograms, and Pharmacokinetic Sampling, for 
Part 1 and Part 2 Patients ........................................................................................... 76 
Table 13. Schedule of Assessments - Part 3:  All Patients ........................................................ 77 
Table 14. Schedule of Dosing and Pharmacokinetic Sampling for Part 3 Patients ................... 79 
 
 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 11 of 133 
Confidential 
List of Figures 
Description 
Page 
Figure 1 
Best Target Lesion Response – Study CO-338-010 Phase 2 (Part 2) ........................ 36 
Figure 2. Study Schema Part 1 .................................................................................................. 46 
Figure 3. Study Schema Part 2 .................................................................................................. 47 
Figure 4. Study Schema Part 3 .................................................................................................. 48 
Figure 5. Dose-Escalation Design ............................................................................................. 60 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 12 of 133 
Confidential 
1 
SYNOPSIS 
Protocol Number 
CO-338-010 
Title 
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy 
Study of Oral Rucaparib in Patients with gBRCA Mutation Ovarian Cancer or 
Other Solid Tumor 
Phase 
Phase I/II 
Introduction and 
Study Overview 
Rucaparib (CO-338; formerly known as PF 01367338 and AG 14699) is a small 
molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase 
(PARP) being developed for antitumor therapy; an oral formulation as 
monotherapy is the focus of current development efforts.  Rucaparib is currently 
being investigated as monotherapy in patients with cancer associated with breast 
cancer 1 or 2 gene (BRCA1 or BRCA2) mutations, or other alterations or 
evidence of homologous recombination deficiency (HRD).    
The purpose of Part 1 of this study is to initially determine the maximum 
tolerated dose (MTD) and recommended Phase II dose (RP2D) of oral rucaparib 
administered on a continuous daily basis to patients with solid tumors, inclusive 
of lymphoma, who have progressed on prior treatment.  Once provisionally 
established, the RP2D will be evaluated in an expanded cohort of patients with a 
solid tumor and evidence of a deleterious germline mutation of BRCA1 or 
BRCA2 (gBRCA).  Once confirmed to be the optimal dose, the RP2D will be 
administered in the Phase II portion to patients with: 
• Part 2A: Platinum-sensitive, relapsed, high-grade serous or endometrioid 
epithelial ovarian, fallopian tube, or primary peritoneal cancer with evidence 
of a gBRCA mutation who have received at least two, but no more than four, 
prior regimens 
• Part 2B: Relapsed, high-grade epithelial ovarian, fallopian tube, or primary 
peritoneal cancer, with evidence of a deleterious BRCA mutation (germline 
or somatic) who have received at least three, but no more than four, prior 
chemotherapy regimens 
• Part 3: Any advanced solid tumor, inclusive of lymphoma, with evidence of a 
BRCA mutation (germline or somatic); prior PARP inhibitor treatment is 
allowed provided it was not the last treatment received and/or treatment was 
not received within the last 6 months 
It is anticipated that rucaparib will promote cell death in the BRCA-deficient 
tumor cells of these patients, thereby limiting tumor progression and providing 
therapeutic benefit. 
The study will encompass 3 parts:  
• Part 1 (Phase I portion) = Six to twelve estimated dose-escalation cohorts in 
patients with solid tumors and RP2D Expansion in patients with  a solid 
tumor and evidence of a deleterious gBRCA mutation  
• Part 2 (Phase II portion) = Evaluation of the RP2D in patients with relapsed, 
high-grade serous or endometrioid epithelial ovarian, fallopian tube, or 
primary peritoneal cancer associated with a known deleterious BRCA 
mutation (germline or somatic) 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 13 of 133 
Confidential 
Introduction and 
Study Overview 
(cont) 
• Part 3 (Phase II PK portion) = Further evaluation of PK of higher dose 
strength tablets at the RP2D in patients with any advanced solid tumor, 
inclusive of lymphoma, with evidence of a BRCA mutation (germline or 
somatic) 
Planned Number 
of Patients 
Number of patients: 
• Part 1:  approximately 50 – 60 patients 
• Part 2:  up to 41 evaluable patients in Part 2A and 40 evaluable patients in 
Part 2B 
• Part 3: approximately 20 evaluable patients 
Patients will enroll in to either Part 1, Part 2, or Part 3 of the study, not in to 
multiple parts. 
Planned Number 
of Sites 
This is a multicenter, multinational study.  Patients will be enrolled from 
approximately 4 – 6 sites in Part 1, approximately 20 sites in Part 2, and 
approximately 8 sites in Part 3. 
Study Objectives 
and Endpoints 
Primary, secondary, and exploratory objectives and endpoints are shown below.  
Primary Objectives 
Primary Endpoints 
To evaluate the safety profile of 
escalating doses of continuous daily 
oral rucaparib in patients with 
advanced solid tumors, and to 
determine the MTD and RP2D (Part 1 
only) 
The incidence of Grade 3 or 4 adverse 
events (AEs) and clinical laboratory 
abnormalities defined as dose-limiting 
toxicities (DLTs) 
To characterize the pharmacokinetic 
(PK) profile of oral rucaparib when 
administered as a continuous daily 
dose (Part 1 and Part 3 only) 
PK parameters:  area under the curve 
from time zero to the time with the last 
measurable concentration (AUC0-t), 
AUC from time zero to infinity 
(AUC0-∞), maximum concentration 
(Cmax), time to maximum concentration 
(Tmax), elimination half-life (t1/2), 
elimination rate constant (kel), apparent 
volume of distribution at steady state 
after nonintravenous administration 
(Vss/F), and apparent total plasma 
clearance (Cl/F) 
To evaluate overall response rate 
(ORR) in patients with relapsed, 
high-grade serous or endometrioid 
epithelial ovarian, fallopian tube, or 
primary peritoneal cancer associated 
with a BRCA mutation (Part 2 only) 
[henceforth abbreviated to ovarian 
cancer (OC) population] 
ORR per Response Evaluation Criteria 
in Solid Tumors (RECIST) Version 
1.1; secondary analysis including 
Gynecologic Cancer InterGroup 
(GCIG) cancer antigen-125 (CA-125) 
criteria  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 14 of 133 
Confidential 
Study Objectives 
and Endpoints 
(cont) 
Secondary Objectives 
Secondary Endpoints 
To characterize the single-dose PK 
profile of oral rucaparib after a 
high-fat breakfast compared to that in 
the fasted state (Part 1 and Part 3 
only) 
PK parameters Cmax and AUC (fasted 
and fed)  
To evaluate the effects of oral 
rucaparib on the QT/QTc interval 
measured by electrocardiogram 
(ECG) (Part 1 only) 
Change from baseline in QT/QTc 
interval 
To evaluate the safety and tolerability 
of oral rucaparib (Parts 1, 2, and 3) 
The incidence of AEs, clinical 
laboratory abnormalities, and ECG 
abnormalities 
To evaluate antitumor activity of oral 
rucaparib in various solid tumors 
(Part 1 and Part 3 only) 
Response per RECIST v1.1;  additional 
analyses including applicable tumor 
markers 
To assess progression-free survival 
(PFS) in the OC population (Part 2 
only) 
PFS defined as the time to first 
occurrence of disease progression per 
RECIST v1.1 or death 
To evaluate duration of response in 
the OC population (Part 2 only) 
Duration of response per RECIST v1.1.   
To evaluate survival (Part 2B only) 
Overall survival (OS) 
Exploratory Objectives 
Exploratory Endpoints 
To explore the relationship between 
the PK of oral rucaparib and the 
potential changes in QT/QTc interval 
(Part 1 only) 
QT/QTc interval correlated with 
plasma concentrations of oral rucaparib 
To profile circulating metabolites of 
oral rucaparib at steady state at the 
RP2D (Part 1 only)  
Metabolic profile in the Day 15 plasma 
samples  
To explore the association between 
genomic alterations identified in 
tumor tissue and clinical outcome 
(Parts 1, 2, and 3) 
Mutational status of BRCA1/2 and 
other homologous recombination 
genes. Genomic scarring/ loss of 
heterozygosity (LOH) assessment in 
tumor tissue. Response by RECIST 
v1.1 and/or tumor markers (i.e., 
CA-125) 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 15 of 133 
Confidential 
Study Design  
All patients will undergo screening assessments within 30 days prior to the first 
dose of oral rucaparib.  Study-procedure-related AEs that occur after signing of 
the informed consent form and before administration of oral rucaparib will also 
be collected during this period. 
Part 1 (Phase I Portion)  
In Part 1, there will be an estimated six to twelve dose-escalation cohorts, with a 
minimum of three patients enrolled in each cohort, and an expanded evaluation 
of the RP2D in up to 15 patients.  Treatment cycles will comprise 21 days of 
continuous dosing.   
All dose escalations will be based on assessment of DLTs, overall safety and 
tolerability, and PK that occur with each cohort, and will be agreed upon 
between the investigators and sponsor. 
The MTD is defined as the maximum daily oral dose at which <33% of patients 
experience a DLT during Cycle 1 (Safety and PK Assessment Period).  If a DLT 
is observed in one of three patients, then three additional patients will be 
enrolled at that same dose level.  Dose escalation will continue until at least two 
of the three to six patients treated at a dose level experience a DLT.  The next 
lower dose will then be considered the MTD.  Alternatively, if the dose between 
the MTD and the maximally delivered dose is significant (such as 100%), then a 
more modestly de-escalated dose may be explored (e.g., 20–50%).   
RP2D Selection and Expansion 
The RP2D for evaluation in Part 2 will be selected based on overall safety and 
tolerability, PK, and estimates of efficacious exposures extrapolated from 
nonclinical data.  The RP2D may or may not be the same as the MTD identified 
in Part 1.  For example, if the MTD is not reached, or if exposure at the MTD is 
much higher than the level believed to be required for efficacy, or if subsequent 
cycles of treatment provide additional insight on the safety profile, then the 
RP2D may be a different, though not higher, dose than the MTD. 
Once the RP2D has been provisionally established, up to 15 additional patients 
with a solid tumor and evidence of a deleterious gBRCA mutation will be 
enrolled and treated at that dose in order to further characterize safety, 
tolerability, and PK and confirm that this is the optimal dose to evaluate in 
Part 2 (Phase II portion).  Since the RP2D may be selected based on evaluation 
of as few as 3 patients, there is low certainty that the RP2D has a DLT rate that 
is <33%.1  Enrolling up to an additional 15 patients will increase the certainty 
that the Phase II component of the study is evaluated at a dose with a DLT rate 
<33%.  If ≥33% of patients at the RP2D experience a DLT, then enrollment into 
the RP2D Expansion cohort will stop and an alternative dose will be explored. 
Food-Effect PK Evaluation 
The effect of food on oral rucaparib PK will be assessed prior to, and during, 
Cycle 1 in three patients.  Food effect PK analysis will be performed once 
evaluation of Cohort 1 (40 mg) is completed, and will be conducted either at the 
next escalated dose or as expanded PK evaluation of the 40 mg dose level.  The 
dose level for evaluation will be established at the safety teleconference call for 
Cohort 1.  Food-effect PK may be conducted in additional cohorts in Part 1, if 
results from prior cohort(s) warrant expanded evaluation.   


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 16 of 133 
Confidential 
Study Design 
(cont) 
Effect on QTc 
ECGs will be collected in all patients enrolled in Part 1, including those in the 
RP2D Expansion cohort, in order to assess the effect of rucaparib on QTc.  
ECGs in Part 1 will be performed on equipment provided by the sponsor (or 
designee) and reviewed by site personnel and a core/central laboratory. Local 
ECG monitoring may be conducted once a sufficient amount of data has been 
reviewed by the core/central laboratory. 
Metabolic Profiling 
The first three patients enrolled into the RP2D Expansion cohort will have 
additional blood samples collected on Day 1 (predose sample only) and Day 15 
of Cycle 1 for assessment of plasma metabolites. 
Treatment-Extension Period 
Upon completion of Cycle 1 (Safety and PK Assessment Period), Part 1 patients 
may participate in an optional Treatment-Extension Period, which begins on 
Day 1 of Cycle 2.  Oral rucaparib will be administered daily during this period 
(21 day cycles) until disease progression, unacceptable toxicity, patient or 
physician request to discontinue, death, or termination of the study. 
Part 2 (Phase II Portion in BRCA-Mutant Ovarian Cancer) 
Enrollment into Part 2 will begin when all patients enrolled into the RP2D 
Expansion cohort have completed 2 cycles of treatment, or have discontinued 
from the study prior to completing 2 cycles.  Patients in Part 2 will be assessed 
for tolerability and efficacy.  Patients will be treated until disease progression, 
unacceptable toxicity, patient or physician request to discontinue, death, or 
termination of the study.  
The study will use a Simon 2-stage design to evaluate the efficacy of rucaparib 
in Part 2 (Phase II portion).  Initially, 21 patients will be treated in Stage 1; if 
two or more patients in Stage 1 have an objective response (complete response 
[CR] or partial response [PR]) then the remaining 20 patients will be treated in 
Stage 2.  If fewer than two patients in Stage 1 have an objective response, then 
no further patients will be enrolled. 
The criteria for Stage 1 success were met in April 2014, and Stage 2 enrollment 
of 41 patients was completed in April 2015. An additional cohort of 
approximately 40 BRCA mutant OC patients will be evaluated in Part 2B.  This 
portion of the study will evaluate the efficacy of rucaparib in ovarian cancer 
patients with a deleterious BRCA mutation (germline or somatic) who received 
≥3 (but no more than 4) prior chemotherapy regimens. 
Part 3 (Phase II PK Portion in Patients with any Advanced Solid Tumor) 
Part 3 will enroll in parallel with Part 2.  Patients in Part 3 will be assessed for 
PK, safety and tolerability, and anti-tumor activity.  Patients will be treated until 
disease progression, unacceptable toxicity, patient or physician request to 
discontinue, death, or termination of the study. All patients enrolled into Part 3 
will have plasma samples drawn in order to evaluate the PK profile of a single 
600 mg dose administered as 300 mg tablets in the fed versus fasted state.  
Plasma samples will also be drawn from all patients to evaluate the steady state 
PK profile of 600 mg BID administered as 300 mg tablets. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 17 of 133 
Confidential 
Study Design 
(cont) 
Part 1, Part 2 and Part 3--End of Treatment and Follow-up Assessments 
All patients should have end of treatment assessments performed upon 
discontinuation of rucaparib and should return to the clinic for AE assessment at 
28 (±3) days after the last dose of rucaparib has been administered.  During 
Parts 1 to 3, AEs will be assessed from the time of informed consent through 28 
days after the last dose.  Part 2B patients will be followed for survival, 
subsequent anti-cancer treatments. and secondary malignancy monitoring every 
12 weeks [±7 days]. 
Dose-Limiting 
Toxicities 
DLTs in Part 1 are defined as any of the following events that occur during 
Cycle 1 (Safety and PK Assessment Period) and are assessed by the investigator 
as related to rucaparib.  Where applicable, events will be classified according to 
the National Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI CTCAE).2 
• Absolute neutrophil count (ANC) <0.5 × 109/L >5 days duration or febrile 
neutropenia (i.e., fever >38.3°C with ANC <1.0 × 109/L) 
• Platelets <25 × 109/L or platelets <50 × 109/L with bleeding requiring a 
platelet transfusion 
• Grade 4 anemia (i.e., life-threatening consequences; urgent intervention 
indicated) 
• Any non-hematological AE CTCAE Grade 3 or greater (except alopecia and 
nausea, vomiting, and diarrhea if well controlled by systemic medication) 
In order to be considered evaluable for dose-escalation decisions, a patient in 
Part 1 must have received at least 17 complete days of dosing, and have 
completed Cycle 1, Day 21 without a DLT, or have experienced a DLT in 
Cycle 1.  If a patient withdraws from the study without having met either of 
these criteria, then an additional patient will be enrolled in that cohort.   
Study Population 
Inclusion Criteria 
All patients enrolling into Part 1 (Phase I portion), Parts 2 or 3 (Phase II 
portions) must meet all of the following inclusion criteria: 
• Understand and voluntarily sign an Institutional Review Board/Independent 
Ethics Committee-approved informed consent form prior to any study-
specific evaluation 
• Be ≥18 years of age at the time the informed consent form is signed 
• Have an Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 to 1 
• Have life expectancy of at least 3 months 
• Have adequate organ function confirmed by the following laboratory values 
obtained within 14 days of the first dose of rucaparib: 
a. Bone Marrow Function 
− ANC ≥1.5 × 109/L 
− Platelets >100 × 109/L  
− Hemoglobin ≥9 g/dL 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 18 of 133 
Confidential 
Study Population 
(cont) 
b. Hepatic Function 
− Aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) ≤3 × upper limit of normal (ULN); if liver metastases, then 
≤5 × ULN  
− Bilirubin ≤1.5 × ULN (<2 × ULN if hyperbilirubinemia is due to 
Gilbert’s syndrome) 
− Serum albumin ≥30 g/L (3.0 g/dL) (Part 2B only) 
c. Renal Function  
− Serum creatinine ≤1.5 × ULN 
Patients enrolling into Part 1 (Phase I portion) must also meet the following 
inclusion criteria: 
• Have a histologically or cytologically confirmed solid tumor (lymphoma is 
included in this category) that is locally recurrent or metastatic and has 
progressed on standard treatment 
• Have left ventricular ejection fraction (LVEF) > lower limit of normal (LLN) 
as determined by echocardiogram (ECHO) or multigated acquisition 
(MUGA) scan evaluation using local institutional standard 
• Have a documented deleterious gBRCA mutation (Note: only applicable for 
patients being screened for enrollment into the RP2D Expansion cohort) 
• Be willing and able to eat a high-fat breakfast on Day 1 of the study (Note: 
only applicable for patients being screened for enrollment into a 
food-effect PK cohort) 
 
All patients enrolling into Part 2 (Phase II portion in OC) must also meet the 
following inclusion criteria: 
• Have a known deleterious BRCA mutation (germline or somatic), as 
determined by a local laboratory that has received an international or 
country-specific quality standards certification  
• Have evidence of measurable disease as defined by RECIST Version 1.1 
• Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor 
tissue available for planned analyses; cytospin blocks from ascites are not 
acceptable 
− Archival tissue from the most recently collected biopsy or debulking 
surgery should be provided, if available.  Otherwise, the next oldest tissue 
collected should be reviewed until a suitable sample can be provided (at 
least 20% tumor content with a minimum of 80% nucleated cellular 
content) 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 19 of 133 
Confidential 
Study Population 
(cont) 
Additional inclusion criteria for patients into Part 2A (Phase II portion in OC) 
include: 
• Have a histologically confirmed diagnosis of high-grade serous or 
endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
− For mixed histology, >50% of the primary tumor must be confirmed to be 
high-grade serous or endometrioid upon re-review by local pathology 
• Have received at least two, but no more than four, prior chemotherapy 
regimens and have relapsed as confirmed by radiologic assessment 
a. Last treatment received must have been platinum-based regimen to which 
patient must have been sensitive (i.e., disease progression occurred at 
least 6 months after last dose of platinum was administered) 
b. A maximum of one non-platinum regimen may have been administered.  
For patients who received four prior regimens, one regimen must have 
been a non-platinum 
c. Prior continuous or switch maintenance treatment is permitted (hormonal 
treatment may be permitted following the last platinum regimen with 
advance approval from the sponsor) 
 
Additional inclusion criteria for patients into Part 2B (Phase II portion in OC) 
include: 
• Have a histologically confirmed diagnosis of high-grade epithelial ovarian, 
fallopian tube, or primary peritoneal cancer. 
• Have received at least three, but no more than four, prior chemotherapy 
regimens and have relapsed disease confirmed by radiologic assessment. 
− 
Hormonal agents (e.g., tamoxifen, letrozole, etc), anti-angiogenic agents 
(e.g., bevacizumab, pazopanib, cediranib, nintedanib, trebananib, etc), 
and other non-chemotherapy agents administered as single agent 
treatment will not be counted as a chemotherapy regimen for the 
purpose of determining patient eligibility 
− 
Agents administered in the maintenance setting will not be counted as a 
separate regimen 
• Have a documented treatment-free interval (TFI) of ≥6 months following the 
first chemotherapy regimen received.  (TFI is determined from the last dose 
administered as part of primary treatment regimen and not from the last dose 
of any agent administered in the maintenance setting). 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 20 of 133 
Confidential 
Study Population 
(cont) 
Patients enrolling into Part 3 (Phase II PK portion in patients with any 
advanced solid tumor) must meet the following inclusion criteria: 
• Have an advanced solid tumor (inclusive of lymphoma)  
• Have a known deleterious BRCA mutation (gBRCA or somatic BRCA 
[sBRCA]) (as determined by a local laboratory that has received an 
international or country-specific, quality standards certification) 
• Have evidence of measurable disease as defined by RECIST Version 1.1 
• Be willing and able to fast, and to eat a high-fat breakfast on Day -7 or Day 1 
of the study  
• Have sufficient archival FFPE tumor tissue available for planned analyses; 
cytospin blocks from ascites are not acceptable 
− Archival tissue from the most recently collected biopsy or debulking 
surgery should be provided, if available.  Otherwise, the next oldest tissue 
collected should be reviewed until a suitable sample can be provided (at 
least 20% tumor content with a minimum of 80% nucleated cellular 
content) 
Exclusion Criteria 
Patients enrolling into either Part 1 (Phase I portion), Parts 2 or 3 (Phase II 
portions) will be excluded from participation if any of the following criteria 
apply: 
• Active second malignancy, i.e., patient known to have potentially fatal 
cancer present for which she may be (but not necessarily) currently receiving 
treatment 
− Patients with a history of malignancy that has been completely treated, 
with no evidence of that cancer currently, are permitted to enroll in the 
trial provided all chemotherapy was completed >6 months prior and/or 
bone marrow transplant (BMT) >2 years prior to first dose of rucaparib 
• Prior treatment with any PARP inhibitor (Part 1, Part 2).  Part 3 patients are 
permitted to have had previous PARPi, if the following conditions are met: 
a. PARPi was not the most recent treatment, and  
b. PARPi was discontinued >6 months before first planned dose of rucaparib 
c. In all study parts, patients who previously received iniparib are eligible 
• Untreated or symptomatic central nervous system (CNS) metastases.  
Patients with asymptomatic CNS metastases are eligible provided they have 
been clinically stable for at least 4 weeks. 
• Known human immunodeficiency virus (HIV) or acquired 
immunodeficiency syndrome (AIDS)-related illness, or history of chronic 
hepatitis B or C. 
• Received treatment with chemotherapy, radiation, antibody therapy or other 
immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or 
experimental drugs ≤14 days prior to first dose of rucaparib and/or ongoing 
adverse effects from such treatment > NCI CTCAE Grade 1 (ongoing Grade 
2 non-hematologic toxicity related to most recent treatment regimen may be 
permitted with prior advanced approval from Sponsor) 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 21 of 133 
Confidential 
Study Population 
(cont) 
• Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that 
would, in the opinion of the Investigator, interfere with absorption of 
rucaparib  
• Administration of strong CYP1A2 or CYP3A4 inhibitors ≤7 days prior to 
first scheduled dose of rucaparib 
• Non-study related minor surgical procedure ≤ 5 days, or major surgical 
procedure ≤ 21 days, prior to first dose of rucaparib; in all cases, the patient 
must be sufficiently recovered and stable before treatment administration  
• Females who are pregnant or breastfeeding. 
• For fertile patients (female able to become pregnant or male able to father a 
child), refusal to use effective contraception during the period of the trial and 
for 6 months after the last dose of rucaparib 
• Presence of any serious or unstable concomitant systemic disorder 
incompatible with the clinical study (e.g., substance abuse, psychiatric 
disturbance, or uncontrolled intercurrent illness including active infection, 
arterial thrombosis, and symptomatic pulmonary embolism) 
• Presence of any other condition that may increase the risk associated with 
study participation or may interfere with the interpretation of study results, 
and, in the opinion of the investigator, would make the patient inappropriate 
for entry into the study 
Patients enrolling into Part 1 (Phase I portion) will also be excluded from 
participation if any of the following criteria apply: 
• Family history of long QT syndrome 
• Implantable pacemaker or implantable cardioverter defibrillator 
• Requires treatment with any medication known to produce QT prolongation, 
with the exception of antiemetics  deemed necessary to control nausea (see 
Appendix C) 
Patients enrolling into Part 2B (Phase II OC portion) will also be excluded 
from participation if any of the following criteria apply: 
• Hospitalization for bowel obstruction within 3 months prior to enrollment 
Pregnancy is an exclusion criterion and women of childbearing potential must 
not be considering getting pregnant during the study. 
Patients of reproductive potential (female able to become pregnant or male able 
to father a child) must practice a highly effective method of contraception during 
treatment and for 6 months following the last dose of rucaparib. 
No waivers of inclusion or exclusion criteria will be granted by the investigator 
and the sponsor or its designee for any patient enrolled into the study. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 22 of 133 
Confidential 
Study Treatment 
Rucaparib tablets (40 mg, 60 mg, 120 mg, 200 mg, 300 mg [as free base]) will be 
supplied to study sites by the sponsor.  Each dose should be taken with 8 oz (240 
mL) of room temperature water.  With the exception of Day -7 and Day 1 of any 
food-effect PK portions of the study, patients may take rucaparib on an empty 
stomach or with food.  Administration conditions may be revised based on 
results from food-effect PK evaluation. 
In Part 1, patients will ingest rucaparib once, twice, or three times a day through 
Day 21 of Cycle 1 (Safety and PK Assessment Period).  Daily treatment with 
oral rucaparib will continue starting on Day 1 of Cycle 2 for patients continuing 
in the optional Treatment-Extension Period.   
In Part 2 and Part 3 (Phase II portion), the starting dose of rucaparib is 600 mg 
BID administered for continuous 21 day cycles (See Section 3.2.2 for additional 
details regarding selection of the RP2D). 
Dose reductions are not permitted during Cycle 1 for all patients in Part 1.  Dose 
reductions for Part 1 patients in Cycle 2 and beyond, and for patients in Parts 2 
and 3, are permitted in the event of unacceptable toxicity.  Up to three dose 
reduction steps are allowed.  If a patient continues to experience toxicity after 
three dose reduction steps, or if dosing with rucaparib is interrupted for 
> 14 consecutive days due to toxicity, treatment should be discontinued, unless 
otherwise agreed between the investigator and the sponsor. 
Intrapatient dose escalation in Part 1 of the study will be permitted after a patient 
completes at least 2 cycles of treatment at their initial dose level without 
experiencing significant drug-related toxicity, provided the dose level to which 
the patient will escalate has been evaluated and deemed tolerable at the time of 
the proposed dose increase, and represents ≤100% increase in total dose.  The 
dose may be increased at the beginning of the next cycle.  There is no limit to the 
number of dose escalations steps permitted for an individual patient provided all 
criteria are met. All dose escalation steps must be approved by the Sponsor’s 
Medical Monitor. 
Concomitant 
Medications 
Concomitant anticancer therapies of any kind are not permitted with the 
exception of ongoing hormonal treatment for prior breast cancer.  Supportive 
care (e.g., antiemetics; analgesics for pain control) may be used at the 
investigator’s discretion and in accordance with institutional procedures.  For 
patients undergoing extensive ECG assessments in Part 1, medications known to 
produce QT prolongation should not be used, with the exception of necessary 
antiemetic medications.  A list of prohibited medications and antiemetic 
medications requiring additional ECG monitoring is provided in Appendix C of 
the protocol.  Preferable antiemetics for patients in Part 1 include phenothiazines 
and corticosteroids.  Administration of prophylactic antiemetics is prohibited 
during Cycle 1 of treatment for all patients in Part 1.  Caution should be used for 
concomitant medicines that are substrates of CYP2C19, CYP2C9, and/or 
CYP3Aand have a narrow therapeutic range (Appendix D).  Caution should be 
exercised in patients receiving oral rucaparib and concomitant warfarin 
(Coumadin) as rucaparib showed a mixed inhibition of CYP2C9 in vitro. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 23 of 133 
Confidential 
Withdrawal 
Criteria 
A patient must be discontinued from protocol-prescribed therapy if any of the 
following apply: 
• Consent withdrawal at the patient’s own request or at the request of their 
legally authorized representative 
• Progression of patient’s underlying disease 
• Any event, adverse or otherwise, that, in the opinion of the investigator, 
would pose an unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the investigator, would affect 
assessments of the clinical status to a significant degree and requires 
discontinuation of therapy 
• A positive pregnancy test at any time during the study 
• Increase in QT/QTc of >60 msec over baseline or QTc >500 msec 
Pharmacokinetic 
Assessments 
All patients enrolled in Part 1 and Part 3 (food-effect PK evaluation cohorts only) 
will have extensive PK sampling prior to and/or during Cycle 1, with collection 
time points predose and from 15 min through 24 h postdose.  For Part 1 patients 
in Cycles 2-9, only single trough-level PK samples will be collected during each 
treatment cycle. For Part 2 and Part 3 patients, single trough-level PK samples 
will be collected at Cycle 1, Day 15 (Part 2 only) and at the end of treatment 
Cycles 1, 2, 4, 6, and 8. 
A profile of circulating metabolites of rucaparib at steady state will be evaluated 
in the first three patients enrolled in the RP2D Expansion cohort (Part 1 only).  
Serum alpha-1 acid glycoprotein (AAG) sampling will occur on the same day as 
PK plasma collection (Parts 2 and 3). 
PK evaluation will be based on the determination of the following parameters for 
oral rucaparib including (but not limited to):  AUC0–t, AUC0–∞, Cmax, Tmax, t1/2, 
and kel, Vss/F, and Cl/F.  A central/core laboratory will be used for the PK assay. 
Tumor Tissue 
Samples 
Part 1: Archival tumor tissue and/or fresh tumor biopsy samples at screening, as 
well as biopsy sample at time of disease progression/discontinuation of 
treatment, are optional. 
Part 2: Archival tumor tissue samples will be collected from all newly enrolled 
patients and from previously enrolled patients who provide appropriate consent; 
a biopsy sample at screening and/or time of disease progression/discontinuation 
of treatment is optional. 
Part 3: Archival tumor tissue samples will be collected; a biopsy sample at time 
of disease progression/discontinuation of treatment is optional 
Electro-
cardiogram 
Assessments 
Patients in Part 1 will have ECGs at screening, at several time points prior to 
(food-effect PK evaluation cohorts only) and/or during Cycle 1, on Day 1 of 
every cycle thereafter, and at the end-of-treatment visit.  Patients in Part 2A will 
have ECGs at screening, on Day 1 of each cycle, and at the end-of-treatment 
visit. Patients in Part 2B and Part 3 have ECGs at screening and at the end-of-
treatment visit. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 24 of 133 
Confidential 
Efficacy 
Assessments 
Efficacy measures will include tumor assessments, consisting of clinical 
examination and appropriate imaging techniques (preferably computed 
tomography (CT) scans of the chest, abdomen, and pelvis with appropriate slice 
thickness per RECIST); other studies (magnetic resonance imaging (MRI), 
X-ray, positron emission tomography [PET], and ultrasound) may be performed 
if required.  Tumor assessments will be performed at screening; prior to the start 
of Cycles 3, 5, and 7; and prior to the start of every three cycles of treatment 
thereafter, beginning with Cycle 10.  For Part 2B patients discontinued from 
study treatment for reason other than disease progression or death, tumor 
assessments will continue to be performed during the long-term follow-up period 
(within 7 days prior to the start of every 9 weeks until radiologically confirmed 
disease progression, death, or initiation of subsequent treatment).  Patients who 
have been on study for at least 18 months may decrease the frequency of tumor 
scans to every 16 weeks (±14 days).  Confirmatory scans 4–6 weeks after 
response was documented are required if initial CR or PR was noted prior to the 
start of Cycle 7 or beyond. CT scans will be collected for all patients enrolled 
into Part 2 and Part 3 for possible evaluation by independent radiology review. 
Tumor Markers 
Part 1: tumor markers applicable to a patient’s tumor type are optional. 
Part 2: CA-125 levels will be collected for all patients. 
Part 3: tumor markers applicable to a patient’s tumor type will be analyzed. 
Safety 
Assessments 
Safety measures will include AEs, hematology, clinical chemistry, urinalysis, 
vital signs, body weight, concomitant medications/procedures, ECOG 
performance status, ECGs, and rucaparib dose modifications. 
Statistical 
Procedures 
Sample Size Justification 
The total enrollment planned for this study is approximately 140 patients:  
56 patients were enrolled into Part 1 (Phase I portion), up to 41 will be enrolled 
into Part 2A, approximately 40 patients will be enrolled into Part 2B, and 
approximately 20 patients will be enrolled into Part 3.   
Clinical trials of olaparib in relapsed ovarian cancer patients associated with a 
gBRCA mutation demonstrated ORRs of 13-41%.3-5 For the part of the study 
evaluating rucaparib in platinum-sensitive, relapsed, high-grade serous and 
endometrioid epithelial ovarian, fallopian tube, and primary peritoneal cancer 
associated with a gBRCA mutation, an ORR of 20% will be set as the target of 
interest. 
Sample size justification for Part 2A:  
The study will use a Simon 2-stage design to evaluate the efficacy of rucaparib in 
Part 2 (Phase II portion).  Initially, 21 patients will be treated in Stage 1 of the 
study; if two or more patients in Stage 1 have an objective response (CR or PR), 
then the remaining 20 patients will be treated in Stage 2.  If fewer than two 
patients in Stage 1 have an objective response, then no further patients will be 
enrolled.  Characteristics of the Simon 2-stage design include: 
• 
5% probability of accepting a poor drug 
• 
90% probability of accepting a good drug 
• 
ORR of 5% for a poor drug 
• 
ORR of 20% for a good drug 
• 
A promising drug will have five or more patients with an objective 
 
response (CR or PR) out of 41 patients at the end of Stage 2. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 25 of 133 
Confidential 
Statistical 
Procedures (cont) 
The criteria for Stage 1 success were met in April 2014, and Stage 2 is ongoing 
with total enrollment of 41 evaluable patients completed in April 2015. 
Sample size justification for Part 2B: 
An ORR ≥20% in this population would be worthy of further exploration.  The 
table below provides 95% confidence intervals (CIs) for ORRs of 30% to 50% 
assuming a sample size of 40 patients.  
Confidence Intervals for Observed Response Rates 
ORR(%) 
[95% CI] 
30 
17,47 
40 
25, 57 
50 
34,66 
CI=Confidence intervals of ORR using Clopper-Pearson methodology.6  
 
Therefore with the sample size of 40 patients an observed ORR of 30% would 
show similar response as current treatment, however, an observed ORR of 40% 
or greater has a 95% CI which exceeds the 20%.  
Sample size justification for Part 3:  
This part of the study will be an initial randomized, single dose, two treatment, 
two period, crossover design, to explore food effect and other PK parameters; 
with subsequent continuous BID dosing. It is estimated that enrolling 
approximately 20 evaluable patients will provide sufficient data for PK analysis. 
Pharmacokinetic Analyses 
PK parameters will be determined using noncompartmental methods.  AUC from 
Time 0 to the last observation will be calculated using the trapezoid rule.  The kel 
will be calculated using log-linear regression on the terminal part of the 
concentration time curve.  The t1/2 and the AUC from the last observation to 
infinity will be calculated from the estimated kel.  Other parameters to be 
determined are Cmax, Tmax, Vss/F, and Cl/F. 
The effect of food on PK parameters including (but not limited to) Cmax and AUC 
will be compared using analysis of variance (ANOVA) techniques. 
Relationship Between PK and QTc 
A linear and nonlinear mixed effect modeling approach will be used to quantify 
the relationship between the plasma concentration and the ΔΔQTc (time-
matched, on-treatment to pretreatment difference in QTc interval, baseline-
adjusted).  Plots of the mean QT/QTc versus drug concentrations and the 
correlation between concentration and QT variables will be explored.   
Metabolite Profiling at the RP2D 
Individual pooled plasma samples, one from each of three included patients, will 
be prepared using the method proposed by Hamilton.7  The pooled plasma 
samples will be further processed before being analyzed by high-performance 
liquid chromatography coupled in-line with ultraviolet spectrophotometric and 
tandem mass spectrometric detection (HPLC-UV-MS/MS). 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 26 of 133 
Confidential 
Statistical 
Procedures (cont) 
Efficacy Analysis 
The ORR will be summarized with frequencies and percentages.  The duration of 
response for CR and PR patients will be summarized with descriptive statistics 
(N, mean, standard deviation, median, minimum, and maximum) as well as 
categorically.  Response will be determined using RECIST Version 1.1.  Kaplan-
Meier methodology will be used to summarize time to event variables. 
 
Safety Analyses 
Data from all patients who receive at least one dose of rucaparib will be included 
in the safety analyses.  AEs, clinical laboratory information, vital signs, ECOG 
performance status, body weight, ECGs, and concomitant 
medications/procedures will be tabulated and summarized.   
AEs will be summarized overall and with separate summaries for serious AEs, 
AEs leading to discontinuation, AEs leading to death, and NCI CTCAE Grade 3 
or higher AEs.   
Body weight and vital signs will be summarized descriptively (N, mean, standard 
deviation, median, minimum, and maximum).  ECOG will be summarized 
categorically and descriptively.   
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 27 of 133 
Confidential 
2 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AAG 
alpha-1 acid glycoprotein 
ADP 
adenosine diphosphate 
AE 
adverse event 
AESI 
adverse event of special interest 
AIDS 
acquired immunodeficiency syndrome 
ALP 
alkaline phosphatase 
ALT 
alanine transaminase 
AML 
acute myeloid leukemia 
ANC 
absolute neutrophil count 
ANOVA 
analysis of variance 
AST 
aspartate transaminase 
AUC 
area under the curve 
AUC0-24 
area under the curve from time zero to 24 hours 
AUC0-∞ 
area under the curve from time zero to infinity 
AUC0-t 
area under the curve from time zero to time t 
BER 
BID 
base excision repair 
twice a day 
BMT 
bone marrow transplant 
BRCA1 
breast cancer 1 
BRCA2 
breast cancer 2 
BUN 
blood urea nitrogen 
CA-125 
cancer antigen-125 
CEA 
Carcinoembryonic antigen 
CFR 
Code of Federal Regulations 
CI 
confidence interval 
Cl/F 
apparent total plasma clearance after oral administration  
Cmax 
maximum concentration 
CNS 
central nervous system 
CR 
complete response  
CRO 
contract research organization  
CT 
computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events  
CYP 
cytochrome P450 
DLT 
DNA 
dose-limiting toxicity  
deoxyribonucleic acid 
DSB 
double-strand break 
ECG 
Electrocardiogram 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 28 of 133 
Confidential 
ECHO 
Echocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
electronic case report form 
EDC 
electronic data capture 
EOS 
end -of- study 
FFPE 
formalin-fixed paraffin-embedded 
FISH 
fluorescence in situ hybridization 
FSH 
follicle stimulating hormone 
HDL 
high density lipoprotein 
GALT 
gut-associated lymphoid tissue 
gBRCA 
germline BRCA 
GCIG 
Gynecologic Cancer InterGroup 
GCP 
Good Clinical Practice 
HGSOC 
high-grade serous ovarian cancer 
HIPAA 
Health Information Portability and Accountability Act 
HIV 
human immunodeficiency virus 
HPLC-UV-
MS/MS 
high-performance liquid chromatography coupled with ultraviolet 
spectrophotometric and tandem mass spectrometric detection  
HR 
homologous recombination 
HRD 
homologous recombination deficiency 
IEC 
Independent Ethics Committee 
INR 
international normalized ratio 
IRB 
Institutional Review Board  
iv 
Intravenous 
kel 
elimination rate constant  
LDL 
low density lipoprotein 
LLN 
lower limit of normal 
LOH 
loss of heterozygosity 
LVEF 
left ventricular ejection fraction 
MDS 
myelodysplastic syndrome 
MedDRA 
Medical Dictionary for Drug Regulatory Activities 
MRI 
magnetic resonance imaging 
MTD 
maximum tolerated dose 
MUGA 
multigated acquisition 
NCI 
National Cancer Institute 
NCCN 
National Comprehensive Cancer Network 
NOAEL 
no-observed-adverse-effect level 
OC 
ovarian cancer 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 29 of 133 
Confidential 
ORR 
overall response rate 
OS 
overall survival 
PARP 
poly(adenosine diphosphate [ADP]-ribose) polymerase 
PARPi 
poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor 
PD 
progressive disease 
PET 
positron emission tomography 
PFS 
progression-free survival 
P-gp 
P-glycoprotein 
PK 
pharmacokinetic(s) 
PR 
partial response 
QD 
once a day 
QTcF 
QT interval corrected using Fridericia’s method 
RECIST 
Response Evaluation Criteria in Solid Tumors  
RP2D 
recommended Phase II dose 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SAS 
statistical analysis software 
sBRCA 
somatic BRCA 
SD 
stable disease 
SOC 
system organ class 
SSB 
single-strand break 
SUSAR 
suspected unexpected serious adverse reaction 
t1/2 
elimination half-life 
TID 
three times a day 
Tmax 
time to maximum concentration 
TMZ 
Temozolomide 
TFI 
treatment-free interval 
ULN 
upper limit of normal 
Vss/F 
apparent volume of distribution at steady state after non-iv administration 
WBC 
white blood cell 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 30 of 133 
Confidential 
3 
INTRODUCTION 
3.1 
DNA Repair and Cancer Therapy 
Deoxyribonucleic acid (DNA) is constantly damaged by environmental factors such as sunlight 
and DNA-binding chemicals.  A common type of DNA damage is the formation of DNA 
single-strand breaks (SSBs), which are normally quickly repaired by a process known as base 
excision repair (BER).  This process is initiated by the activity of the poly(adenosine diphosphate 
[ADP]-ribose) polymerase (PARP) enzyme.8  During normal cell cycling, DNA is replicated and 
replication forks are eventually stalled by persistent SSBs.  If stalled replication forks are not 
rapidly repaired, they can often degenerate and form DNA double-strand breaks (DSBs), which 
are highly likely to be lethal to the cell.3  In normal cells, an additional DNA repair process 
known as homologous recombination (HR) can repair DSBs.3  HR is mediated by breast cancer 
1 and 2 genes (BRCA1 and BRCA2) and acts as a functional buffer to enable normal cells to 
survive the effects of PARP and BER inhibition.3  Homologous recombination defects or PARP 
inhibition on their own can be withstood by a cell, but the combination is fatal, a concept termed 
“synthetic lethality”.3-5  
Mutations in BRCA1 and BRCA2 have been identified as a cause of hereditary breast and ovarian 
cancer,9 accounting for about 60% of inherited breast cancer and a smaller percent of ovarian 
cancer.10  These patients carry heterozygous deleterious mutations in their germline DNA, and 
develop tumors when the remaining wild-type functional allele is inactivated (i.e., “second hit”).  
Interestingly, approximately 51% of high-grade serous ovarian cancers have genetic alterations 
in DNA repair pathways, commonly involving germline and somatic defects in BRCA.11  
Synthetic lethality has been exploited in two proof-of-concept clinical trials with an oral PARP 
inhibitor in patients with BRCA-deficient tumor types.  These trials evaluated the efficacy of 
continuous oral dosing in women with confirmed germline BRCA1 or BRCA2 mutations, and 
either ovarian cancer or advanced breast cancer.12, 13  In these patients, who had received a 
median of three prior chemotherapy regimens, encouraging overall response rates (ORRs) of 
33% and 41%, respectively, were observed. 
In addition to use as monotherapy to drive synthetic lethality in the context of a BRCA 
mutation,12-14 PARP inhibitors have been administered in combination with cytotoxic agents (and 
radiation) in vitro and in vivo.15-18  In particular, DNA damaging agents such as temozolomide 
(TMZ), irinotecan, and platinums have been shown to synergize with PARP inhibitors in 
nonclinical experiments.19-21  The explanation offered is that PARP inhibition limits the ability of 
the cell to repair “therapeutic” DNA damage and thus potentiates the therapeutic effect of the co-
administered chemotherapy. 
3.2 
Background 
Rucaparib (CO-338; formerly known as PF 01367338 and AG 14699) is a small molecule 
inhibitor of PARP that has been in clinical development since 2003.  Initial animal model studies 
evaluating rucaparib administered in combination with chemotherapeutic agents (e.g., TMZ) 
suggested that a dose-dependent inhibition of PARP activity correlated with antitumor activity.  
Hence, the initial clinical program assessed safety and efficacy in patients with malignancies 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 31 of 133 
Confidential 
commonly treated with selected chemotherapeutic agents.  Initial Phase I and Phase II clinical 
studies were conducted with an intravenous formulation of rucaparib administered in 
combination with a variety of chemotherapeutic agents.  An oral formulation as monotherapy is 
the focus of current development efforts.   
Nonclinical evaluation has also demonstrated exquisite sensitivity of BRCA1 and BRCA2 
homozygous cell lines to rucaparib, which is attributed to PARP inhibition alone, and provides a 
rationale for the clinical assessment of rucaparib as monotherapy in patients with deficiencies of 
BRCA1 and BRCA2. 
Details of ongoing/completed studies and other nonclinical experiments are provided in the 
Investigator’s Brochure. 
3.2.1 
Nonclinical Experience 
3.2.1.1 Rucaparib Absorption, Distribution, Metabolism, and Excretion 
The pharmacokinetics (PK) and toxicokinetics of rucaparib following oral administration of the 
camsylate salt, the intended route of administration in humans, was evaluated in the mouse, rat, 
and dog.  The time at which the peak plasma concentrations were observed (Tmax) occurred at 1 – 
3 hours post-dose in the mouse and dog, with the rat generally exhibiting a later Tmax (4 – 8 
hours).  The oral bioavailability was 17%, 36%, and 62% respectively, in the mouse (50 mg/kg), 
rat (100 mg/kg), and dog (20 mg/kg).  In the rat and dog, there were no marked gender-related 
differences and no accumulation after repeat oral administration.   A less than dose-proportional 
increase in exposure was observed in the rat and dog when rucaparib was administered as a 
suspension in 0.5% methylcellulose; however, a greater than dose-proportional increase in 
exposure was observed in the 1-month dog toxicity study when rucaparib was administered in 
capsules. 
Quantitative whole-body autoradiography studies in rats showed that [14C] rucaparib 
radioequivalents were rapidly and widely distributed to tissues following intravenous 
administration, consistent with the large volume of distribution.  At 2 min after dosing, the 
highest concentrations were found in the kidney, lung, thyroid gland, heart, stomach mucosa, 
liver, adrenal glands, spleen, and blood.  Little radioactivity was present in brain; none was 
detected at 15 min after dosing. Activity was undetectable in most tissues by 96 hours after 
dosing, however levels in the choroid/retina declined more slowly, and persistent radioactivity 
was also found in hair follicles through 192 hours, indicating that drug equivalents have high 
affinity and long half-life in pigmented tissues.  High levels of radioactivity were observed in 
ureters, bladder, and bile ducts, indicating both renal and biliary routes eliminated drug 
equivalents.   
In vitro studies indicated that rucaparib reversibly inhibited (in order of decreasing potency) 
CYP1A2, CYP2C19, CYP2C9, CYP3A, CYP2C8, and CYP2D6.  Rucaparib also moderately 
inhibited uridine diphosphate-glucuronosyletransferase (UGT) 1A1.  Rucaparib demonstrated 
concentration-dependent induction of CYP1A2 and downregulation of CYP3A4 and CYP2B6 at 
clinically relevant concentrations in a hepatocyte incubation study.  No time-dependent CYP 
inhibition was observed.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 32 of 133 
Confidential 
Based on in vitro CYP interaction data, the drug-drug interaction (DDI) potential of rucaparib as 
a CYP inhibitor and/ or inducer was assessed by calculating the ratio of AUC (AUCR) of CYP 
substrate drugs in the presence and absence of rucaparib at target clinical exposures (600 mg 
BID) using the mechanistic static modeling.22, 23  AUCR allows a conservative estimation of the 
magnitude of DDIs. Based on this analysis, the DDI potential for rucaparib was estimated to be 
moderate (AUCR 2 to 5) for CYP3A (AUCR=5.0), CYP1A2 (AUCR=2.9), CYP2C8 
(AUCR=2.6), and CYP2D6 (AUCR=2.3); but appeared to be strong (AUCR > 5) for CYP2C19 
(AUCR=11) and CYP2C9 (AUCR=5.2).  Clinical implication of CYP3A downregulation was 
unknown and thus not considered in the modeling.  However, the downregulation could further 
increase AUCR for CYP3A and result in elevated exposures of drugs that are CYP3A substrates. 
Based on bi-directional experiments of digoxin transport carried out using Caco-2 cells, it was 
determined that rucaparib is a moderate P-glycoprotein (P-gp) inhibitor.  Patients taking dixogin 
should have their dixogin levels monitored regularly according to standard institutional 
practices.22, 23 
Rucaparib protein binding was determined in the human, dog, rat, and mouse plasma over a 
concentration range of 0.5 to 100 µM.  In humans, the percent protein bound ranges from 54.6% 
to 74.9%.  The percent protein bound ranges from 58.1% to 65.2%, 53.4% to 60.2%, and 49.5% 
to 73.4% in mouse, rat, and dog plasma, respectively. 
3.2.1.2 Multiple-Dose Toxicity Studies 
Rucaparib was evaluated in both rat and dog in oral and IV infusion toxicity studies.  Only the 
multiple-dose toxicity studies utilizing the oral formulation are summarized below.  Details of all 
other toxicity studies are provided in the Investigator’s Brochure.  Target organs identified in 
studies where rucaparib was administered orally include the hematopoietic system and 
gastrointestinal tract.  No cardiovascular findings were noted in any of the oral toxicity studies 
Multiple-Dose Oral Toxicity in Rats 
Administration of rucaparib camsylate salt via oral gavage was generally well-tolerated in the rat 
up to 1000 mg/kg/day for 7 days and up to 150 mg/kg/day for 28 days.  Decreases in body 
weight gain and food consumption were noted in both studies.  In the 7-day study, target organs 
identified microscopically were bone marrow, spleen, and thymus.  Minimal to mild bone 
marrow hypocellularity was noted in all dose groups.  The no-observed-adverse-effect-level 
(NOAEL) was established at 500 mg/kg/day. 
In the 28-day study, there were 3 rucaparib-related deaths at 500 mg/kg/day immediately after 
blood collection on Day 28 (n=1) or Day 29 (first day of recovery phase (n=2).  These deaths 
likely resulted from the marked anemia identified hematologically.  Other rucaparib-related 
clinical signs at 500 mg/kg/day included thinning haircoat and pale eyes.  Identified target organs 
included bone marrow, spleen, lymphoid tissue (thymus, gut-associated-lymphoid tissue 
[GALT], and lymph nodes), and cecum (at 500 mg/kg/day only).  Following cessation of 
rucaparib dosing, most findings reversed.  In this study, the severe toxic dose in 10% of the 
animals (STD10) was 500 mg/kg/day and the NOAEL was 50 mg/kg/day. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 33 of 133 
Confidential 
Multiple-Dose Oral Toxicity in Dogs 
Oral gavage administration of the camsylate salt form of rucaparib to dogs for 7 days resulted in 
gastrointestinal clinical signs at the 80 mg/kg/day high-dose group.  Hematopoietic effects of 
decreased reticulocytes were noted in mid- to high-dose groups and leukopenia was exhibited in 
all treatment groups.  Lymphoid atrophy occurred in both sexes and in all treatment groups.  
Decreased bone marrow cellularity was seen in both sexes (males at all doses; females at 80 
mg/kg/day).  A 7-day repeat-dose toxicity study using oral capsules in dogs was repeated in 
order to characterize the toxicity of a new lot of rucaparib camsylate.  Similar to the results of the 
prior 7-day study in dog, gastrointestinal clinical findings were noted at 80 mg/kg/day. Vomiting 
was observed throughout the dosing phase for males as well as liquid and/or mucoid feces in 
both genders. Decreased food consumption was observed at 80 mg/kg/day that correlated with 
the body weight loss that was considered adverse.  Decreases in erythroid, platelet, and leukocyte 
parameters were observed primarily at 80 mg/kg/day and occasionally at 20 or 5 mg/kg/day.  
These data indicated that the drug targeted multiple bone marrow lineages in a dose-related 
pattern. 
Rucaparib camsylate salt in capsules was administered orally to dogs for 30 consecutive days 
with a 29-day recovery.  Gastrointestinal clinical signs were noted at ≥ 5 mg/kg/day, with 
decrease in food consumption at 75 mg/kg/day.  Adverse hematological changes (decrease in 
erythroid, myeloid, and megokaryocytic lineages) occurred at ≥ 20 mg/kg/day.  Effects were 
fully reversible.  The NOAEL in this study was 5 mg/kg/day. 
Rucaparib camsylate in capsules was also given orally to dogs at doses of 3, 15/10, 40/30/20 
mg/kg/day for 91 consecutive days with a 29-day recovery period.  Body weight losses and 
inappetance observed at the high dose in both sexes during the first quarter of the dosing phase 
were considered adverse and resulted in dose reductions (40 to 30 to 20 mg/kg/day for toxicity 
and 15 to 10 mg/kg day in order to maintain multiples of exposures for optimal testing of dose 
response) for the remainder of the study.  Clinical pathology findings were indicative of bone 
marrow toxicity; these changes were non-progressive over time suggesting potential adaptation 
to these initial effects.  Hematological findings at 40/30/20 mg/kg/day correlated with erythroid 
atrophy of the bone marrow detected microscopically.  By Day 29 of recovery, most effects 
reversed. The highest non-severely toxic dose (HNSTD) for this study was 20 mg/kg/day for 
male dogs.  No HNSTD was established for female dogs.  The NOAEL was 10 and 20 
mg/kg/day for male and female dogs, respectively. 
3.2.1.3 Additional Observations 
In vitro genetic toxicology assays demonstrated oral rucaparib to be clastogenic.  Bacterial 
mutagenicity data for rucaparib were clearly negative in four microbial tester strains, both with 
and without metabolic activation, and equivocal in a fifth tester strain.    
In an in vitro assay for human ether-a-go-go-related gene channel blockade (hERG) activity, the 
IC20 and IC50 values for the inhibitor effects of rucaparib (50% inhibitor concentration and 20% 
inhibitory concentration) on the hERG potassium currents were 7 (2264 ng/mL) and 24 µM 
(7761 ng/mL), respectively.  These values are 9-fold and 2.6-fold higher, respectively, than the 
mean unbound steady state plasma concentration (858 ng/mL) observed to date in humans at a 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 34 of 133 
Confidential 
dose of 600 mg BID rucaparib administered orally. Effects on appearance and behavior, motor 
activity, body temperature, and a number of neurofunctional tests and reflexes were evaluated in 
rats.  A dose of 50 mg/kg of rucaparib administered via IV infusion (mean Cmax=13629 ng/mL) 
resulted in a significant reduction in motor activity compared with vehicle-treated animals; 
however, there were no effects on neurofunctional or reflex testing at this dose.  The plasma 
concentration measured at this dose is 4.7-fold above the mean steady state plasma concentration 
(2880 ng/mL) observed to date in humans at a dose of 600 mg BID rucaparib administered 
orally. 
Administration of rucaparib to Long-Evans rats orally at doses up to 750 mg/kg/dose, followed 
by a single exposure to solar-simulated ultraviolet radiation approximately 4 hours after the final 
dose elicited no skin or ocular reactions indicative of phototoxicity.  The no-observed-effect-
level (NOEL) for phototoxicity was >750 mg/kg/day. 
Complete information on the preclinical PKs and drug metabolism of rucaparib may be found in 
the current Investigator’s Brochure. 
3.2.2 
Clinical Experience 
The early clinical program assessed safety and efficacy of rucaparib in patients with 
malignancies commonly treated with chemotherapeutic agents. Initially, the IV formulation of 
rucaparib was administered in combination with a variety of chemotherapies; later, the oral 
formulation of rucaparib was administered in combination with chemotherapy and as a 
monotherapy.  The oral formulation as monotherapy is the focus of current development efforts.   
Additional information regarding clinical studies with rucaparib is available in the Investigator’s 
Brochure. 
3.2.2.1 Rucaparib Monotherapy 
Rucaparib monotherapy is currently being evaluated in the treatment setting for relapsed ovarian 
cancer in two Clovis-sponsored clinical studies: Study CO-338-017 (ARIEL2) and this study, 
CO-338-010. Over 200 patients have been treated with the oral formulation of monotherapy 
rucaparib in open-label trials; over 150 patients have been treated with the recommended Phase 2 
dose of 600 mg BID. 
This Clovis-sponsored study CO-338-010 is a 3-part, open-label, safety, PK, and preliminary 
efficacy study of oral rucaparib administered daily for continuous 21-day cycles, initiated in Q4 
2011.  Fifty-six patients enrolled into Part 1 of the study (median age 50 yrs [range 21−71]; 51 
female; 27 breast cancer, 20 ovarian/peritoneal cancer, 9 other tumor) have been treated at dose 
levels of 40, 80, 160, 300, and 500 mg once daily (QD), and 240, 360, 480, 600, and 840 mg 
twice daily (BID) rucaparib administered continuously. Two patients are still receiving treatment 
as of December 2014. One of 6 patients treated with 360 mg BID rucaparib experienced a dose-
limiting toxicity (DLT) of Common Toxicity Criteria for Adverse Events (CTCAE) Grade 3 
nausea despite maximal intervention; no DLTs were observed in the 480 (n=9), 600 (n=5), or 
840 mg BID (n=3) cohorts during Cycle 1. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 35 of 133 
Confidential 
In the ongoing Phase 2 portion (Part 2A), 40 ovarian cancer patients (median age 55 [range 
42-84]; ECOG performance status 0/1=16/24; median number of anticancer regimens=2 [range 
2-4]; were enrolled as of April 2015. 
In the ongoing CO-338-017 (ARIEL2) trial, 204 ovarian cancer patients (median age 65 [range 
31-86]; ECOG performance status 0/1/pending=137/61/7; median number of anticancer 
regimens=1 [range 1-6); median number of platinum-based regimens=1 [range 1-5]) have 
enrolled into Part 1 of the study as of December 2014; enrollment into Part 1 completed.   
Safety 
As of November 2014, safety data are available for n=163 ovarian cancer patients treated with 
600 mg BID rucaparib monotherapy in the ongoing Phase 2 studies, including Part 1 of this trial. 
Treatment-related adverse events (all grades) reported in ≥15% of patients include: 
gastrointestinal and related events (nausea, vomiting, dysgeusia, diarrhea, abdominal pain, and 
decreased appetite); anemia; fatigue/asthenia, and headache.  Elevations of ALT and/or AST are 
also commonly observed.  The ALT/AST elevations occur early (within first 2-4 weeks of 
treatment), are generally mild to moderate (Gr 1-2), are not accompanied by any changes in 
bilirubin levels, and are often transient, and resolve to within normal ranges, or stabilize.  No 
patient has met the laboratory criteria for Hy’s Law.24  As has been observed with rucaparib and 
other PARP inhibitors, myelosuppression may be delayed and observed after a period of 
continuous dosing.  Grade 3/4 adverse events assessed as treatment-related and occurring in >5% 
of patients include: anemia/decreased hemoglobin and increased ALT. All treatment-related 
adverse events have been successfully managed with concomitant medications, and treatment 
interruption and/or dose reduction.  No patient has discontinued rucaparib treatment due to a 
treatment-related adverse event.  A total of five patients have died on study or within 30 days of 
last dose of rucaparib; all deaths were due to disease progression and were assessed as not related 
to rucaparib. 
Extensive centrally-reviewed electrocardiogram (ECG) monitoring was conducted in the Phase 1 
portion of study CO-338-010.  ECG results (as triplicate reads) are available for all 56 treated 
patients.  No patient had a QTcF measurement ≥500 msec at any time during study participation.  
Only one patient had a QTcF measurement ≥480 msec.  This measurement occurred in a patient 
receiving 480 mg BID rucaparib and concomitant administration of citalopram, a medication 
with known potential to cause QT prolongation.  This patient has continued to receive 
monotherapy rucaparib at a dose of 480 mg BID with no further QTcF measurement ≥480 msec.  
No patient experienced a ≥60 msec increase in QTcF over baseline.  A total of 11 patients 
experienced a QTcF increase ≥30 msec over baseline.  Further analyses suggest a lack of 
relationship between QTcF increase ≥30 msec and dose or exposure.  In addition, there were no 
adverse events suggestive of cardiac arrhythmia (e.g., presyncope, syncope, sudden death) in any 
patient.  ECG and adverse event data to date in patients receiving monotherapy rucaparib at 
doses up to 840 mg BID suggest there is a minimal risk of QTc prolongation. 
Efficacy 
In the Phase 1 portion, 2 patients (breast cancer and ovarian cancer, both gBRCAmut) achieved a 
RECIST CRs and 7 patients (3 ovarian cancer, 4 breast cancer, 1 pancreatic cancer; all 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 36 of 133 
Confidential 
gBRCAmut) achieved a RECIST PR during the dose escalation phase (n=2 at 300 mg QD; n=2 at 
360 mg BID; n=3 at 480 mg BID; and n=2 at 600 mg BID).  Responses were durable across 
tumor types.  In addition, 3 patients with ovarian cancer achieved a cancer antigen 125 (CA-125) 
response as defined by Gynecologic Cancer InterGroup (GCIG) criteria.  The disease control rate 
(CR, PR, or SD>12 weeks) in evaluable ovarian cancer patients treated at doses ≥360 mg BID 
was 92% (11/12).  Responses were observed in platinum-resistant as well as platinum-sensitive 
ovarian cancer patients.  In platinum-resistant ovarian cancer patients treated with ≥360 mg BID 
rucaparib, 50% (4/8) achieved either a RECIST (25%, 2/8) or GCIG CA-125 response (25%, 
2/8).  The disease control rate (CR, PR, or SD>24 weeks) in this group was 75% (6/8) and 
median time on treatment was approximately 9 months (range 1.5-14.5). 
In the Phase 2 portion of Study CO-338-010 (Part 2A) in ovarian cancer patients, compelling 
activity has been observed in patients who had received 2-4 prior chemotherapy regimens and a 
deleterious BRCA mutation, with 15 of 20 (75%) achieving a RECIST PR and 17 of 20 (85%) 
achieving a RECIST PR and/or a GCIG CA-125 response.  The vast majority of patients had 
some level of target lesion measurement reduction as shown in Figure 1.  
Figure 1 
Best Target Lesion Response – Study CO-338-010 Phase 2 (Part 2) 
Best Response in % Change From Baseline Longest Sum of Diameters 
Study CO-338-010 
Phase 2 Patients (Rucaparib 600 mg BID) 
 
 
The efficacy of rucaparib in ovarian cancer patients with a deleterious BRCA mutation (germline 
or somatic) who received ≥3 prior chemotherapy regimens and were treated with 600 mg BID 
rucaparib in Studies CO-338-017 (ARIEL2) and Part 2A of CO-338-010 has been evaluated.  In 
this group, which included both patients with platinum-sensitive and platinum-resistant disease, 
ORRs of 47% (RECIST) and 73% (RECIST & GCIG CA-125) have been observed, suggesting 
that rucaparib may be a suitable treatment alternative in this patient population with advanced 
disease and limited treatment options. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 37 of 133 
Confidential 
Pharmacokinetics 
After once daily oral administration of rucaparib for 15 days, steady state Cmax and AUC0-24 
generally increased dose proportionally.  Tmax and t1/2 were independent of dose.  Steady state 
exposure increased by an average of 89%, consistent with accumulation expected for a 
compound exhibiting a t1/2 of approximately 17 hours administered once daily.  Following BID 
oral administration of rucaparib for 15 days, steady state Cmax and AUC0-24 generally increased 
dose proportionally.  Moreover, BID dosing delivered a lower Cmax with a low peak to trough 
plasma concentration variation.  The target trough level of 2 µM was achieved in 100% of 
patients (n=23) at ≥240 mg BID with low inter-patient variability (≤5-fold) within each dose 
group.  Steady state trough levels also exhibited low intra-patient variability (24% CV). No 
sporadically high exposures were observed.  The effect of food on rucaparib PK was evaluated at 
40 mg (n=3) and 300 mg (n=6) doses administered once daily.  There was no food effect; 
patients may take rucaparib on an empty stomach or with food. 
3.2.2.2 Recommended Phase II Dose (RP2D) of Rucaparib Monotherapy 
The dose of 600 mg BID rucaparib was selected as the recommended dose for Part 2 and Part 3 
of this study based on the overall safety & tolerability, PK, and clinical activity profile observed 
in the dose-escalation phase of this trial. There was one DLT at 360 mg BID and none at higher 
dose levels; however, similar to other PARP inhibitors, non-DLT myelosuppression was 
observed beyond Cycle 1. In addition, a rucaparib exposure plateau was observed at total daily 
doses ≥960 mg (480 mg BID). This is well above the dose (300 mg QD) at which activity was 
first observed and the modeled activity threshold based on clinical activity of other PARP 
inhibitors and rucaparib trough levels. Taken in total, these data support the selection of 600 mg 
BID as the RP2D for the Phase II portion of this study. 
Study A4991002, Study A4991014 and Study A4991005 
Further details of these Phase I (Study A4991002 and Study A4991014) and Phase II (Study 
A4991005) studies are provided in the Investigator’s Brochure. 
3.2.2.3 Absorption, Distribution, Metabolism, and Elimination 
PK data are available for a total of 136 patients:  23 from Study A4991002 (30 min intravenous 
infusion), 62 from Study A4991014 (32 with 30 min intravenous infusion and oral dosing; 30 
with oral dosing only), and 51 from Study CO-338-010 (oral dosing).  Results indicate that the 
free base of rucaparib, after a 30 min intravenous infusion of rucaparib alone, declined in a 
multi-exponential manner with a mean (CV %) terminal half-life of about 13.5 h (58).  The mean 
(CV %) total plasma clearance was 18.7 L/hours (48), which is approximately 25% of hepatic 
blood flow.  The mean (CV %) Vdss was 276 L (64), indicating distribution into tissues.  The 
area under the curve (AUC) and Cmax of rucaparib increased proportionally with the intravenous 
dose, indicating linear PKs over the dose range up to 40 mg.  Approximately 50% accumulation 
of rucaparib was observed after 4 days of multiple intravenous dosing. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 38 of 133 
Confidential 
Following administration of a single intravenous dose of rucaparib alone, mean (CV %) 24 h 
urine recovery of rucaparib was 10.5% (41), indicating that renal elimination is not the major 
elimination pathway of rucaparib.    
After single oral administration, rucaparib was rapidly absorbed with Cmax generally achieved 
within 2.5 - 4 h.  Following attainment of Cmax, plasma concentrations of orally administered 
rucaparib declined in a multiple exponential manner.  Dose-proportional increase in Cmax and 
AUC0-24 was generally observed at doses up to 600 mg BID.  Apparent terminal half-life after 
the oral rucaparib dose was similar to that after intravenous administration.  The mean absolute 
bioavailability of the rucaparib immediate release tablet was estimated to be 36%.    
Results of genotyping data indicate that the exposure measured by the AUC from time zero to 
24 h (AUC0-24) were similar between extensive and poor metabolizers of both CYP2D6 and 
CYP3A5 enzymes.  These CYPs were chosen for analysis because CYP2D6 shows genetic 
polymorphisms, and CYP3A5 appears to be an important genetic contributor to interindividual 
and interracial differences in CYP3A-dependent drug metabolism. 
3.3 
Rationale for Study  
Over the past decade there has been little improvement in the cure rate of ovarian cancer.  The 
combination of carboplatin and paclitaxel is an effective standard first-line therapy with 
responses observed in the vast majority of patients but unfortunately most patients will 
eventually relapse.  Although initial recurrences are also still frequently platinum-sensitive (i.e. 
disease relapse occurs >6 months after the last dose of platinum), most patients will eventually 
develop resistance to platinum-based chemotherapy, thus there remains a significant need for 
additional treatment options.   
Recent studies have shown that PARP inhibitors provide meaningful clinical benefit for relapsed 
ovarian cancer patients who are known to harbor a BRCA mutation and that the benefit is 
enhanced in the platinum sensitive group.13, 25, 26  Rucaparib is a potent small molecule inhibitor 
of PARP1 and PARP2 being studied in cancer indications, such as ovarian, that are associated 
with a defect in homologous recombination DNA repair.   
The first objective in this study was to determine the optimal monotherapy dose and schedule for 
orally administered rucaparib.  As described in Section 3.2.2, 600 mg BID has been selected as 
the rucaparib RP2D based on overall safety & tolerability, PK, and the clinical activity profile.  
Responses have been observed in patients with ovarian, breast and pancreatic patients harboring 
a BRCA mutation.  The data generated with rucaparib and other PARP inhibitors, suggest that 
platinum-sensitive ovarian cancer patients who harbor a BRCA mutation may benefit from 
treatment with a well-tolerated PARP inhibitor, such as rucaparib.   
The Phase II portion (Part 2A) established robust efficacy of the RP2D of rucaparib (600 mg 
BID) in this patient population: the criteria for Stage 1 success were met in April 2014, and 
Stage 2 enrollment of 41 patients was completed in April 2015. In this initial cohort the median 
number of prior treatments was 2 [range 2-4]. Cohort 2B will characterize the signal in a later 
line sub-population, where unmet need is greatest. Other than the requirement for 3-4 previous 
treatment lines, the demographic and baseline characteristics of cohorts 2A and 2B are similar. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 39 of 133 
Confidential 
Therefore, overall, part 2 of the study will provide a comprehensive evaluation of the efficacy of 
rucaparib in advanced ovarian cancer patients with a germline and/or tissue, deleterious BRCA 
mutation. The Phase II PK portion (Part 3) will evaluate the PK profile of 300 mg dose strength 
tablets in the fed versus fasted state, in an exploratory food effect assessment and at steady state 
and also assess the safety and tolerability, and anti-tumor activity of the higher dose strength 
tablets. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 40 of 133 
Confidential 
4 
STUDY OBJECTIVES 
4.1 
Objectives and Endpoints 
This is a three-part, open-label, safety, PK, and preliminary efficacy study of oral rucaparib 
administered once, twice, or three times a day for continuous 21-day cycles: 
• Part 1 is the Phase I portion in patients with locally advanced or metastatic solid tumors, 
including lymphoma, who have progressed on standard therapy. Patients enrolled into the 
Part 1 RP2D Expansion must also have a documented deleterious gBRCA mutation. 
• Part 2A is a Phase II portion in patients with platinum-sensitive, relapsed, high-grade 
serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
associated with a gBRCA mutation.  
• Part 2B is a Phase II portion in patients with relapsed, high-grade epithelial ovarian, 
fallopian tube, or primary peritoneal cancer, with evidence of a deleterious BRCA 
mutation (germline or somatic). 
• Part 3 is a Phase II PK portion to evaluate higher dose strength tablets in patients with any 
advanced solid tumor, inclusive of lymphoma, with evidence of a BRCA mutation 
(germline or somatic). 
Primary and secondary objectives and endpoints are shown in Table 1; exploratory objectives 
and endpoints are shown in Table 2.  
Table 1. 
Primary and Secondary Objectives and Endpoints 
Primary Objectives 
Primary Endpoints 
1. To evaluate the safety profile of escalating 
doses of continuous daily oral rucaparib in 
patients with advanced solid tumors, and to 
determine the MTD and RP2D (Part 1 only) 
1. The incidence of Grade 3 or 4 AEs and clinical 
laboratory abnormalities defined as DLTs  
2. To characterize the PK profile of oral 
rucaparib when administered as a continuous 
daily dose (Part 1 and Part 3 only) 
2. PK parameters:  area under the curve from time 
zero to the time with the last measurable 
concentration (AUC0-t), AUC from time zero to 
infinity (AUC0-∞), Cmax, time to maximum 
concentration (Tmax), elimination half-life (t1/2), 
elimination rate constant (kel), apparent volume of 
distribution at steady state after non-iv 
administration (Vss/F), and apparent total plasma 
clearance (Cl/F) 
3. To evaluate ORR in patients with relapsed, 
high-grade serous or endometrioid epithelial 
ovarian, fallopian tube, or primary peritoneal 
cancer associated with a BRCA mutation  
(Part 2 only) [henceforth abbreviated to 
ovarian cancer (OC) population]  
3. ORR per Response Evaluation Criteria in Solid 
Tumors (RECIST) Version 1.1; secondary 
analysis including GCIGCA-125 criteria 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 41 of 133 
Confidential 
Table 1. 
Primary and Secondary Objectives and Endpoints 
Secondary Objectives 
Secondary Endpoints 
1. To characterize the single-dose PK profile of 
oral rucaparib after a high-fat breakfast 
compared to that in the fasted state 
(Part 1 and Part 3 only) 
1. PK parameters Cmax and AUC (fasted and fed) 
2. To evaluate the effects of oral rucaparib on 
the QT/QTc interval measured by ECG 
(Part 1 only) 
2. Change from baseline in QT/QTc interval 
3. To evaluate the safety and tolerability of oral 
rucaparib (Parts 1, 2, and 3) 
3. The incidence of AEs, clinical laboratory 
abnormalities, and ECG abnormalities 
4. To evaluate duration of response in the OC 
population (Part 2 only) 
4. Duration of response per RECIST v1.1.   
5. To evaluate antitumor activity of oral 
rucaparib in various solid tumors (Part 1 and 
Part 3 only) 
5. Response per RECIST v1.1; additional analyses 
including applicable tumor markers 
6. To assess progression-free survival (PFS) in 
the OC population (Part 2 only) 
6. PFS defined as the time to first occurrence of 
disease progression per RECIST v1.1 or death 
7. To evaluate survival (Part 2B only) 
7. Overall survival (OS) 
 
Table 2. 
Exploratory Objectives and Endpoints 
Exploratory Objectives 
Exploratory Endpoints 
1. To explore the relationship between the PK of 
oral rucaparib and the potential changes in 
QT/QTc interval (Part 1 only) 
1. QT/QTc interval correlated with plasma 
concentrations of oral rucaparib  
2. To profile circulating metabolites of oral 
rucaparib at steady state at the RP2D 
(Part 1 only) 
2. Metabolic profile in the Day 15 plasma samples  
3. To explore the association between genomic 
alterations identified in tumor tissue and 
clinical outcome (Part 1, 2, and 3) 
3. Mutational status of BRCA1/2 and other 
homologous recombination genes. Genomic 
scarring/ loss of heterozygosity (LOH) 
assessment in tumor tissue and response by 
RECIST v1.1 and/or tumor markers (ie, CA-125) 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 42 of 133 
Confidential 
5 
STUDY DESIGN 
5.1 
Overall Study Design and Plan 
This is a 3-part, open-label, safety, PK, and preliminary efficacy study of oral rucaparib 
administered once, twice, or three times a day for continuous 21-day cycles.  Part 1 is a Phase I 
portion in patients with any solid tumor, including lymphoma, who have progressed on standard 
treatment.  Part 2A is a Phase II portion in patients with platinum-sensitive, relapsed, high-grade 
serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer associated 
with a gBRCA mutation who have progressed after at least two, but no more than four, prior 
regimens.  Part 2B is a Phase II portion in patients with relapsed, high-grade epithelial ovarian, 
fallopian tube, or primary peritoneal cancer, with evidence of a deleterious BRCA mutation 
(germline or somatic) who have received at least three, but no more than four, prior 
chemotherapy regimens.  Part 3 is a Phase II PK portion to evaluate higher dose strength tablets 
in patients with any advanced solid tumor, inclusive of lymphoma, with evidence of a BRCA 
mutation (germline or somatic). Patients will enroll into either Part 1, Part 2, or Part 3 of the 
study, not in to multiple parts.   
5.1.1 
Screening Period 
All patients will undergo screening assessments within 30 days prior to the first dose of oral 
rucaparib.  Study-procedure-related AEs that occur after signing of the informed consent form 
and before administration of the first oral rucaparib dose will also be collected during this period. 
5.1.2 
Part 1 (Phase I Portion) 
In Part 1 of the study, there will be an estimated six to twelve dose-escalation cohorts, with a 
minimum of three patients enrolled in each cohort, and an expanded evaluation of the RP2D in 
up to 15 patients.  Treatment cycles will comprise 21 days of continuous dosing.   
The MTD is defined as the maximum daily oral dose at which <33% of patients experience a 
DLT during Cycle 1 (Safety and PK Assessment Period).  If a DLT is observed in one of three 
patients, then three additional patients will be enrolled at that same dose level.  Dose escalation 
will continue until at least two of the three to six patients treated at a dose level experience a 
DLT.  The next lower dose will then be considered the MTD.  Alternatively, if the dose between 
the MTD and the maximally delivered dose is significant (such as 100%), then a more modestly 
de-escalated dose may be explored (e.g., 20 to 50%). 
The three patients initially enrolled at each dose level will be used for dose escalation decisions.  
Up to three additional patients may be enrolled at any previously evaluated dose level in order to 
further characterize inter-patient PK variability.  Evaluation of the next dose level and expanded 
evaluation of the previously evaluated dose may occur simultaneously; however, enrollment into 
these cohorts will be sequential.  The first three eligible patients will be enrolled into the dose 
escalation cohort.  Once the dose escalation cohort has been filled, up to three additional patients 
may be enrolled at a previously evaluated dose level if additional PK assessment is warranted. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 43 of 133 
Confidential 
Prior to initiating each new dose level or expanding an existing dose level, a safety 
teleconference will be held wherein investigators and the sponsor’s medical monitor will review 
patient data, including but not limited to demographics, PK results, oral rucaparib dosing, 
concomitant medications, hematology and serum chemistry, and AEs, and then confer and 
document agreement that dose escalation and/or expanding an existing dose level is/are 
considered appropriately safe. 
RP2D Selection and Expansion 
The RP2D for evaluation in Part 2 (Phase II portion) will be selected based on overall safety and 
tolerability, PK, and estimates of efficacious exposures extrapolated from nonclinical data.  The 
RP2D may or may not be the same as the MTD identified in Part 1.  For example, if the MTD is 
not reached, if exposure at the MTD is much higher than the level believed to be required for 
efficacy, or if subsequent cycles of treatment provide additional insight on the safety profile, then 
the RP2D may be a different, although not higher, dose than the MTD. 
Once the RP2D has been provisionally established, up to 15 additional patients with a solid 
tumor and a deleterious gBRCA mutation will be enrolled and treated at that dose in order to 
further characterize safety, tolerability, and PK, and confirm that this is the optimal dose to 
evaluate in Part 2.  Since the RP2D may have been selected based on evaluation of as few as 3 
patients, there is low certainty that the RP2D has a toxicity rate that is <33%.  Enrolling up to an 
additional 15 patients will increase the certainty that the Phase II component of the study is 
evaluated at a dose with a DLT rate <33%.  If ≥33% of patients at the RP2D experience a DLT, 
then enrollment into the RP2D Expansion cohort will stop and a lower dose will be explored. 
The dose of 600 mg BID rucaparib has been selected as the recommended dose for Phase II and 
Phase III studies based on the overall safety & tolerability, PK, and clinical activity profile. The 
MTD was not reached in Part 1 (See Section 3.2.2). 
Food-Effect PK Evaluation 
The effect of food on oral rucaparib PK will be assessed prior to, and during, Cycle 1 in three 
patients.  Food effect PK analysis will be performed once evaluation of Cohort 1 (40 mg) is 
completed, and will be conducted either at the next escalated dose, or as expanded PK evaluation 
of the 40 mg dose level.  The dose level for evaluation will be established at the safety 
teleconference call for Cohort 1.  Food-effect PK may be conducted in additional cohorts in 
Part 1 if results from prior cohort(s) warrant expanded evaluation.   
Effect on QTc 
ECGs will be collected in all patients enrolled in Part 1, including those in the RP2D Expansion 
cohort, in order to assess the effect of oral rucaparib on QTc.  ECGs in Part 1 will be performed 
on equipment provided by the sponsor (or designee) and reviewed by site personnel and a 
core/central laboratory.  The Sponsor will allow local ECG testing once sufficient centrally 
obtained data has been collected. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 44 of 133 
Confidential 
Metabolite Profiling 
The first three patients enrolled into the RP2D Expansion cohort will have additional blood 
samples collected on Day 1 (predose sample only) and Day 15 of Cycle 1 for assessment of 
plasma metabolites. 
Tumor Mutation Status 
Optional formalin-fixed paraffin-embedded (FFPE) archival and/or fresh tumor tissue samples 
collected at screening, and at disease progression/treatment discontinuation in Part 1 will be 
analyzed for changes in mutation status. 
Treatment-Extension Period 
Upon completion of Cycle 1 (Safety and PK Assessment Period), Part 1 patients may participate 
in an optional Treatment-Extension Period, which begins on Day 1 of Cycle 2.  Oral rucaparib 
will be administered daily during this period (21 day cycles) until disease progression, 
unacceptable toxicity, patient or physician request to discontinue, death, or termination of the 
study. 
5.1.3 
Part 2 (Phase II Portion in Patients with BRCA-Mutant Ovarian Cancer) 
Enrollment into Part 2 (Phase II portion) will begin when all patients enrolled into the RP2D 
Expansion cohort have completed two cycles of treatment, or have discontinued from the study 
prior to completing two cycles of treatment. 
Patients enrolled into Part 2 will be assessed for tolerability and efficacy.  Patients will be treated 
until disease progression, unacceptable toxicity, patient or physician request to discontinue, 
death, or termination of the study.   
The Part 2A study will use a Simon 2-stage design to evaluate the efficacy of rucaparib.  Initially 
21 patients will be treated in Stage 1; if two or more patients in Stage 1 have an objective 
response (complete response [CR] or partial response [PR]) then the remaining 20 patients will 
be treated in Stage 2.  If fewer than two patients in Stage 1 have an objective response, then no 
further patients will be enrolled. 
The criteria for Stage 1 success were met in April 2014, and Stage 2 enrollment of 41 patients 
was completed in April 2015. 
An additional cohort of 40 BRCA mutant OC patients will be evaluated in Part 2B.  Enrollment 
of this portion of the study will begin after enrollment of Part 2A has been completed.  Part 2B 
will run concurrently with Part 3. 
5.1.4 
Part 3 (Phase II PK Portion in Patients with any Advanced Solid Tumor) 
Part 3 will enroll in parallel with Part 2. Part 3 is an initial randomized, single dose, two 
treatment, two period, crossover design, to explore food effect; with subsequent continuous BID 
dosing. It is estimated that enrolling approximately 20 evaluable patients will provide sufficient 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 45 of 133 
Confidential 
data for PK analysis. A randomization scheme using blocks of four will assign patients to either 
a sequence of fasted at Day -7 and fed at Day 1 or a sequence with fed at Day -7 and fasted at 
Day 1.   
After Day 1 patients will continue with BID continuous dosing and will also be assessed for 
safety and tolerability. Additional detailed PK to assess steady state will be done at Day 15 of 
Cycle 1.  Patients will be treated until disease progression, unacceptable toxicity, patient or 
physician request to discontinue, death, or termination of the study. 
Food-Effect PK Evaluation 
All patients enrolled into Part 3 will have plasma samples drawn in order to evaluate the PK 
profile of a single dose of 600 mg administered as 300 mg tablets in the fed versus fasted state. 
5.1.5 
End-of-Treatment and Follow-Up (Part 1, Part 2, and Part 3) 
All patients should return to the clinic for end-of-treatment assessments upon discontinuation of 
rucaparib and for follow-up of AEs at 28 (±3) days after the last dose of oral rucaparib has been 
administered.  During Parts 1 to 3, AEs will be assessed from the time of informed consent 
through 28 days after the last dose.  Part 2B patients will be followed for survival, subsequent 
treatments, and secondary malignancy monitoring every 12 weeks [±7 days]. 
5.1.6 
End of Study 
The trial will be completed when all enrolled patients have experienced PD, or have discontinued 
the study due to another reason. 
5.2 
Study Schema 
The study schema in Figure 2, Figure 3, and Figure 4 summarize the treatment designs for Part 1, 
Part 2, and Part 3 of the study. 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 46 of 133 
Confidential 
Figure 2. 
Study Schema Part 1 
 
a 
The Dose-Escalation Evaluation Period comprises one cycle of treatment (21 day cycle) within each cohort, with the exception of the RP2D Expansion cohort (anticipated to 
receive at least two cycles of treatment). 
b 
The food-effect PK evaluation will be conducted in three patients (see Table 10 and Table 12) at a dose level to be determined once the Cohort 1 evaluation is completed. 
c 
Once RP2D is established, up to 15 additional patients will be treated at the RP2D and undergo further PK and QT evaluations; in addition, 3 of these patients will have 
additional blood collection for metabolite profiling (see Table 9 and Table 12). 
d 
After completing Cycle 1, patients may enter an optional Treatment-Extension Period.  
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 47 of 133 
Confidential 
Figure 3. 
Study Schema Part 2 
EOT 
Evaluation
 After last 
dose of 
rucaparib
Screening 
Assessments
Within 30 days 
of first dose of 
rucaparib
Part 2:  Phase II Portion
Screening Period
(Day -30 to Day -1)
End of Study (EOS)
Tumor Scans
Prior to start of 
Cycles 3, 5, 7 
and every 3rd 
cycle 
thereafter (i.e., 
Cycle 10, 13, 
etc.)
Follow-up 
Evaluation 
 
(28 ± 3 
days after 
last dose of 
rucaparib)  
Oral Rucaparib: RP2D (600 mg BID)
Disease Progression, Unacceptable Toxicity, or Other Reason for 
discontinuation of Rucaparib
D
A
Y 
1
D
A
Y 
1
Cycle 1a
(21-day cycle)
Cycle 2 and subsequent cycles
(21-day cycles)
D
A
Y 
15
LTFUb
 Every 
12wks ± 7 
days
and every 
16wks ± 14 
days (after 
18Mo)
 
a 
At Cycle 1 only, patients will undergo assessments on Days 1 and 15. 
b 
Part 2B only 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 48 of 133 
Confidential 
Figure 4. 
Study Schema Part 3 
EOT Visit
 After last 
dose of 
rucaparib
Screening 
Assessments
Within 30 days 
of first dose of 
rucaparib
Part 3:  Phase II PK Portion in Solid Tumors
Screening Period
(Day -37 to Day -7)
Post-Treatment Phase
Tumor Scans
Prior to start of 
Cycles 3, 5, 7 
and every 3rd 
cycle 
thereafter (i.e., 
Cycle 10, 13, 
etc.)
Follow-up 
Evaluation 
 
(28 ± 3 days 
after last 
dose of 
rucaparib)  
Repeat Dose Oral Rucaparib: RP2D (600 mg BID)
Disease Progression, Unacceptable Toxicity, or Other Reason for 
discontinuation of Rucaparib
D
A
Y 
1
D
A
Y 
1
PK Evaluationa
Cycle 2 and subsequent cycles
(21-day cycles)
D
A
Y 
15
Cycle 1b
(21-day cycle)
Single Dose Oral 
Rucaparib
Day -7 & Day 1
 
a 
The food-effect PK evaluation will be conducted in approximately 20 patients (see Table 13 and Table 14). 
b 
At Cycle 1 only, patients will undergo assessments on Days 1 and 15. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 49 of 133 
Confidential 
6 
STUDY POPULATION 
6.1 
Number of Patients and Sites 
In Part 1 (Phase I portion), approximately 50 – 60 patients with locally advanced or metastatic 
solid tumors, inclusive of lymphoma, who have progressed on standard treatment will be 
enrolled at up to six study sites.  Patients enrolled into the RP2D Expansion Cohort must also 
have a documented deleterious gBRCA mutation. 
In Part 2A (Phase II portion), up to a total of 41 evaluable patients with platinum-sensitive, 
relapsed, high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary 
peritoneal cancer associated with a gBRCA mutation, will be enrolled from approximately 
20 study sites. 
In Part 2B (Phase II portion), up to a total of 40 evaluable patients with relapsed, high-grade 
epithelial ovarian, fallopian tube, or primary peritoneal cancer with evidence of a deleterious 
BRCA mutation (germline or somatic), will be enrolled from approximately 20 study sites. 
In Part 3 (Phase II portion), approximately 20 evaluable patients with any advanced solid tumor, 
inclusive of lymphoma, with evidence of a BRCA mutation (germline or somatic), will be 
enrolled from approximately 8 study sites. Evaluable patients are defined as patients who have 
complete PK analysis data in both periods for the initial randomized cross-over design exploring 
the food effect during assessment Day -7 and Day 1. 
6.2 
Inclusion Criteria 
All patients enrolling into Part 1 (Phase I portion), Part 2 or Part 3 (Phase II portions) must 
meet all of the following inclusion criteria: 
1. Understand and voluntarily sign an Institutional Review Board/Independent Ethics 
Committee-approved informed consent form prior to any study-specific evaluation 
2. Be ≥18 years of age at the time the informed consent form is signed 
3. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 
4. Have a life expectancy of at least 3 months 
5. Have adequate organ function, confirmed by the following laboratory values obtained 
≤14 days prior to the first dose of rucaparib: 
 
Bone Marrow Function 
− Absolute neutrophil count (ANC) ≥1.5 × 109/L 
− Platelets >100 × 109/L  
− Hemoglobin ≥9 g/dL 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 50 of 133 
Confidential 
 
Hepatic Function 
− Aspartate aminotransferase (AST) and ALT ≤3 × upper limit of normal (ULN); if 
liver metastases, then ≤5 × ULN  
− Bilirubin ≤1.5 × ULN (<2 × ULN if hyperbilirubinemia is due to Gilbert’s syndrome) 
− Serum albumin ≥30 g/L (3.0 g/dL) (Part 2B only) 
 
Renal Function  
− Serum creatinine ≤1.5 × ULN 
Patients enrolling into Part 1 (Phase I portion) must also meet the following inclusion criteria: 
6. (a) Have a histologically or cytologically confirmed solid tumor (lymphoma is included in 
this category) that is locally recurrent or metastatic and has progressed on standard treatment. 
7. (a) Have left ventricular ejection fraction (LVEF) > lower level of normal (LLN) as 
determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan evaluation 
using local institutional standard   
8. (a) Be willing and able to eat a high-fat breakfast on Day 1 of the study (Note: only 
applicable for patients being screened for enrollment into a food-effect PK cohort) 
9. (a) Have a deleterious gBRCA mutation (Note: only applicable for patients being screened 
for enrollment into the RP2D Expansion cohort) 
All patients enrolling into Part 2 (Phase II portion in OC patients) must also meet the 
following inclusion criteria:  
6. (d) Have a known deleterious BRCA mutation (germline or somatic), as determined by a 
local laboratory that has received an international or country-specific quality standards 
certification  
7. (d) Have evidence of measurable disease as defined by RECIST v1.1 
8. (d) Have sufficient archival FFPE tumor tissue available for planned analyses; cytospin 
blocks from ascites are not acceptable 
• Archival tissue from the most recently collected biopsy or debulking surgery should be 
provided, if available.  Otherwise, the next oldest tissue collected should be reviewed 
until a suitable sample can be provided (at least 20% tumor content with a minimum of 
80% nucleated cellular content) 
Additional inclusion criteria for patients into Part 2A (Phase II portion in OC) include: 
9. (b) Have a histologically confirmed diagnosis of high-grade serous or endometrioid epithelial 
ovarian, fallopian tube, or primary peritoneal cancer 
• For mixed histology, >50% of the primary tumor must be confirmed to be high-grade 
serous or endometrioid upon re-review by local pathology 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 51 of 133 
Confidential 
10. (b) Have received at least two, but no more than four, prior chemotherapy regimens and have 
relapsed as confirmed by radiologic assessment 
a. Last treatment received must have been platinum-based regimen to which patient 
must have been sensitive (i.e., disease progression occurred at least 6 months after 
last dose of platinum was administered) 
b. A maximum of one non-platinum regimen may have been administered.  For patients 
who received four prior regimens, one regimen must have been a non-platinum 
c. Prior continuous or switch maintenance treatment is permitted (hormonal treatment 
may be permitted following the last platinum regimen with advance approval from 
the sponsor) 
Additional inclusion criteria for patients into Part 2B (Phase II portion in OC) include: 
9. (d) Have a histologically confirmed diagnosis of high-grade epithelial ovarian, fallopian tube, 
or primary peritoneal cancer. 
10. (d)Have received at least three, but no more than four, prior chemotherapy regimens and 
have relapsed disease confirmed by radiologic assessment 
• Hormonal agents (e.g., tamoxifen, letrozole, etc), anti-angiogenic agents (e.g., 
bevacizumab, pazopanib, cediranib, nintedanib, trebananib, etc), and other non-
chemotherapy agents administered as single agent treatment will not be counted as a 
chemotherapy regimen for the purpose of determining patient eligibility 
• Agents administered in the maintenance setting will not be counted as a separate regimen 
11. (d) Have a documented treatment-free interval (TFI) of ≥6 months following the first 
chemotherapy regimen received.  (TFI is determined from the last dose administered as part 
of primary treatment regimen and not from the last dose of any agent administered in the 
maintenance setting) 
Patients enrolling into Part 3 (Phase II PK portion in patients with any advanced solid 
tumor) must also meet the following inclusion criteria: 
6. (c) Have an advanced solid tumor (inclusive of lymphoma)  
7. (c) Have a known deleterious BRCA mutation (gBRCA or somatic BRCA [sBRCA]), as 
determined by a local laboratory that has received an international or country-specific, 
quality standards certification 
8. (c) Have evidence of measurable disease as defined by RECIST Version 1.1 
9. (c) Be willing and able to fast, and to eat a high-fat breakfast on Day -7 or Day 1 of the study 
10. (c) Have sufficient archival FFPE tumor tissue available for planned analyses; cytospin 
blocks from ascites are not acceptable 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 52 of 133 
Confidential 
• Archival tissue from the most recently collected biopsy or debulking surgery should be 
provided, if available.  Otherwise, the next oldest tissue collected should be reviewed 
until a suitable sample can be provided (at least 20% tumor content with a minimum of 
80% nucleated cellular content) 
6.3 
Exclusion Criteria 
Patients enrolling into Part 1 (Phase I portion), Part 2 or Part 3 (Phase II portions) will be 
excluded from participation if any of the following criteria apply: 
1. Active second malignancy, i.e., patient known to have potentially fatal cancer present for 
which she/he may be (but not necessarily) currently receiving treatment   
• Patients with a history of malignancy that has been completely treated, with no evidence 
of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was 
completed >6 months prior and/or any bone marrow transplant (BMT) >2 years prior to 
first dose of rucaparib 
2. Prior treatment with any PARP inhibitor (Part 1 and Part 2).  Part 3 patients are permitted to 
have had previous PARPi, if the following conditions are met: 
• PARPi was not the most recent treatment, and  
• PARPi was discontinued >6 months before first planned dose of rucaparib 
• In all study parts, patients who previously received iniparib are eligible 
3. Untreated or symptomatic central nervous system (CNS) metastases.  Patients with 
asymptomatic CNS metastases are eligible provided they have been clinically stable for at 
least 4 weeks 
4. (Criterion removed in Amend 5). 
5. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome 
(AIDS)-related illness, or history of chronic hepatitis B or C 
6. Received treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, 
gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs ≤14 days prior 
to first dose of rucaparib and/or ongoing adverse effects from such treatment > National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 
(ongoing Grade 2 non-hematologic toxicity related to most recent treatment regimen may be 
permitted with prior advanced approval from Sponsor) 
7. Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the 
opinion of the investigator, interfere with absorption of rucaparib 
8. Administration of strong CYP1A2 or CYP3A4 inhibitors ≤7 days prior to first scheduled 
dose of rucaparib 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 53 of 133 
Confidential 
9. Non-study related minor surgical procedure ≤5 days, or major surgical procedure ≤21 days, 
prior to first dose of rucaparib; in all cases, the patient must be sufficiently recovered and 
stable before treatment administration 
10. Females who are pregnant or breastfeeding 
11. For fertile patients (female able to become pregnant or male able to father a child), refusal to 
use effective contraception during the period of the trial and for 6 months after the last dose 
of oral rucaparib 
12. Presence of any serious or unstable concomitant systemic disorder incompatible with the 
clinical study (e.g., substance abuse; psychiatric disturbance; or uncontrolled intercurrent 
illness including active infection, arterial thrombosis, and symptomatic pulmonary 
embolism) 
13. Presence of any other condition that may increase the risk associated with study participation 
or may interfere with the interpretation of study results and, in the opinion of the investigator, 
would make the patient inappropriate for entry into the study 
14. (Criterion removed in Amend 5). 
Patients enrolling into Part 1 (Phase I portion) of the study will also be excluded from 
participation if any of the following criteria apply: 
15. Family history of long QT syndrome 
16. Implantable pacemaker or implantable cardioverter defibrillator, and 
17. Requires treatment with any medication known to produce QT prolongation, with the 
exception of necessary antiemetic medications (see Appendix C) 
Patients enrolling into Part 2B (Phase II OC portion) will also be excluded from participation 
if any of the following criteria apply: 
18. Hospitalization for bowel obstruction within 3 months prior to enrollment 
6.4 
Patients or Partners of Patients of Reproductive Potential 
Pregnancy is an exclusion criterion and women of childbearing potential must not be considering 
getting pregnant during the study.  Female patients are considered to be of childbearing potential 
unless 1 of the following applies: 
• Is postmenopausal, defined as no menses for 12 months without an alternative medical 
cause.  A high follicle-stimulating hormone (FSH) level consistently in the 
postmenopausal range (30 mIU/mL or higher) may be used to confirm a postmenopausal 
state in women not using hormonal contraception or hormonal replacement therapy; 
however, in the absence of 12 months of amenorrhea, a single FSH measurement is 
insufficient to confirm a postmenopausal state; or 
• Considered to be permanently sterile.  Permanent sterilization methods include 
hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 54 of 133 
Confidential 
Female patients of childbearing potential must have a negative serum pregnancy ≤ 3 days prior 
to administration of the first dose of oral rucaparib.  In addition, a serum pregnancy test must be 
performed ≤ 3 days prior to Day 1 of every cycle from Cycle 2 and beyond during the treatment 
phase.  A serum pregnancy test will be performed at the End-of-Treatment Visit.  Pregnancy 
testing will be conducted locally.   
Female patients of childbearing potential and male patients of reproductive potential must 
practice a highly effective method (failure rate < 1% per year) of contraception during treatment 
and for 6 months following the last dose of rucaparib.  Highly effective contraception includes: 
• 
Ongoing use of progesterone-only injectable or implantable contraceptives (e.g., 
Depo Provera, Implanon, Nexplanon); 
• 
Placement of an intrauterine device (IUD) or intrauterine system (IUS); 
• 
Bilateral tubal occlusion; 
• 
Male sterilization, with appropriate post-vasectomy documentation of absence of 
sperm in ejaculate; or 
• 
Sexual abstinence as defined as complete or true abstinence, acceptable only when it 
is the usual and preferred lifestyle of the patient; periodic abstinence (e.g., calendar, 
symptothermal, post-ovulation methods) is not acceptable. 
It is recommended that opposite sex partners of patients use a highly effective contraception 
method as specified above during and for 6 months following the patient’s treatment. 
Patients will be instructed to notify the investigator if pregnancy is discovered either during or 
within 6 months of completing treatment with rucaparib.   
6.5 
Waivers of Inclusion/Exclusion Criteria 
No waivers of these inclusion or exclusion criteria will be granted by the investigator and the 
sponsor or its designee for any patient enrolling into the study.   


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 55 of 133 
Confidential 
7 
DESCRIPTION OF STUDY TREATMENTS AND DOSE MODIFICATIONS 
7.1 
Description of Investigational Product 
Rucaparib camsylate (also known as CO-338; previously known as PF-01367338-BW) is an oral 
formulation with a molecular weight of 555.67 Daltons.  Rucaparib tablets for oral 
administration will be supplied to the study sites by the sponsor.  A brief description of the 
investigational product is provided below. 
Drug Name: 
Rucaparib camsylate (CO-338) 
INN: 
Rucaparib 
 
 
Formulation: 
Tablet; film coated; 40 mg – white, 60 mg – white, 120 mg – salmon, 200 
mg – blue, 300 mg – yellow  
How Supplied: 
40, 60, 120, 200 and/or 300 mg (as free base) strength in high-density 
polyethylene bottles or equivalent with child-resistant caps.  Patients may 
receive one or more strengths.  
Storage Conditions: 
15–30 °C 
 
Bottles containing rucaparib tablets will be labeled according to national regulations for 
investigational products. 
7.2 
Method of Assigning Patients to Treatment Groups 
All patients enrolled in the study will receive oral rucaparib. 
7.3 
Preparation and Administration of Protocol-Specified Treatment 
The investigator or designee will be responsible for distributing the appropriate strength(s) of 
oral rucaparib tablets to all patients.  Study sites should follow local guidelines for the handling 
of oral cytotoxic drugs. 
With the exception of Day -7 and Day 1 of the food effect PK portions of the study in Part 1 and 
Part 3, patients may take rucaparib on an empty stomach or with food.  Each dose should be 
taken with 8 oz (240 mL) of room temperature water.  Tablets should be swallowed whole.  
Patients on a BID dosing schedule should take rucaparib doses as close to 12 hours apart as 
possible.  In the event TID dosing is explored, patients on this schedule should take doses 
approximately 8 hours apart.  Administration conditions may be revised based on PK results 
obtained in Part 1 or Part 3. 
Part 1 (Phase I Portion) 
In each cohort, patients will ingest rucaparib once, twice, or three times a day through Day 21 of 
Cycle 1.  Patients who enter the optional Treatment-Extension Period will continue treatment 
with rucaparib starting on Day 1 of Cycle 2. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 56 of 133 
Confidential 
Part 2 and Part 3 (Phase II Portions) 
Patients enrolled in Part 2 or Part 3 will ingest oral rucaparib (21 day cycles) at 600 mg BID, as 
determined in Part 1. 
Part 2A patients will receive 120 mg tablets.  Following the assessment of higher dose strength 
tablets in Part 3, Part 2A patients may be transferred to 200/300 mg tablets if supply of 120 mg 
tablets is exhausted. Part 2B and Part 3 patients will receive 200/300 mg tablets only. 
Where applicable, changing from 120 mg to 200/300 mg strength tablets should be made 
according to Table 3 below: 
Table 3. 
Comparison of Dose Levels when Switching to 200/300 mg 
Strength Tablets from 120 mg Tablets 
 
Dose with 120 mg 
Dose with 200/300 mg 
Starting Dose Level 
600 mg BID  
Dose Level -1 
480 mg BID 
500 mg BID 
Dose Level -2 
360 mg BID 
400 mg BID 
Dose Level -3 
240 mg BID 
300 mg BID 
 
If a patient misses a dose (i.e., does not take it within 4 h of the scheduled time on a BID 
schedule), she should resume taking rucaparib with her next scheduled dose.  Missed or vomited 
doses will not be made up. 
A sufficient number of tablets will be provided to the patient to last until the next scheduled visit.  
Patients will be instructed to record daily doses taken or not taken on a patient diary, and will be 
instructed to bring their rucaparib tablets and diary to the next scheduled visit for reconciliation 
by site personnel. 
7.3.1 
Dietary Restrictions 
Patients should be instructed to limit their coffee intake to one 8 oz (240 mL) cup of black coffee 
(no cream or sugar) and to not consume alcohol, tea, chocolate, or cola beverages within 2 h 
prior to collection of PK samples on days where PK sampling is extensive (i.e., pre- and post-
rucaparib administration).  This restriction does not apply on days when only a predose trough 
level PK sample is collected. 
7.3.2 
Fed and Fasted Requirements for Food-Effect PK Analysis 
Fasted Condition 
Following an overnight fast of at least 10 h, and following performance of all required predose 
assessments, patients will ingest oral rucaparib with 8 oz (240 mL) of room temperature water.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 57 of 133 
Confidential 
No food will be allowed for at least 4 h postdose. No water will be allowed for at least 2 h 
postdose. 
Fed Condition 
Following an overnight fast of at least 10 h, and following performance of all required predose 
assessments, patients will consume a high-fat (approximately 50% of total caloric content), 
high-calorie (approximately 800–1000 calories total) breakfast meal containing approximately 
500 to 600 calories from fat, approximately 250 calories from carbohydrates, and approximately 
150 calories from protein, in the clinic.  Patients must begin eating the meal 30 (±5) min prior to 
the planned administration of oral rucaparib.  Patients should eat this meal in 30 min or less; 
however, oral rucaparib should be administered 30 min after the start of the meal, regardless of 
whether the meal was completed or not.  Patients will ingest oral rucaparib with 8 oz (240 mL) 
of room temperature water.  No food will be allowed for at least 4 h postdose.  No water will be 
allowed for at least 2 h postdose.   
The breakfast meal will be provided by the clinical site or patient.  A list of appropriate breakfast 
meals will be provided to clinical sites and patients by the sponsor.  An example test meal would 
be two eggs fried in butter, two strips of bacon (or ham or cheese of similar caloric content), two 
slices of toast with butter, 4 oz of hash brown potatoes, and 8 oz (240 mL) of whole-fat milk.  A 
different breakfast meal to suit specific dietary requirements may be substituted by the clinical 
site or patient, provided that it has a similar amount of calories and protein, and carbohydrate and 
fat content.  The nutrient content of the proposed meal must be calculated and submitted to the 
sponsor (or designee) for review and approval at least 3 days in advance of the patient’s 
scheduled fed day. 
7.4 
Starting Dose and Dose Modifications of Protocol-Specified Treatment 
7.4.1 
Part 1 (Phase I Portion) 
7.4.1.1 Dose Escalation 
In Cohort 1, three patients will be enrolled initially at a starting dose of 40 mg oral rucaparib.  
Enrollment, treatment, and evaluation of each patient can occur in parallel.  There is no period of 
observation between patients enrolled into a dose-escalation cohort.  The occurrence of DLTs 
(Section 7.4.1.3) will determine whether the dose level will be escalated in subsequent cohorts.  
The dose-escalation decision rules are summarized in Table 4. 
Table 4. 
Dose-Escalation Decision Rules 
Number of Patients with  
DLT at a Dose Level 
Decision  
0 of 3  
Escalate dose as specified in Table 5 and evaluate in 3 subsequent 
patients. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 58 of 133 
Confidential 
Table 4. 
Dose-Escalation Decision Rules 
Number of Patients with  
DLT at a Dose Level 
Decision  
1 of 3 
Enroll 3 additional patients at this dose level.  Then: 
• If 0 of these 3 additional patients has a DLT, proceed to the next 
dose level.  Escalate dose as specified in Table 5 and evaluate in 3 
subsequent patients. 
• If 1 or more of these additional patients has a DLT, then dose 
escalation is stopped and this dose is declared the maximum 
administered dose.  Three additional patients will be enrolled at 
the previously evaluated dose level if only 3 patients were treated 
at that dose previously.   
≥2 of 3 
The MTD has been exceeded.  Dose escalation will stop and this dose 
level will be declared the maximum administered dose.   
Evaluate 3 additional patients at the prior dose level if only 3 were 
treated at that dose previously. 
(An interim de-escalated dose may be explored if the increment 
between MTD and maximally administered dose was >50%). 
1 of 6 
Proceed to next dose level (if not evaluated previously) and evaluate 3 
patients.  Escalate dose as specified in Table 5 and evaluate in 3 
subsequent patients. 
≤1 out of 6 at the Highest Dose 
Below the Maximum 
Administered Dose 
This is the MTD.   
≥2 of 6 
The MTD has been exceeded.  Dose escalation will stop and this dose 
level will be declared the maximum administered dose. 
Evaluate 3 additional patients at the prior dose level if only 3 were 
treated at that dose previously. 
(An interim de-escalated dose may be explored if the increment 
between MTD and maximally administered dose was >50%). 
 
Dose escalation based on DLTs observed, overall tolerability, and PK results will proceed as 
specified in Table 5 until an MTD is determined.  Dose escalation steps above 360 mg BID will 
be agreed upon between the Investigators and Sponsor’s Medical Monitor, but will not exceed 
100%.  In the event TID dosing is explored, the starting dose will be determined based on safety 
and PK observed in prior BID cohorts and will be agreed upon between the Investigators and 
Sponsor’s Medical Monitor. Additional subjects may be treated at any previously evaluated dose 
level in a treatment schedule in order to better characterize safety and PK/PD parameters.  
Intermediate or lower dose levels may also be explored for determining the RP2D following 
discussion and agreement between the Investigators and the Sponsor’s Medical Monitor.   


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 59 of 133 
Confidential 
Table 5. 
Dose-Escalation Plan 
Dose and Frequency 
Total Daily Dose 
Increase in Total Dose 
(Actual or Planned) 
40 mg QD 
40 mg 
----- 
80 mg QD 
80 mg 
100% (Actual) 
160 mg QD 
160 mg 
100% (Actual) 
300 mg QD 
300 mg 
88% (Actual) 
500 mg QD 
500 mg 
67% (Actual) 
240 mg BID 
480 mg 
50% (Actual) 
360 mg BID 
720 mg 
50% (Actual) 
480 mg BID 
960 mg 
33% (Actual) 
600 mg BID 
1200 mg 
25% (Actual) 
840 mg BID 
1680 mg 
40% (Actual) 
 
7.4.1.2 Maximum Tolerated Dose 
The MTD is defined as the maximum daily oral dose at which <33% of patients experience a 
DLT during Cycle 1 (Safety and PK Assessment Period).  If a DLT is observed in one of three 
patients, then three additional patients will be enrolled at that same dose level.  Dose escalation 
will continue until at least two of the three to six patients treated at a dose level experience a 
DLT.  The next lower dose will then be considered the MTD.  Alternatively, if the dose between 
the MTD and the maximally delivered dose is significant (such as 100%), then a more modestly 
de-escalated dose may be explored (e.g., 20 to 50%). 
7.4.1.3 Dose-Escalation Design 
The dose-escalation design for this study is presented graphically in Figure 5 below. 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 60 of 133 
Confidential 
Figure 5. 
Dose-Escalation Design 
 
 
MTD 
Exceeded 
Escalate 
Dose 
(≤100%) 
Evaluate 
3 
Additional 
Patients 
 
Initial Dose 
Level 
(n = 3) 
 
 
Number of 
Patients 
with DLTs 
Total 
Number of 
Patients 
with DLTs 
≥ 2/3 
= 1/3 
= 0/3 
≥ 2/6 
= 1/6 
Prior Dose Level = 
MTD 
(or intermediate 
dose level to be 
explored) 
 
Expand to Confirm 
DLT Rate 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 61 of 133 
Confidential 
7.4.1.4 Dose-Limiting Toxicity 
DLTs in Part 1 will be defined as any of the following events that occur during Cycle 1 (Safety 
and PK Assessment Period) and are assessed by the investigator as related to rucaparib.  Where 
applicable, events will be classified according to the NCI CTCAE.2  
• ANC <0.5 × 109/L >5 days duration or febrile neutropenia (i.e., fever > 38.3°C with ANC 
<1.0 × 109/L) 
• Platelets <25 × 109/L or platelets <50 × 109/L with bleeding requiring a platelet 
transfusion 
• Grade 4 anemia (i.e., life-threatening consequences; urgent intervention indicated) 
• Any nonhematological AE CTCAE Grade 3 or greater (except alopecia and nausea, 
vomiting, and diarrhea if well-controlled by systemic medication) 
7.4.1.5 Definition of DLT-Evaluable Patient  
In order to be considered evaluable for dose-escalation decisions, a patient in Part 1 must have: 
• Received at least 17 complete days of dosing, and have completed Cycle 1, Day 21 
without a DLT, or 
• Have experienced a DLT in Cycle 1 
If a patient withdraws from the study without having met either of these criteria, then an 
additional patient will be enrolled in that cohort.   
7.4.1.6 In the Event of Toxicity at Lowest Dose Level 
In the event 240 mg BID rucaparib exceeds the MTD, a dose of 180 mg (or lower) BID 
rucaparib may be explored.  In the event TID dosing is explored and the starting dose of 
rucaparib on that schedule exceeds the MTD, a lower dose of rucaparib may be explored. 
7.4.1.7 Recommended Phase II Dose 
The RP2D for evaluation in Part 2 and Part 3 will be selected based on overall safety and 
tolerability, PK, and estimates of efficacious exposures extrapolated from nonclinical data.  The 
RP2D may or may not be the same as the MTD identified in Part 1 of the study.  For example, if 
the MTD is not reached, if exposure at the MTD is much higher than the level believed to be 
required for efficacy, or if subsequent cycles of treatment provide additional insight on the safety 
profile, then the RP2D may be a different, although not a higher, dose than the MTD. 
Note: The dose of 600 mg BID rucaparib was selected as the recommended dose for Part 2 and 
Part 3 based on the overall safety and tolerability, PK, and clinical activity profile (See 
Section 3.2.2). The MTD was not reached in Part 1. 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 62 of 133 
Confidential 
7.4.1.8 Dose Modification Criteria  
In Part 1, no dose reduction is permitted in Cycle 1.  After Cycle 1, dose reductions are permitted 
as indicated in Table 6.  
If a patient in Part 1 is confirmed to have experienced a DLT in Cycle 1, then the investigator 
may do either of the following: 
• Continue treating the patient at the next lower dose level evaluated (oral rucaparib is not to 
be reduced below 40 mg) if the investigator expects clinical benefit from further 
treatment with rucaparib, the toxicity is manageable, and the investigator and the 
sponsor’s medical monitor (or designee) agree.  A patient who receives a modified dose 
will be evaluated for safety at that dose level, but will not be counted towards the number 
of patients with DLTs at that dose level. 
• Discontinue the patient from rucaparib treatment and the study. 
During the optional Treatment-Extension Period, the dose of oral rucaparib may be reduced to 
the next lower dose level evaluated if any of the following are observed: 
• Grade 3 or 4 hematologic toxicity 
• Grade 3 or 4 nonhematologic toxicity (except for alopecia, and nausea, vomiting, or 
diarrhea adequately controlled with systemic antiemetic/antidiarrheal medication 
administered in standard doses according to the study center routines).  Grade 3 or 
Grade 4 ALT/AST elevations should be managed as described below.  
• In addition, and at the discretion of the investigator, the dose of rucaparib may be held 
and/or reduced for Grade 2 toxicity not adequately controlled by concomitant medications 
and/or supportive care. 
7.4.1.8.1 
Management of Rucaparib Treatment-emergent ALT/AST Elevations  
• Grade 4 ALT/AST elevations: hold rucaparib until values have returned to Grade 2 or 
better, then resume rucaparib with a dose reduction.  Monitor liver function tests weekly 
for 3 weeks after rucaparib has been restarted. 
• Grade 3 ALT/AST elevations, in the absence of other signs of liver dysfunction, should 
be managed as follows:  
– Monitor liver function tests weekly until resolution to ≤ Grade 2. 
– Continuation of rucaparib with elevation of ALT/AST up to Grade 3 is permitted 
provided bilirubin is < ULN and alkaline phosphatase is < 3 x ULN.  
– If patient has Grade 3 ALT/AST and continues on rucaparib, and levels do not 
decline within 2 weeks or they continue to rise, treatment interruption and 
resolution to ≤ Grade 2 will be required before rucaparib can be resumed, either at 
the current dose or at a reduced dose. 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 63 of 133 
Confidential 
Treatment with rucaparib should be held until the toxicity resolves to ≤Grade 2.  Dosing may 
then be resumed at either the same dose or the next lower dose level evaluated, per investigator 
discretion.  If treatment is resumed at the same dose, and the patient experiences the same 
toxicity, the dose should be reduced following resolution of the event.  If the patient continues to 
experience toxicity, a second and third dose reduction to a previously evaluated lower dose are 
permitted.  Up to three dose reduction steps are allowed.  If a patient continues to experience 
toxicity after three dose reduction steps, or if dosing with rucaparib is interrupted for >14 
consecutive days due to toxicity, treatment should be discontinued, unless otherwise agreed 
between the investigator and the sponsor. 
Dose reduction levels from doses that may be administered during the study are presented in 
Table 6, Table 7, and Table 8. 
Table 6. 
Example Dose Reduction Steps  
Possible Dose 
Levels 
First Adjustment 
 
Second Adjustment* 
 
40 mg QD 
NA 
NA 
80 mg QD 
40 mg QD 
NA 
160 mg QD 
80 mg QD 
40 mg QD 
300 mg QD 
160 mg QD 
80 mg QD 
500 mg QD 
300 mg QD 
160 mg QD 
240 mg BID 
180 mg BID 
To be agreed upon between Sponsor’s 
Medical Monitor and Investigator 
360 mg BID 
240 mg BID 
To be agreed upon between Sponsor’s 
Medical Monitor and Investigator 
Additional 
Dose Level(s) 
BID 
To be agreed upon between Sponsor’s 
Medical Monitor and Investigator 
To be agreed upon between Sponsor’s 
Medical Monitor and Investigator 
TID 
In the event TID dosing is explored, dose 
adjustments will be agreed upon between 
the Sponsor’s Medical Monitor and the 
Investigator. 
In the event TID dosing is explored, dose 
adjustments will be agreed upon between 
the Sponsor’s Medical Monitor and the 
Investigator. 
NA=Not applicable. 
*Additional Dose reduction allowed as agreed upon between Sponsor’s Medical Monitor and Investigator 
 
7.4.1.9 Intrapatient Dose Escalation 
Intrapatient dose escalation in Part 1 of the study will be permitted after a subject completes at 
least 2 cycles of treatment at their initial dose level without experiencing significant drug-related 
toxicity, provided the dose level to which the patient will escalate has been evaluated and 
deemed tolerable at the time of the proposed dose increase, and represents ≤100% increase in 
total dose.  The dose may be increased at the beginning of the next cycle.  There is no limit to the 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 64 of 133 
Confidential 
number of dose escalation steps permitted for an individual patient provided all criteria are met.  
All dose escalation steps must be approved by the Sponsor’s Medical Monitor. 
7.4.1.10 Criteria for Re-Treatment 
A new cycle of treatment may begin if: 
• ANC ≥1.0 x 109/L 
• Platelet count ≥75.0 x 109/L 
• Non-hematologic toxicities have returned to baseline or ≤ CTCAE Grade 1 severity (or, at 
the investigator’s discretion, ≤ CTCAE Grade 2 severity if not considered a safety risk for 
the patient) 
7.4.2 
Part 2 and Part 3 (Phase II Portion) 
7.4.2.1 Starting Dose  
The RP2D identified in Part 1 (Phase I portion) will be the starting dose for patients enrolled into 
Part 2 and Part 3 (Phase II portion).  The dose of 600 mg BID was selected as the recommended 
dose for Part 2 and Part 3 based on the overall safety & tolerability, PK, and clinical activity 
profile. Refer to Section 3.2.2 for more detail.  
7.4.2.2 Dose Modification Criteria  
Patients in Part 2A using 120 mg tablets should have their dose of oral rucaparib modified as 
needed (see Section 7.4.1.8 and Table 7). 
Table 7. 
Dose Reduction Steps in Part 2A (Phase II in Patients with OC) 
using 120 mg tablets 
Starting Dose 
600 mg BID 
Dose Level -1 
480 mg BID 
Dose Level -2 
360 mg BID 
Dose Level -3 
240 mg BID 
 
Patients in Part 2A, Part 2B, and Part 3 using 200/300 mg tablets should have their dose of oral 
rucaparib modified as needed (see Section 7.4.1.8 and Table 8). 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 65 of 133 
Confidential 
Table 8. 
Dose Reduction Steps in Part 2A and Part 2B (Phase II in 
Patients with OC) and Part 3 (Phase II in Patients with any 
Advanced Solid Tumor) using 300 and 200 mg tablets 
Starting Dose 
600 mg BID 
Dose Level -1 
500 mg BID 
Dose Level -2 
400 mg BID 
Dose Level -3 
300 mg BID 
Dose Level -4 
200 mg BID* 
*200 mg dose level is only permitted following discussion with the Sponsor 
 
If a patient was required to reduce their dose level due to a toxicity, and the toxicity subsequently 
resolved, the dose may be re-escalated at the discretion of the investigator.  
7.4.3 
In the Event of Torsade de Pointes 
In the event of ECG result or adverse event(s) suggestive of “torsade de pointes,” the following 
procedures are recommended: 
1. Hold rucaparib. 
2. Check for hypokalemia, hypomagnesemia, and hypocalcemia. 
3. Check cardiac enzymes.  Rule out myocardial ischemia, especially in patients without QT 
prolongation. 
4. Perform chest radiographs and ECHO to rule out structural heart disease, if any clinical 
suggestion is present. 
5. Order other tests as appropriate, depending on the etiological factors being considered. 
6. Administer treatment (if required) appropriate to diagnosis. 
7. Submit SAE Report, if applicable. 
8. Resume treatment with rucaparib if appropriate, or discontinue treatment permanently 
and schedule an end-of-study visit. 
7.4.4 Treatment Beyond Progression 
If the patient has met the criteria for radiologic progression by RECIST, but the patient is still 
receiving benefit from rucaparib (e.g., patient has mixed radiologic response or is continuing 
to have symptomatic benefit) according to the Investigator, then continuation of treatment 
will be considered.  In such cases, the decision to continue will be made jointly between the 
Investigator and the Sponsor, and must be documented prior to continuing treatment with 
rucaparib.  Patients will continue to have all protocol-required assessments specified in 
Table 9, Table 10, Table 11, and Table 13. 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 66 of 133 
Confidential 
7.5 
Accountability of Protocol-Specified Treatment 
Study personnel will maintain accurate records of oral rucaparib shipments/receipts, 
administration, and drug reconciliation.  The site is responsible for the return or destruction of 
oral rucaparib as required.  A drug management system will manage oral rucaparib inventory at 
all sites.  The system will be required to manage study treatment requests and shipments. 
Any oral rucaparib accidentally or deliberately destroyed must be accounted for.  All bottles 
must be accounted for prior to their destruction at the study center, according to institutional 
procedures for disposal of cytotoxic drugs.  Unused bottles should be destroyed locally.  If 
destruction at the site is not possible, supply should be returned to the drug depot.  During the 
course of the study and at completion of the study, the number of bottles of oral rucaparib 
shipped, destroyed, and returned must be reconciled.   
7.6 
Blinding/Masking of Treatment 
This is an open-label study; the investigational product will not be blinded or masked.  All 
patients enrolled will receive oral rucaparib. 
7.7 
Treatment Compliance 
Documentation of dosing will be recorded in a study specific diary (paper or electronic) provided 
by the sponsor (or designee).  Study site personnel will provide instructions regarding the 
scheduled daily doses and the number of tablets to be taken each day.  Study site personnel will 
review dosing information with the patient (or legally authorized representative) on scheduled 
clinic visit days.  Patients (or legally authorized representative) will be asked to record dosing 
information for oral rucaparib taken at home in the diary and to bring the diary and all unused 
tablets with them to scheduled clinic visits.  A compliance check and tablet count will be 
performed by study personnel.  In the event paper diary cards are utilized, study site personnel 
will record compliance information on the case report form (CRF) and retain the diary card in the 
patient’s medical record.   


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 67 of 133 
Confidential 
8 
PRIOR AND CONCOMITANT THERAPIES 
Patients who have received prior treatment with a PARP inhibitor, including intravenous and oral 
rucaparib, are not eligible to participate in Part 1 or Part 2 of this study.  Patients in Part 3 are 
allowed to receive prior treatment with a PARP inhibitor provided that it was not the most recent 
treatment and that the PARPi was discontinued at least 6 months before the first planned dose of 
rucaparib. Patients having received prior treatment with iniparib are eligible. 
During the study, supportive care (e.g., antiemetics; analgesics for pain control) may be used at 
the investigator’s discretion and in accordance with institutional procedures.  For patients 
undergoing ECG assessments in Part 1, medications known to produce QT prolongation should 
not be used, with the exception of necessary antiemetic medications. A list of prohibited 
medications and antiemetic medications requiring additional ECG monitoring is provided in 
Appendix C. These restrictions do not apply to Part 2 or Part 3. 
All procedures performed (e.g., thoracentesis, etc.) and medications used during the study must 
be documented on the electronic case report form (eCRF).   
8.1 
Anticancer or Experimental Therapy 
No other anticancer therapies (including chemotherapy, radiation, hormonal treatment [except 
corticosteroids and megestrol acetate], antibody or other immunotherapy, gene therapy, vaccine 
therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, or other experimental drugs) 
of any kind will be permitted while the patient is participating in the study with the exception of 
ongoing hormonal treatment for prior breast cancer.  Prior treatment with such therapies must 
have been completed >14 days prior to the first scheduled dose or oral rucaparib. 
8.2 
Hematopoietic Growth Factors and Blood Products 
Erythropoietin, darbepoetin alfa, and/or hematopoietic colony-stimulating factors for treatment 
of cytopenias should be administered according to institutional guidelines.  Prophylactic use of 
these agents is not permitted. 
Transfusion thresholds for blood product support will be in accordance with institutional 
guidelines. 
8.3 
Antiemetics 
Some antiemetics commonly administered to the patient population in this study are associated 
with QT prolongation; these should be avoided (from the time of informed consent until the time 
of the last ECG) whenever possible for all patients enrolled into Part 1 of the study.  Preferable 
antiemetics in Part 1 include phenothiazines and corticosteroids.  Administration of prophylactic 
antiemetics is prohibited during Cycle 1 of treatment for patients in Part 1 to ensure patients are 
fully evaluable for dose-limiting toxicity evaluation during this cycle of treatment. There are no 
restrictions on antiemetics in Part 2 or Part 3. 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 68 of 133 
Confidential 
Patients in Part 1 receiving antiemetic medications known to produce QT prolongation will 
require additional ECG measurements at estimated Tmax.  ECGs should be performed 
approximately 2, 4, and 6-7 hours after dosing with rucaparib when the patient begins treatment 
with the antiemetic and again at the same timepoints 1 to 2 weeks later. 
8.4 
CYP450 Isoenzyme Inhibitors and Inducers 
Based on results of in vitro CYP interaction studies (Section 3.2.1.1), caution should be used for 
concomitant medications that are substrates of CYP2C19, CYP2C9, and/or CYP3A and have a 
narrow therapeutic range (Appendix D). Selection of an alternative concomitant medication is 
recommended.   
Caution should also be exercised for concomitant use of certain statin drugs (e.g., rosuvastatin 
and fluvastatin) due to potential increase in exposure from inhibition of BCRP and CYP2C9. 
8.5 
Bisphosphonates 
Bisphosphonates are permitted. 
8.6 
Anticoagulants 
Caution should be exercised in patients receiving oral rucaparib and concomitant warfarin 
(Coumadin) as rucaparib showed a mixed inhibition of CYP2C9 in vitro. Patients taking warfarin 
should have international normalized ratio (INR) monitored regularly according to standard 
institutional practices. 
8.7 
Other Concomitant Medications 
Therapies considered necessary for the patient’s well-being may be given at the discretion of the 
investigator and should be documented on the eCRF.  Other concomitant medications, except for 
analgesics, chronic treatments for concomitant medical conditions, or agents required for life-
threatening medical problems, should be avoided.  Herbal and complementary therapies should 
not be encouraged because of unknown side effects and potential drug interactions, but any taken 
by the patient should be documented appropriately on the eCRF. 
In vitro data showed that rucaparib is an inhibitor of P-gp and thus patients taking digoxin, a 
P-gp substrate, should have their digoxin levels monitored regularly via standard clinical 
practice. 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 69 of 133 
Confidential 
9 
STUDY PROCEDURES 
9.1 
Schedule of Assessments 
Table 9 summarizes the procedures and assessments to be performed for all Part 1 patients 
except those enrolled into a food-effect PK evaluation cohort. 
Table 10 summarizes the procedures and assessments to be performed for all Part 1 patients 
enrolled into a food-effect PK evaluation cohort. 
Table 11 summarizes the procedures and assessments to be performed for all patients enrolled in 
Part 2. 
Table 12 summarizes the timing of ECGs, PK samples (including additional samples for 
metabolite profiling), PD samples, and dosing of oral rucaparib related to these assessments. 
Table 13 summarizes the procedures and assessments to be performed for all patients enrolled in 
Part 3. 
Table 14 summarizes the schedule of dosing and PK sampling for patients in Part 3. 
All procedures and assessments are to be completed within ±1 day of the scheduled time point 
and are synchronized with administration day of oral rucaparib treatment unless indicated. 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 70 of 133 
Confidential 
Table 9. 
Schedule of Assessments - Part 1:  All Cohorts Except Food-Effect Evaluation 
 
Screening 
Dose-Escalation Evaluation 
Optional Treatment- 
Extension Period 
End of Treatment 
(After Last Dose) 
 
 
Follow-up 
(28 [±3] Days 
After Last Dose) 
 
Cycle 1 
Cycles 2+ 
Procedurea 
Day -30 to 
Day -1 
Day -1 
Day 1b 
Days 8, 15, 
& 22 
Day 1c 
Informed Consent 
X 
 
 
 
 
 
 
Medical/Oncology History 
X 
 
 
 
 
 
 
Physical Examination  
X 
 
X 
Xd 
X 
X 
 
Height 
X 
 
 
 
 
 
 
Weight 
X 
 
X 
X 
X 
X 
 
ECOG Performance Status 
X 
 
X 
 
X 
X 
 
Vital Signse 
X 
X 
X 
X 
X 
X 
 
Prior/Concomitant Medications  
X 
X 
X 
X 
X 
X 
 
12-lead ECG (in Triplicate)f 
X  
Xg 
Xh 
Xh,i 
X 
X 
 
ECHO or MUGA Scanj 
X 
 
 
 
 
 
 
Hematologyk 
Xl 
 
X 
X 
X 
X 
 
Serum Chemistrym 
Xl 
 
X 
X 
X 
X 
 
Serum Pregnancy Test 
Xn 
 
 
 
 
X 
 
Urinalysiso 
X 
 
 
 
 
 
 
Tumor Markers (optional)p 
(X) 
 
(X) 
 
(X) 
(X) 
 
Tumor Scansq 
X  
 
 
 
Xr 
X 
 
Tumor Samples (optional)s 
(X) 
 
 
 
 
(X) 
 
Adverse Eventst 
X 
X 
X 
X 
X 
X 
X 
Plasma PK Samples 
 
 
Xu 
Xu,v 
Xv 
 
 
Duplicate Set of Plasma PK Samples for 
Metabolite Profiling 
 
 
(X)w 
(X)i,x 
 
 
 
Oral Rucaparib 
Dispensation/Administration 
 
 
X 
X 
X 
 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 71 of 133 
Confidential 
BUN = blood urea nitrogen, CT = computer tomography, EOS = end of study, MRI = magnetic resonance imaging, PET = positron emission tomography, SAE = serious 
adverse event 
a 
= Unless specified, procedure is to be completed within ±1 day of scheduled time point and be synchronized with administration day of rucaparib. 
b 
= Any procedures required on Day 1 of Cycle 1, except for the ECGs, may be omitted if completed ≤3 days earlier during the screening period. 
c 
= Cycle 2, Day 1 assessments do not need to be repeated if the visit is the same day as Cycle 1, Day 22 or no more than 7 days later.  Note: the plasma PK sample 
should be collected on Day 22 of Cycle 1 only.  No additional sample should be collected if a separate Cycle 2, Day 1 visit is required. 
d 
= Limited/targeted physical exam to be performed on Days 8 and 15 of Cycle 1. 
e 
= Vital signs (blood pressure, pulse, and temperature) to be taken predose on drug administration days, after the patient has been resting for at least 5 min. 
f 
= Predose 12-lead ECGs (in triplicate) will be run for 10 seconds, >2 min apart, with patient resting for 5 min prior to recording. 
g 
= At a time point equivalent to the estimated postdose Tmax of oral rucaparib administered on the following day.  This ECG will be time-matched to the 12-lead ECG 
taken on the following day at estimated Tmax [2 h after administration] following oral dosing with rucaparib.   
h 
= Postdose 12-lead ECG (in triplicate) taken at estimated Tmax (2 h after administration) and at 7 h after administration of rucaparib on Day 1 and Day 15; 12-lead 
ECG (in triplicate) on Day 22 (prior to dosing, if Cycle 1, Day 22 = Cycle 2, Day 1). 
i 
= Day 15 and Day 22 only. 
j 
= To be repeated during treatment period as clinically indicated. 
k 
= Includes hemoglobin, hematocrit, WBC and differential (with ANC), and platelet count.  Blood will be analyzed by a local laboratory and must be reviewed by the 
investigator prior to dosing with rucaparib.   
l 
= To be performed ≤14 days prior to the first dose of rucaparib. 
m = Includes total protein, albumin, creatinine, BUN or urea, total bilirubin, ALP, ALT, AST, total cholesterol, glucose, sodium, potassium, chloride, CO2, calcium, 
and phosphorus.  Blood will be analyzed by a local laboratory. 
n 
= Serum ß-hCG (evaluated by local labs) will be performed only on women of childbearing potential ≤3 days prior to the first dose of rucaparib, . 
o 
= Includes dipstick for protein, glucose, blood, pH, and ketones.  If dipstick findings abnormal, perform microscopic evaluation to assess abnormal findings. 
p 
= Optional: tumor markers appropriate to a patient’s cancer diagnosis will be measured by a local laboratory. 
q 
= Tumor assessments to consist of clinical examination and appropriate imaging techniques (preferably CT scans of the chest, abdomen and pelvis, with appropriate 
slice thickness per RECIST); other studies (MRI, X-ray, PET, and ultrasound) may be performed if required.  The same methods used to detect lesions at baseline 
are to be used to follow the same lesions throughout the clinical study. 
r 
= Tumor scans to be performed within 7 days prior to the start of Cycles 3, 5, and 7, and then within 7 days prior to the start of every third cycle of treatment 
thereafter, beginning with Cycle 10.  If initial CR or PR noted at Cycle 7 or beyond, confirmatory scans must be performed 4–6 weeks later. 
s 
= Tumor tissue samples are optional.  Patient must provide consent to provide archival and/or fresh tumor tissue samples at screening and at time of disease 
progression/treatment discontinuation. For archival tissue, the most recent sample collected prior to treatment should be provided.  Refer to the Laboratory Manual 
for detailed sample collection, preparation, and shipment instructions. 
t 
= AEs are recorded from time of signing of informed consent through 28 days after last dose of rucaparib.  Ongoing SAEs should be followed to resolution. 
u 
= PK samples to be collected predose (any time on Day 1; 5-10 min prior to dosing on Day 15) and at 15 (±2) min, 30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h 
(±5 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) postdose on Days 1 and 15 of Cycle 1. 
v 
= PK sample to be collected any time prior to dosing on Days 8 and 22 of Cycle 1, and on Day 1 of Cycles 3-9 
w = PK sample for metabolite profiling on Day 1 is predose only. 
x 
= Duplicate set of PK samples to be collected from first 3 patients enrolled into the RP2D Expansion cohort only.  PK samples to be collected predose (5–10 min 
prior to dosing) and at 15 (±2) min, 30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min), 10 h (±30 min), and 24 
h (±30 min) postdose. 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 72 of 133 
Confidential 
Table 10. 
Schedule of Assessments - Part 1:  Food-Effect Evaluation Cohort(s) Only 
 
Screening 
 
Dose-Escalation Evaluation 
Optional 
Treatment-
Extension 
Period 
End of 
Treatment 
(After Last 
Dose) 
 
  
 
Follow-up 
(28 [±3] Days 
After Last 
Dose) 
 
Cycle 1 
Cycles 2+ 
Procedurea 
Day -30 to 
Day -1 
Day -8b 
Day -7b 
Day -1 
Day 1 
Days 8, 
15, & 22 
Day 1c 
Informed Consent 
X 
 
 
 
 
 
 
 
 
Medical/Oncology History 
X 
 
 
 
 
 
 
 
 
Physical Examination 
X 
 
Xd 
 
X 
Xd 
X 
X 
 
Height 
X 
 
 
 
 
 
 
 
 
Weight 
X 
 
X 
 
X 
X 
X 
X 
 
ECOG Performance Status 
X 
 
X 
 
X 
 
X 
X 
 
Vital Signse 
X 
X 
X 
X 
X 
X 
X 
X 
 
Prior/Concomitant Medications  
X 
X 
X 
X 
X 
X 
X 
X 
 
12-lead ECG (in Triplicate)f 
X 
Xg 
Xh 
Xg 
Xh 
Xh,i 
X 
X 
 
ECHO or MUGA Scanj 
X 
 
 
 
 
 
 
 
 
Hematologyk 
Xl 
 
X 
 
X 
X 
X 
X 
 
Serum Chemistrym 
Xl 
 
X 
 
X 
X 
X 
X 
 
Serum Pregnancy Test 
Xn 
 
 
 
 
 
 
X 
 
Urinalysiso 
X 
 
 
 
 
 
 
 
 
Tumor Markers (optional)p 
(X) 
 
 
 
(X) 
 
(X) 
(X) 
 
Tumor Scansq 
X 
 
 
 
 
 
Xr 
X 
 
Tumor Tissue Samples 
(optional)s 
(X) 
 
 
 
 
 
 
(X) 
 
Adverse Eventst 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Plasma PK Samples 
 
 
Xu 
 
Xu 
Xu,v 
Xv 
 
 
Oral Rucaparib 
Dispensation/Administration 
 
 
X 
 
X 
X 
X 
 
 
High-Fat Breakfast 
 
 
 
 
X 
 
 
 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 73 of 133 
Confidential 
BUN = blood urea nitrogen, CT = computer tomography, EOS = end of study, MRI = magnetic resonance imaging, PET = positron emission tomography, SAE = serious 
adverse event 
a 
= Unless specified, procedure is completed within ±1 day of scheduled time point and be synchronized with administration day of rucaparib. 
b 
= Any procedure, except for the ECGs, may be omitted if completed ≤3 days earlier during the screening period. 
c 
= Cycle 2, Day 1 assessments do not need to be repeated if visit is same day as Cycle 1, Day 22 or no more than 7 days later.  Note: the plasma PK sample should be 
collected on Day 22 of Cycle 1 only.  No additional sample should be collected if a separate Cycle 2, Day 1 visit is required. 
d 
= Limited/targeted physical exam to be performed on Day -7 prior to Cycle 1, and on Day 8 and 15 of Cycle 1. 
e 
= Vital signs (blood pressure, pulse, and temperature) to be taken predose on drug administration days, after the patient has been resting for at least 5 min. 
f 
= 12-lead ECGs (in triplicate) will be run for 10 seconds, >2 min apart, with patient resting for 5 min prior to recording.   
g 
= At a time point equivalent to the estimated postdose Tmax of oral rucaparib administered on the following day.  This ECG will be time-matched to the 12-lead ECG 
taken on the following day at estimated Tmax [2 h after administration] following oral dosing with rucaparib.   
h 
= Postdose 12-lead ECG (in triplicate) taken at estimated Tmax (2 h after administration) and at 7 h after administration of rucaparib on Day -7, Day 1 and Day 15; 
12-lead ECG (in triplicate) on Day 22 (prior to dosing, if Cycle 1, Day 22 = Cycle 2, Day 1). 
i 
= Day 15 and Day 22 only. 
j 
= To be repeated during treatment period as clinically indicated. 
k 
= Includes hemoglobin, hematocrit, WBC and differential (with ANC), and platelet count.  Blood will be analyzed by a local laboratory and must be reviewed by the 
investigator prior to dosing with oral rucaparib. 
l 
= To be performed ≤14 days prior to the first dose of rucaparib. 
m = Includes total protein, albumin, creatinine, BUN or urea, total bilirubin, ALP, ALT, AST, total cholesterol, glucose, sodium, potassium, chloride, CO2, calcium, 
and phosphorus.  Blood will be analyzed by a local laboratory. 
n 
= Serum ß-hCG (evaluated by local labs) will be performed only on women of childbearing potential ≤3 days prior to the first dose of rucaparib. 
o 
= Includes dipstick for protein, glucose, blood, pH, and ketones.  If dipstick findings abnormal, perform microscopic evaluation to assess abnormal findings. 
p 
= Optional: tumor markers appropriate to a patient’s cancer diagnosis will be measured by a local laboratory. 
q 
= Tumor assessments to consist of clinical examination and appropriate imaging techniques (preferably CT scans of the chest, abdomen, and pelvis, with appropriate 
slice thickness per RECIST); other studies (MRI, X-ray, PET, and ultrasound) may be performed if required.  The same methods used to detect lesions at baseline 
are to be used to follow the same lesions throughout the clinical study. 
r 
= Tumor scans to be performed within 7 days prior to the start of Cycles 3, 5, and 7, and then within 7 days prior to the start of every third cycle thereafter, 
beginning with Cycle 10.  If initial CR or PR noted at Cycle 7 or beyond, confirmatory scans must be performed 4-6 weeks later. 
s 
= Tumor tissue samples are optional.  Patient must provide consent to provide archival and/or fresh tumor tissue sample at screening and at time of disease 
progression/treatment discontinuation. For archival tissue, the most recent sample collected prior to treatment should be provided.  Refer to the Laboratory Manual 
for detailed sample collection, preparation, and shipment instructions. 
t 
= AEs are recorded from time of signing of informed consent through 28 days after last dose of rucaparib.  Ongoing SAEs should be followed to resolution. 
u 
= PK samples to be collected predose (any time on Day -7 and Day 1; 5–10 min prior to dosing on Day 15) and at 15 (±2) min, 30 (±3) min, 1 h (±5 min), 1.5 h 
(±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) postdose on Day -7, Day 1 and Day 15 of Cycle 1. 
v 
= PK sample to be collected any time prior to dosing on Days 8 and 22 of Cycle 1, and on Day 1 of Cycles 3-9. 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 74 of 133 
Confidential 
Table 11. 
Schedule of Assessments - Part 2A and 2B:  All Patients 
Procedurea 
Screening 
Dosing Period 
 
End of 
Treatment 
(After 
Last Dose) 
Follow-up 
(28 [±3] 
Days 
After Last 
Dose) 
Long-term 
Follow-up 
Cycle 1 
Cycles 2 and 
Beyond 
Day -30 to Day -1 
Day 1b 
Day 15 
Day 1 
Informed Consent 
X 
 
 
 
 
 
 
Medical/Oncology History 
X 
 
 
 
 
 
 
Physical Examination  
X 
X 
Xc 
X 
X 
 
 
Height 
X 
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
 
 
ECOG Performance Status 
X 
X 
 
X 
X 
 
 
Vital Signsd 
X 
X 
X 
X 
X 
 
 
Prior/Concomitant Medications  
X 
X 
X 
X 
X 
 
 
12-lead ECG (in Triplicate)e 
X 
Xs 
 
Xs 
X 
 
 
Hematologyf 
Xg 
X 
X 
X 
X 
 
 
Serum Chemistryh 
Xg 
X 
X 
X 
X 
 
 
Serum Pregnancy Testi 
X 
 
 
X 
X 
 
 
CA-125 Measurementj 
X 
X 
 
X 
X 
 
 
Urinalysisk 
X 
 
 
 
 
 
 
Tumor Scansl 
X 
 
 
Xm 
X 
 
Xt 
Archival Tumor Tissuen 
(X) 
 
 
 
X 
 
 
Adverse Eventso 
X 
X 
X 
X 
X 
X 
 
Plasma PK Samples 
 
 
Xp 
Xq 
 
 
 
Serum AAG Samplesr 
 
 
Xp 
Xq 
 
 
 
Oral Rucaparib 
Dispensation/Administration 
 
X 
X 
X 
 
 
 
Part 2B Only: Survival, Subsequent 
Treatments, and Secondary Malignancy 
Monitoring 
 
 
 
 
 
 
Xu 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 75 of 133 
Confidential 
BUN = blood urea nitrogen, CT = computer tomography, EOS = end of study, MRI = magnetic resonance imaging, PET = positron emission tomography, SAE = serious 
adverse event 
a 
= Unless specified, procedure is completed within ±1 day of scheduled time point and is synchronized with administration day of rucaparib. 
b 
= At Day 1 of Cycle 1, any procedure may be omitted if completed ≤3 days earlier during the screening period. 
c 
= Limited/targeted physical exam to be performed on Day 15 of Cycle 1. 
d 
= Vital signs (blood pressure, pulse, and temperature) taken predose on drug administration days, after the patient has been resting for at least 5 min. 
e 
= 12-lead ECGs (in triplicate) (predose, where applicable) will be run for 10 seconds, >2 min apart, with patient resting for 5 min prior to recording.   
f 
= Includes hemoglobin, hematocrit, WBC and differential (with ANC), and platelet count.  Blood will be analyzed by a local laboratory and must be reviewed by the 
investigator prior to dosing with rucaparib. 
g 
= To be performed ≤14 days prior to the first dose of rucaparib. 
h 
= Includes total protein, albumin, creatinine, BUN or urea, total bilirubin, ALP, ALT, AST, total cholesterol, glucose, sodium, potassium, chloride, CO2, calcium, 
and phosphorus.  Blood will be analyzed by a local laboratory.   
i 
= Serum ß-hCG (evaluated by local laboratory) will be performed only on women of childbearing potential at the following time points: ≤ 3 days prior to the first 
dose of rucaparib, ≤ 3 days prior to Day 1 of every cycle from Cycle 2 and beyond, and at the End-of-Treatment Visit.  
j 
= CA-125 as measured by a local laboratory. 
k 
= Includes dipstick for protein, glucose, blood, pH, and ketones.  If dipstick findings are abnormal, then a microscopic evaluation will be performed to assess the 
abnormal findings. 
l 
= Tumor assessments to consist of clinical examination and appropriate imaging techniques (preferably CT scans of the chest, abdomen, and pelvis, with appropriate 
slice thickness per RECIST); other studies (MRI, X-ray, PET, and ultrasound) may be performed if required.  The same methods used to detect lesions at baseline 
are to be used to follow the same lesions throughout the clinical study.  Tumor scans will be collected and sent for evaluation by independent radiology review. 
m = Tumor scans to be performed within 7 days prior to the start of Cycles 3, 5, and 7, and then within 7 days prior to the start of every third cycle of treatment 
thereafter, beginning at Cycle 10.  If initial CR or PR is noted prior to start of Cycle 7 or beyond, confirmatory scans must be performed4–6 weeks later. 
n 
= A mandatory archival tumor biopsy will be collected from newly enrolled patients and from previously enrolled patients who provide additional consent.  Refer to 
the Pathology Charter for detailed sample handling instructions.  May be collected at Any time during study. 
o 
= AEs are recorded from time of signing of informed consent through 28 days after last dose of rucaparib.  Ongoing SAEs should be followed until resolution. 
p 
= PK sample to be collected approximately 12 h after the last dose, but prior to the next dose (i.e., typically 5–10 min prior to dosing).  
q 
= PK sample to be collected any time prior to dosing for Cycles 2, 3, 5, 7, and 9. If dosing is held for toxicity or any other reason, PK sample should still be collected 
at the end of treatment Cycles 1, 2, 4, 6, and 8. 
r 
= Serum AAG sample to be collected on the same day as the PK sample.   
s 
= Part 2A only 
t 
= Part 2B only. For any patient who discontinued from study treatment for reason other than disease progression or death.  To be performed within 7 days prior to the 
start of every 9 weeks of until radiologically confirmed disease progression, death, or initiation of subsequent treatment.  Patients who have been on study at least 
18 months may decrease the frequency of tumor scans to every 16 (±14 days) weeks. 
u 
= All Part 2B patients discontinued from treatment, regardless of reason, should be followed for survival, subsequent therapies, and secondary malignancy every 12 
weeks (±7 days) until death, loss to follow-up, withdrawal of consent from study, or study closure, whichever happens first.  Follow-up can be performed via the 
telephone.  Diagnosis of any secondary malignancy requires appropriate documentation (i.e., laboratory and/or pathology reports).  
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 76 of 133 
Confidential 
Table 12. 
Schedule of Dosing, Electrocardiograms, and Pharmacokinetic Sampling, for Part 1 and Part 2 
Patients 
 
 
 
 
 
 
Procedure and Time Points 
Part 1 Food-
Effect PK 
Cohort(s) Only 
Part 1 All Cohorts 
(Unless Otherwise Specified) 
Part 2 All Patients 
Cycle 1 
Cycles 
2+ 
Cycle 1 
Cycles 2+ 
Day       
-8 
Day     
-7 
Day    
-1 
Day 
1 
Day 
8 
Day 
15 
Day 
22 
Day 1a 
Day 
1 
Day 
15 
Day 1 
Oral Rucaparib Administrationb 
 
Xc 
 
Xd 
X 
X 
 
X 
X 
X 
X 
Plasma PK Samples (Any Time Prior to Dosing, if Applicable) 
 
X 
 
X 
X 
 
X 
Xe 
 
 
X 
Plasma PK Sample, Predose  
 
 
 
 
 
X 
 
 
 
X 
 
Plasma PK Samples, Postdose (15 [±2] min, 30 [±3] min, 1 h 
[±5 min], 1.5 h [±5 min], 2.5 h [±5 min], 4 h [±15 min], 6 h 
[±15 min], 8 h [±15 min], 10 h [±30 min], and 24 h [±30 min]) 
 
X 
 
X 
 
X 
 
 
 
 
 
Duplicate Set of Plasma PK Samples for Metabolite Profiling, 
Predose (Any Time Prior to Dosing) 
 
 
 
(X)f 
 
 
 
 
 
 
 
 
Duplicate Set of Plasma PK Samples for Metabolite Profiling, 
Postdose (15 [±2] min, 30 [±3] min, 1 h [±5 min], 1.5 h [±5 
min], 2.5 h [±5 min], 4 h [±15 min], 6 h [±15 min], 8 h [±15 
min], 10 h [±30 min], and 24 h [±30 min]) 
 
 
 
 
 
(X)f 
 
 
 
 
 
12-Lead ECGs (in Triplicate, >2 min Apart) (Any Time Prior to 
Dosing) 
 
 
 
 
 
 
X 
X 
X 
 
Xg 
12-Lead ECGs (in Triplicate, >2 min Apart) (At Time Point 
Equivalent to Estimated Postdose Tmax [approx. 2 h postdose] 
of Dose Administered the Following Day) 
X 
 
X 
 
 
 
 
 
 
 
 
12-Lead ECGs (in Triplicate, >2 min Apart) (At Estimated Tmax 
[2 h Postdose] and 7 h postdose) 
 
X 
 
X 
 
X 
 
 
 
 
 
a = Cycle 2, Day 1 assessments do not need to be repeated if the visit is the same day as Cycle 1, Day 22 or no more than 7 days later.  Note:  the plasma PK sample should be 
collected on Day 22 of Cycle 1 only.  No additional sample should be collected if a separate Cycle 2, Day 1 visit is required. 
b 
= Unless otherwise specified or instructed based on results of food effect PK evaluation, patients may take rucaparib on an empty stomach or with food (with a regular meal 
or within 30 minutes after a regular meal). 
c = Patients enrolled into a food effect PK evaluation cohort must fast for 10 h prior to, and 2 h after, rucaparib administration. 
d = Patients enrolled into a food effect PK evaluation cohort must fast for 10 h prior, and 4 h after, rucaparib administration. 
e 
= Cycle 2, Day 1 PK sample is the same as the Cycle 1, Day 22 sample. 
f 
= Duplicate set of PK samples, pre- and postdose, for metabolite profiling to be collected from first 3 patients enrolled into the RP2D Expansion cohort. 
g 
= Part 2A only 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 77 of 133 
Confidential 
Table 13. 
Schedule of Assessments - Part 3:  All Patients 
Procedurea 
Screening 
Dosing Period (21 day cycles) 
 
End of 
Treatment 
(After Last 
Dose) 
Follow-up 
(28 [±3] Days 
After Last 
Dose) 
Cycle 1 
Cycles 2 and 
Beyond 
Day -37 to Day -7 
Day -7b 
Day 1b 
Day 15 
Day 1 
Informed Consent 
X 
 
 
 
 
 
 
Medical/Oncology History 
X 
 
 
 
 
 
 
Physical Examination  
X 
X 
X 
Xc 
X 
X 
 
Height 
X 
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
 
ECOG Performance Status 
X 
X 
X 
 
X 
X 
 
Vital Signsd 
X 
X 
X 
X 
X 
X 
 
Prior/Concomitant Medications  
X 
X 
X 
X 
X 
X 
 
12-lead ECG (in Triplicate)e 
X 
 
 
 
 
X 
 
Hematologyf 
Xg 
X 
X 
X 
X 
X 
 
Serum Chemistryh 
Xg 
X 
X 
X 
X 
X 
 
Serum Pregnancy Testi 
X 
 
 
 
X 
X 
 
Tumor Marker Measurementj 
X 
X 
X 
 
X 
X 
 
Urinalysisk 
X 
X 
X 
 
X 
X 
 
Tumor Scansl 
X 
 
 
 
Xm 
X 
 
Archival Tumor Tissuen 
X 
 
 
 
 
X 
 
Adverse Eventso 
X 
X 
X 
X 
X 
X 
X 
Plasma PK Samples 
 
X 
X 
Xp 
Xq 
 
 
Randomization to fed/fasted sequencer 
X 
 
 
 
 
 
 
Serum AAG Sampless 
 
X 
X 
Xp 
Xq 
 
 
Oral Rucaparib 
Dispensation/Administration 
 
X 
X 
Xt 
X 
 
 
High-Fat Breakfastu 
 
(X) 
(X) 
 
 
 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 78 of 133 
Confidential 
BUN = blood urea nitrogen, CT = computer tomography, EOS = end of study, HDL = high density lipoprotein; LDL = low density lipoprotein; MRI = magnetic 
resonance imaging, PET = positron emission tomography, SAE = serious adverse event 
a = Unless specified, procedure is completed within ±1 day of scheduled time point and is synchronized with administration day of rucaparib. 
b = At Day -7 and Day 1 of Cycle 1, any procedure may be omitted if completed ≤3 days earlier during the screening period.  
c 
= Limited/targeted physical exam to be performed on Day 15 of Cycle 1. 
d = Vital signs (blood pressure, pulse, and temperature) taken predose on drug administration days, after the patient has been resting for at least 5 min. 
e 
= 12-lead ECGs (in triplicate) (predose, where applicable) will be run for 10 seconds, >2 min apart, with patient resting for 5 min prior to recording.   
f 
= Includes hemoglobin, hematocrit, WBC and differential (with ANC), and platelet count.  Blood will be analyzed by a local laboratory and must be reviewed by the 
investigator prior to dosing with rucaparib. 
g = To be performed ≤14 days prior to the first dose of rucaparib. 
h = Includes total protein, albumin, creatinine, BUN or urea, total bilirubin, ALP, ALT, AST, lipid panel (total cholesterol, LDL, HDL, and triglycerides), glucose, 
sodium, potassium, chloride, CO2, calcium, and phosphorus.  Blood will be analyzed by a local laboratory.   
i 
= Serum ß-hCG (evaluated by local labs) will be performed only on women of childbearing potential at the following time points:  ≤ 3 days prior to the first dose of 
rucaparib, ≤ 3 days prior to Day 1 of every cycle from Cycle 2 and beyond, and at the End-of-Treatment Visit. 
j 
= Markers as measured by local and central laboratories at screening and by central laboratory for all other time points. 
k 
= Includes dipstick for protein, glucose, blood, pH, and ketones.  Microscopic evaluation will be performed routinely. 
l 
= Tumor assessments to consist of clinical examination and appropriate imaging techniques (preferably CT scans of the chest, abdomen, and pelvis, with appropriate 
slice thickness per RECIST); other studies (MRI, X-ray, PET, and ultrasound) may be performed if required.  The same methods used to detect lesions at baseline 
are to be used to follow the same lesions throughout the clinical study. Tumors scans will be collected and sent for evaluation by independent radiology review. 
m = Tumor scans to be performed within 7 days prior to the start of Cycles 3, 5, and 7, and then within 7 days prior to the start of every third cycle of treatment 
thereafter, beginning at Cycle 10.  If initial CR or PR is noted prior to start of Cycle 7 or beyond, confirmatory scans must be performed 4–6 weeks later. 
n = Archival tumor tissue will be confirmed available at screening (submitted during study).  An optional biopsy sample may be taken at time of disease 
progression/discontinuation of treatment.  Refer to the Pathology Charter for detailed sample handling instructions. 
o = AEs are recorded from time of signing of informed consent through 28 days after last dose of rucaparib.  Ongoing SAEs should be followed until resolution. 
p = First PK/AAG sample to be collected approximately 12 h after the last dose, but prior to the next dose (i.e., typically 5–10 min prior to dosing [see detailed table for 
additional details]). 
q = PK sample to be collected any time prior to dosing for Cycles 2, 3, 5, 7, and 9. If dosing is held for toxicity or any other reason, PK sample should still be collected 
at the end of treatment Cycles 1, 2, 4, 6, and 8. 
r 
= Prior to Day -7 to allow advanced preparation of high fat breakfast for fed condition. 
s 
= Serum AAG sample to be collected on the same day as the PK sample.   
t 
= Second dose of rucaparib to be given at 12 hours ± 30 minutes after the first (morning dose). 
u = High fat breakfast will be on either Day -7 or Day 1. 
 


Clovis Oncology, Inc. 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
Page 79 of 133 
Confidential 
Table 14. 
Schedule of Dosing and Pharmacokinetic Sampling for Part 3 Patients 
 
 
 
 
Procedure and Time Points 
Cycle 1 
Cycles 2+ 
Day -7 
Day 1 
Day 15 
Day 22 
Day 1a 
Oral Rucaparib Administrationb 
Xc 
Xd 
X 
 
X 
Plasma PK Samples (Any Time Prior to Dosing, if Applicable) 
X 
X 
 
X 
Xe 
Plasma PK Sample, Predose (5–10 min Prior to Dosing) 
 
 
X 
 
 
Plasma PK Samples, Postdose (15 [±2] min, 30 [±3] min, 1 h [±5 min], 1.5 h [±5 
min], 2.5 h [±5 min], 4 h [±15 min], 6 h [±15 min], 8 h [±15 min], 10 h [±30 
min], and 24 h [±30 min]) 
X 
X 
X 
 
 
a 
= 
Cycle 2, Day 1 assessments do not need to be repeated if the visit is the same day as Cycle 1, Day 22 or no more than 7 days later.  Note:  the plasma PK sample should 
be collected on Day 22 of Cycle 1 only.  No additional sample should be collected if a separate Cycle 2, Day 1 visit is required. 
b 
= 
Unless otherwise specified or instructed based on results of food effect PK evaluation, patients may take rucaparib on an empty stomach or with food. 
c 
= 
Patients must fast for 10 h prior to, and 4 h after, rucaparib administration. 
d 
= 
Patients must fast for 10 h prior, and 4 h after, rucaparib administration. 
e 
= 
Cycle 2, Day 1 PK sample is the same as the Cycle 1, Day 22 sample. 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 80 of 133 
Confidential 
9.2 
Screening Period (Parts 1-3) 
Following written informed consent, and unless otherwise specified, the following assessments 
will be performed during the 30 day period prior to the first dose of oral rucaparib.  Assessments 
performed prior to patient signing informed consent are acceptable only if confirmed to have 
been standard of care. 
• Medical history, including demographic information (birth date, race, gender, etc.) and 
smoking status, and oncology history, including date of cancer diagnosis, and any surgical 
procedures 
• Physical examination by body system, height, and weight 
• ECOG performance status (Appendix B) 
• Vital signs (blood pressure, pulse, and temperature) 
• Prior and concomitant medications 
• 12-lead ECG (in triplicate >2 min apart) 
• ECHO or MUGA scan (Part 1 Only) 
• Hematology (hemoglobin, hematocrit, WBC and differential [with ANC], and platelet 
count) ≤14 days prior to the first day of dosing 
• Serum chemistry (total protein, albumin, creatinine, blood urea nitrogen [BUN] or urea, 
total bilirubin, ALP, ALT, AST, glucose, sodium, potassium, chloride, CO2, calcium, and 
phosphorus) and lipid panel (total cholesterol, low density lipoprotein [LDL], high density 
lipoprotein [HDL], and triglycerides: part 3 only) ≤14 days prior to the first day of dosing 
• Tumor marker(s) (optional for all patients in Part 1); CA-125 measurement required for all 
patients in Part 2; appropriate tumor markers to be collected for all patients in Part 3.  
(Note: tumor marker data will be collected retroactively for all Part 1 patients who were 
enrolled under other protocol versions) 
• Serum pregnancy test (by local laboratory) ≤ 3 days prior to the first day of dosing for 
women of childbearing potential 
• Urinalysis performed on freshly voided clean sample (dipstick for protein, glucose, blood, 
pH, and ketones).  If dipstick findings are abnormal based on investigator judgment, then a 
microscopic evaluation will be performed to assess the abnormal findings (Parts 1 & 2). In 
Part 3, urinalysis to be performed ≤14 days prior to the first day of dosing; microscopic 
evaluation will performed routinely 
• Tumor assessments should consist of clinical examination and appropriate imaging 
techniques (preferably computed tomography [CT] scans of the chest, abdomen, and pelvis 
with appropriate slice thickness per RECIST); other studies (MRI, X-ray, positron emission 
tomography [PET], and ultrasound) may be performed if required.  The same methods used 
to detect lesions at baseline are to be used to follow lesions throughout the clinical study. 
• AE monitoring (after signing informed consent) 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 81 of 133 
Confidential 
• Tumor tissue sample – archival tissue and/or fresh biopsy are required as follows:   
− Part 1, an optional archival and/or fresh biopsy may be collected 
− Part 2, an archival tumor tissue sample will be required from all newly enrolled patients 
and will also be collected from previously enrolled patients who provide appropriate 
consent.  The sample is not required to be provided before enrollment, but should be 
submitted as soon as possible after a patient begins treatment.  An optional fresh biopsy 
may be collected at screening and/or at time of disease progression/treatment 
discontinuation  
− Part 3, archival tissue will be collected after being confirmed as being available. The 
sample is not required to be provided before enrollment, but should be submitted as soon 
as possible after a patient begins treatment. For archival tissue, the most recent sample 
collected prior to treatment should be provided.  Refer to the Laboratory Manual for 
detailed sample collection, preparation, and shipment instructions. An optional fresh 
biopsy may be collected at time of disease progression/treatment discontinuation 
9.3 
Part 1 - Dose-Escalation Evaluation Period 
Before enrolling a patient into Part 1, all eligibility criteria must be satisfied.  Patients who 
qualify for the study will be enrolled into the first available cohort. 
Unless otherwise specified, all patients in Part 1 will undergo the following procedures and 
assessments. 
9.3.1 
Day -8 Prior to Cycle 1 (Food Effect PK Cohort Only) 
• Vital signs 
• Concomitant medications since screening 
• 12-lead ECG (in triplicate >2 min apart) at a time point equivalent to the estimated 
postdose Tmax of oral rucaparib (this ECG will be time-matched to the 12-lead ECG taken 
on Day -7 at estimated Tmax [2 h postadministration] following dosing with oral rucaparib) 
• AE monitoring 
9.3.2 
Day -7 Prior to Cycle 1 (Food Effect PK Cohort Only) 
Patients will be instructed to arrive for their visit having fasted for at least 10 h.  The following 
procedures will be completed before receiving the first dose of oral rucaparib.  Any procedure, 
except for the ECGs, may be omitted if completed ≤3 days earlier during the screening period.   
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 82 of 133 
Confidential 
• Concomitant medications  
• Hematology and serum chemistry 
• AE monitoring 
• PK blood sample (any time prior to dosing) 
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered with 8 oz 
(240 mL) of room temperature water.  Patients must fast for at least 2 h after dosing.  The 
following procedures will be performed over a 24-h period after dosing.  The frequency of the 
PK blood samples may require patients to stay overnight either at the clinic or in the vicinity.   
• Postdose PK blood sampling collected at the following time points:  15 (±2) min, 30 (±3) 
min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 8 h 
(±15 min), 10 h (±30 min), and 24 h (±30 min) 
• Postdose 12-lead ECG (in triplicate >2 min apart) taken at estimated Tmax (2 h 
postadministration) and at 7 h postadministration of oral rucaparib 
• AEs experienced by the patient since dosing and/or before leaving the clinic will be 
documented 
• Concomitant medications administered since dosing will be recorded 
9.3.3 
Day -1 Prior to Cycle 1 
The following procedures will be completed on Day -1: 
• Vital signs 
• Concomitant medications 
• 12-lead ECG (in triplicate >2 min apart) at a time point equivalent to the estimated 
postdose Tmax of oral rucaparib (this ECG will be time-matched to the 12-lead ECG taken 
on Day 1 at estimated Tmax [2 h postadministration] following oral dosing with oral 
rucaparib) 
• AE monitoring 
9.3.4 
Day 1 of Cycle 1 
Patients enrolled into a food effect PK evaluation cohort will be instructed to arrive for their visit 
having fasted for at least 10 h.  All other patients can take rucaparib on an empty stomach or with 
food (with a regular meal or within 30 minutes after a regular meal).  The following procedures 
will be completed before oral rucaparib is administered: 
• Physical examination 
• Weight 
• ECOG performance status (Appendix B) 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 83 of 133 
Confidential 
• Vital signs 
• Concomitant medications 
• Hematology and serum chemistry 
• Tumor marker(s) (optional).  Note: tumor marker data will be collected retroactively for 
all Part 1 patients who were enrolled under other protocol versions. 
• AE monitoring 
• High-fat breakfast started (and completed within) 30 min prior to dosing with oral 
rucaparib (patients enrolled in a food-effect PK evaluation cohort only) 
• PK blood sample (any time prior to dosing) (Note:  A duplicate set of samples is to be 
collected from the first three patients enrolled into the RP2D Expansion cohort.  The 
second sample will serve as the baseline sample for metabolite profiling.) 
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered with 8 oz 
(240 mL) of room temperature water.  Patients enrolled into a food effect PK evaluation cohort 
must fast for at least 4 h after dosing.  The following procedures will be performed over a 24 h 
period after dosing.  The frequency of the PK blood samples may require patients to stay 
overnight either at the clinic or in the vicinity.   
• Postdose PK blood sampling collected at the following time points:  15 (±2) min, 
30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 
8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) 
• Postdose 12-lead ECG (in triplicate >2 min apart) taken at estimated Tmax (2 h after 
administration) and at 7 h after administration of oral rucaparib 
• AEs experienced by the patient since dosing will be documented 
• Concomitant medications administered since dosing will be recorded 
Patients will continue dosing with oral rucaparib at home on an empty stomach or with food 
(with a regular meal or within 30 minutes after a regular meal) at about the same time every day.  
Oral rucaparib should be taken with 8 oz of room temperature water.  Patients will record dosing 
information in their daily dosing diary. 
9.3.5 
Days 8, 15, and 22 of Cycle 1 
Patients will be instructed to refrain from taking their first dose of oral rucaparib at home on the 
day of their clinic visits because the dose will be taken during the clinic visit.  
The following procedures will be completed prior to administration of oral rucaparib on Days 8, 
15, and 22 of Cycle 1: 
• Physical examination (limited/targeted on Day 8 and Day 15) 
• Weight 
• Vital signs 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 84 of 133 
Confidential 
• Concomitant medications 
• Hematology and serum chemistry 
• AE monitoring 
• PK blood sample (any time prior to dosing) (Day 8 and Day 22) 
• PK blood sample (5–10 min prior to dosing) (Day 15 only) 
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered with 8 oz 
(240 mL) of room temperature water.  Patients can take rucaparib on an empty stomach or with 
food (with a regular meal or within 30 minutes after a regular meal).   
On Day 15, the following procedures will be performed over a 24 h period after dosing.  The 
frequency of the PK blood samples may require patients to stay overnight either at the clinic or 
in the vicinity.  
• Postdose PK blood sampling collected at the following time points:  15 (±2) min, 
30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 
8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) (Note:  A duplicate set of samples is to 
be collected from the first three patients enrolled into the RP2D Expansion cohort.  The 
second set of samples will be for metabolite profiling.) 
• Postdose 12-lead ECG (in triplicate >2 min apart) taken at estimated Tmax (2 h after 
administration) and at 7 h after administration of oral rucaparib 
• AEs experienced by the patient since dosing will be documented 
• Concomitant medications administered since dosing will be recorded 
Patients will continue dosing with oral rucaparib at home on an empty stomach or with food 
(with a regular meal or within 30 minutes after a regular meal), unless instructed otherwise based 
on results from PK food-effect analyses, and record dosing information in the daily dosing diary.   
9.4 
Part 1 - Optional Treatment-Extension Period 
Patients may participate in an optional Treatment-extension Period that begins on Day 1 of 
Cycle 2. 
9.4.1 
Day 1 of Cycle 2 and Beyond 
Note:  Cycle 2, Day 1 assessments do not need to be repeated if visit is the same day as 
Cycle 1, Day 22 or no more than 7 days later. 
Patients will be instructed to refrain from taking their first dose of oral rucaparib at home on the 
day of their clinic visit because the dose will be taken during the clinic visit.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 85 of 133 
Confidential 
On Day 1 of each cycle, patients participating in the optional Treatment-Extension Period will 
undergo the following procedures prior to rucaparib administration:   
• Physical examination 
• Weight 
• Vital signs and ECOG performance status 
• 12-lead ECG (in triplicate >2 min apart) 
• Hematology and serum chemistry 
• Tumor marker(s) (optional).  (Note: tumor marker data will be collected retroactively for 
all Part 1 patients who were enrolled under other protocol versions).   
• Predose PK blood sample (Note:  Applies to Cycle 3, Day 1-Cycle 9, Day 1only; the 
Cycle 2, Day 1 PK sample will be collected as a Cycle 1, Day 22 assessment.) 
• Concomitant medications 
• AE monitoring 
• Tumor scans (using the same methodology as was used at screening) within 7 days prior 
to the start of Cycles 3, 5, and 7, and then within 7 days prior to the start of every third 
cycle of treatment thereafter, beginning with Cycle 10 
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered with 8 oz 
(240 mL) of room temperature water.  Patients can take rucaparib on an empty stomach or with 
food (with a regular meal or within 30 minutes after a regular meal).   
Patients will continue dosing with oral rucaparib at home on an empty stomach or with food, 
unless instructed otherwise based on results from PK food-effect analyses, and record dosing 
information in the daily dosing diary. 
9.5 
Part 2 (Phase II Portion in OC Patients) 
Patients will be enrolled into Part 2 once the RP2D has been determined in Part 1 and all patients 
enrolled into the RP2D Expansion cohort have completed two cycles of treatment or 
discontinued from the study prior to completing two cycles of treatment. 
Before enrolling a patient into Part 2, all eligibility criteria must be satisfied. 
9.5.1 
Day 1 of Cycle 1 
The following procedures will be completed before oral rucaparib is administered.  Any 
procedures that were conducted ≤3 days earlier during the screening period may be omitted.   
• Physical examination 
• Weight 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 86 of 133 
Confidential 
• ECOG performance status 
• Vital signs 
• Concomitant medications 
• 12-lead ECG (in triplicate >2 min apart) (Part 2A only) 
• Hematology and serum chemistry 
• CA-125 measurement 
• AE monitoring 
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered with 8 oz 
(240 mL) of room temperature water. 
Patients will continue dosing with oral rucaparib at home on an empty stomach or with food at 
about the same time every day, and record dosing information in the daily dosing diary. 
9.5.2 
Day 15 of Cycle 1 
Patients will be instructed refrain from taking their first dose of oral rucaparib at home on the 
day of their clinic visit until safety assessments have been completed. Patients can then take 
rucaparib at home or in the clinic on this day.  
The following procedures will be completed before oral rucaparib is administered. 
• Physical examination 
• Weight 
• Vital signs 
• Concomitant medications  
• Hematology and serum chemistry 
• Alpha-1 acid glycoprotein (AAG) serum sample 
• PK blood sample (approximately 12 hrs after the last dose, but prior to the next dose [i.e., 
typically 5–10 min prior to dosing])  
• AE monitoring 
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered with 8 oz 
(240 mL) of room temperature water.  Patients can take rucaparib on an empty stomach or with 
food.   
Patients will continue dosing with oral rucaparib at home on an empty stomach or with food and 
record dosing information in the daily dosing diary. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 87 of 133 
Confidential 
9.5.3 
Day 1 of Cycle 2 and Beyond 
The following procedures will be completed:   
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• Concomitant medications  
• 12-lead ECG (in triplicate >2 min apart) (Part 2A only) 
• Hematology and serum chemistry 
• Serum pregnancy test for women of childbearing potential (≤ 3 days prior to start of cycle) 
• CA-125 measurement 
• AAG serum sample (Any time PK sample is collected) 
• PK blood sample (any time prior to dosing) for Cycles 2, 3, 5, 7, and 9. If dosing is held 
for toxicity or any other reason, PK sample should still be collected at the end of treatment 
Cycles 1, 2, 4, 6, and 8 
• AE monitoring 
• Tumor scans (using the same methodology as was used at screening) within 7 days prior 
to the start of Cycles 3, 5, and 7, and then within 7 days prior to the start of every third 
cycle of treatment thereafter, beginning with Cycle 10 
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered with 8 oz 
(240 mL) of room temperature water.  Patients can take rucaparib on an empty stomach or with 
food. 
Patients will continue dosing with oral rucaparib at home on an empty stomach or with food and 
record dosing information in the daily dosing diary. 
9.6 
Part 3 (Phase II PK in Patients with Any Advanced Solid Tumor) 
Patients enrolled into Part 3 will be treated at the RP2D. 
Before enrolling a patient into Part 3, all eligibility criteria must be satisfied. 
Screening assessments to be completed prior to day -7 and first dose given. A randomization 
assignment call must be made before Day -7 in order to allow preparation of a high-fat breakfast 
in advance of the appropriate day. Patients will be randomized to a sequence of fed on Day -7 
and then fasted on Day 1, or, fasted on Day -7 and then fed on Day 1. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 88 of 133 
Confidential 
All patients enrolled into Part 3 will have plasma samples drawn in order to evaluate the PK 
profile of 600 mg single dose rucaparib administered as 300 mg tablets in the fed versus fasted 
state and 600 mg BID (Day 15 of Cycle 1). Patients receive do not receive rucaparib between 
dose given on morning of Day -7 and dose given on morning of Day 1. 
9.6.1 
Day -7 Prior to Cycle 1 (single dose fed or fasted PK) 
Patients will be instructed to arrive for their visit having fasted for at least 10 h.  A PK blood and 
serum AAG sample must be collected from the patient before they receive the first dose of oral 
rucaparib, unless a sample was obtained ≤3 days earlier during the screening period.  The 
following procedures will be completed before oral rucaparib is administered. 
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• Concomitant medications 
• Hematology and serum chemistry 
• Urinalysis 
• AE monitoring 
• Serum AAG sample 
• High-fat breakfast if randomized to fed sequence; started (and completed within) 30 min 
prior to dosing with oral rucaparib 
Oral rucaparib will be administered with 8 oz (240 mL) of room temperature water.  Patients 
must fast for at least 4 h after dosing.  The following procedures will be performed over a 24-h 
period after dosing.  The frequency of the PK blood samples may require patients to stay 
overnight either at the clinic or in the vicinity.   
• Postdose PK blood sampling collected at the following time points:  15 (±2) min, 
30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 8 h 
(±15 min), 10 h (±30 min), and 24 h (±30 min) 
9.6.2 
Day 1 of Cycle 1 (single dose fasted or fed PK) 
Patients will be instructed to arrive for their visit having fasted for at least 10 h.  The following 
procedures will be completed before oral rucaparib is administered.  
• Physical examination 
• Weight 
• ECOG performance status 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 89 of 133 
Confidential 
• Vital signs 
• Concomitant medications 
• Hematology and serum chemistry (to be collected prior to high-fat breakfast) 
• Urinalysis (to be collected prior to high-fat breakfast) 
• Tumor markers (as appropriate for tumor type) 
• AE monitoring 
• PK blood sample (any time prior to dosing)  
• Serum AAG sample 
• High-fat breakfast started if randomized to fed sequence; started (and completed within) 
30 min prior to dosing with oral rucaparib  
Oral rucaparib will be administered with 8 oz (240 mL) of room temperature water.  Patients 
must fast for at least 4 h after dosing.  The following procedures will be performed over a 24 h 
period after dosing.  The frequency of the PK blood samples may require patients to stay 
overnight either at the clinic or in the vicinity.  Rucaparib tablets will be dispensed to the patient 
after 24 h blood draw for 600 mg BID dosing.   
• Postdose PK blood sampling collected at the following time points:  15 (±2) min, 
30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 
8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) 
• AEs experienced by the patient since dosing will be documented 
• Concomitant medications administered since dosing will be recorded 
Starting on Day 2 Cycle 1 (after 24h sampling point), patients will start dosing with oral 
rucaparib BID at home (first dose may be at hospital site) on an empty stomach or with food  at 
about the same time every day, and record dosing information in the daily dosing diary. 
9.6.3 
Day 15 of Cycle 1 
Patients will be instructed refrain from taking their first dose of oral rucaparib at home on the 
day of their clinic visit because the dose will be taken during the clinic visit.  
The following procedures will be completed before oral rucaparib is administered. 
• Physical examination 
• Weight 
• Vital signs 
• Concomitant medications  
• Hematology and serum chemistry (including lipid panel) 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 90 of 133 
Confidential 
• AAG serum sample 
• PK blood sample (5–10 min prior to dosing)  
• AE monitoring 
Oral rucaparib will be administered with 8 oz (240 mL) of room temperature water.  Patients can 
take rucaparib on an empty stomach or with food  
The following procedures will be performed over a 24 h period after morning dosing.  The 
frequency of the PK blood samples may require patients to stay overnight either at the clinic or 
in the vicinity.  
• Postdose PK blood sampling collected at the following time points:  15 (±2) min, 
30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 
8 h (±15 min), 10 h (±30 min), and 24 h (±30 min)  
• AEs experienced by the patient since dosing will be documented 
• Concomitant medications administered since dosing will be recorded 
Patients will continue dosing with oral rucaparib BID at home on an empty stomach or with food 
and record dosing information in the daily dosing diary. The second dose of Day 15 will be taken 
12(±30 min) hours after the morning dose. 
9.6.4 
Day 1 of Cycle 2 and Beyond 
The following procedures will be completed:   
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• Concomitant medications  
• Hematology and serum chemistry (including lipid panel) 
• Serum pregnancy test for women of childbearing potential (≤ 3 days prior to start of cycle) 
• Urinalysis 
• Tumor markers (as appropriate for tumor type) 
• AAG serum sample (any time PK sample is collected) 
• PK blood sample (any time prior to dosing) for Cycles 2, 3, 5, 7, and 9. If dosing is held 
for toxicity or any other reason, PK sample should still be collected at the end of treatment 
Cycles 1, 2, 4, 6, and 8 
• AE monitoring 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 91 of 133 
Confidential 
• Tumor scans (using the same methodology as was used at screening) within 7 days prior 
to the start of Cycles 3, 5, and 7, and then within 7 days prior to the start of every third 
cycle of treatment thereafter, beginning with Cycle 10.  Additional consent will be taken 
for tumor scans to be collected and stored for possible evaluation by independent 
radiology review  
Rucaparib tablets will be dispensed to the patient.  Oral rucaparib will be administered BID with 
8 oz (240 mL) of room temperature water.  Patients can take rucaparib on an empty stomach or 
with food.   
Patients will continue dosing with oral rucaparib at home on an empty stomach or with food and 
record dosing information in the daily dosing diary. 
9.7 
End-of-Treatment Visit (Parts 1-3) 
The following procedures will be performed for all patients after the last dose of oral rucaparib: 
• Physical examination 
• Weight 
• ECOG performance status 
• Vital signs 
• Concomitant medications since last visit 
• ECGs (in triplicate >2 min apart) 
• Hematology and serum chemistry (including lipid panel) 
• Serum pregnancy test for women of childbearing potential  
• Urinalysis (Part 3 only) 
• Tumor marker(s) (optional for all patients in Part 1; in Part 2 CA-125 required for all 
patients and in Part 3, appropriate markers according to tumor type e.g., CA-125 or CEA 
are collected).  (Note: tumor marker data will be collected retroactively for all Part 1 
patients who were enrolled under other protocol versions). 
• Serum pregnancy test for women of childbearing potential 
• Tumor scans (using the same methodology as was used at screening). Tumor scans to be 
collected and stored for possible evaluation by independent radiology review (for Part 2A, 
Part 2B, and Part 3 patients) 
• Tumor tissue sample – archival and/or fresh biopsy.  Refer to the Laboratory Manual for 
detailed sample collection, preparation, and shipment instructions.  
− Part 1, an optional fresh biopsy may be collected at time of disease progression/treatment 
discontinuation  
− Part 2, an archival tumor tissue sample will be required from all newly enrolled patients 
and will also be collected from previously enrolled patients who provide appropriate 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 92 of 133 
Confidential 
consent. The sample is not required to be provided before enrollment, but should be 
submitted as soon as possible after a patient begins treatment.  An optional fresh biopsy 
may be collected at time of disease progression/treatment discontinuation 
− Part 3, an optional fresh biopsy may be collected at time of disease progression/treatment 
discontinuation  
• AE monitoring 
9.8 
Follow-up Visit 
The following procedures will be performed at 28 (±3) days after the last dose of rucaparib: 
• AE monitoring (ongoing SAEs and AEs of special interest [AESI]should be followed until 
resolution, stabilization, or patient is lost to follow-up) 
9.9 
Long-term Follow-up 
For Part 2B patients only: 
• All Part 2B patients discontinued from treatment, regardless of reason, should be followed 
for survival, subsequent anti-cancer treatments, and secondary malignancy monitoring 
every 12 weeks [±7 days] until death, loss to follow-up, withdrawal of consent from study, 
or study closure, whichever happens first.  Follow-up can be performed via the telephone.  
Diagnosis of any secondary malignancy requires appropriate documentation (i.e., 
laboratory and/or pathology reports).  
• Tumor scans (using the same methodology as was used at screening) for any patient who 
discontinued from study treatment for reason other than disease progression or death to be 
performed within 7 days prior to the start of every 9 weeks until radiologically confirmed 
disease progression, death, or initiation of subsequent treatment.  Patients who have been 
on study at least 18 months may decrease the frequency of tumor scans to every 16 weeks 
[±14 days] 
9.10 Methods of Data Collection 
9.10.1 Pharmacokinetic Evaluations 
9.10.1.1 Pharmacokinetic Blood Sample Collection in Part 1 
For patients in Part 1, 4 mL venous blood samples for the PK analysis of oral rucaparib will be 
drawn at the following time points: 
• Day -7 prior to Cycle 1 (food-effect PK evaluation cohort[s] only):  Prior to rucaparib 
administration, and at 15 (±2) min, 30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 
min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) 
after dosing 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 93 of 133 
Confidential 
• Day 1 of Cycle 1 (all patients in Part 1):  Prior to rucaparib administration, and at 15 (±2) 
min, 30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h 
(±15 min), 8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) after dosing 
− An additional 4 mL sample will be collected prior to rucaparib administration from the 
first 3 patients enrolled into the RP2D Expansion cohort.  This will serve as the baseline 
sample for subsequent profiling of circulating metabolites of rucaparib that will be 
performed on PK samples collected on Day 15 of Cycle 1. 
• Day 8 of Cycle 1 (all patients in Part 1):  Prior to rucaparib administration 
• Day 15 of Cycle 1 (all patients in Part 1):  At 5–10 min prior to rucaparib administration, 
and at 15 (±2) min, 30 (±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h 
(±15 min), 6 h (±15 min), 8 h (±15 min), 10 h (±30 min), and 24 h (±30 min) after dosing 
− In order to profile circulating metabolites of rucaparib at steady state, additional 4 mL 
samples will be collected pre- and postdose (at the same time points as noted above) from 
the first three patients enrolled into the RP2D Expansion cohort. 
• Day 22 of Cycle 1 (all patients in Part 1):  Prior to rucaparib administration (Note:  This 
sample is equivalent to Day 1 of Cycle 2.) 
• Day 1 of Cycle 3-Cycle 9 (all patients in Part 1 who opt to continue with rucaparib 
treatment for additional cycles), prior to rucaparib administration 
9.10.1.2 Pharmacokinetic Blood Sample Collection in Part 2 
For patients in Part 2, 4 mL venous blood samples for the PK analysis of rucaparib will be drawn 
at the following time points: 
• Day 1 of Cycles 2, 3, 5, 7, and 9, prior to dosing with rucaparib. If dosing is held for 
toxicity or any other reason, PK sample should still be collected at the end of treatment 
Cycles 1, 2, 4, 6, and 8  
• Day 15 of Cycle 1, 5–10 min prior to dosing with rucaparib 
9.10.1.3 Pharmacokinetic Blood Sample Collection in Part 3 
For patients in Part 3, 3 mL venous blood samples for the PK analysis of oral rucaparib will be 
drawn at the following time points: 
• Day -7 prior to Cycle 1:  Prior to rucaparib administration, and at 15 (±2) min, 30 (±3) 
min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 8 h 
(±15 min), 10 h (±30 min), and 24 h (±30 min) after dosing 
• Day 1 of Cycle 1:  Prior to rucaparib administration, and at 15 (±2) min, 30 (±3) min, 1 h 
(±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min), 10 h 
(±30 min), and 24 h (±30 min) after dosing  
• Day 15 of Cycle 1:  At 5–10 min prior to rucaparib administration, and at 15 (±2) min, 30 
(±3) min, 1 h (±5 min), 1.5 h (±5 min), 2.5 h (±5 min), 4 h (±15 min), 6 h (±15 min), 8 h 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 94 of 133 
Confidential 
(±15 min), 10 h (±30 min), and 24 h (±30 min) after morning dosing (second dose of 
rucaparib is given 12 h ±30 min after first [morning] dose) 
• Day 22 of Cycle 1:  Prior to rucaparib administration (Note:  This sample is equivalent to 
Day 1 of Cycle 2.) 
• Day 1 of Cycles 2, 3, 5, 7, and 9, prior to dosing with rucaparib. If dosing is held for toxicity 
or any other reason, PK sample should still be collected at the end of treatment Cycles 1, 2, 4, 
6, and 8 
9.10.1.4 Pharmacokinetic Evaluations 
PK evaluation will be based on the determination of (not limited to) AUC0–t, AUC0–∞, Cmax, Tmax, 
t1/2, and elimination rate constant (kel), volume of distribution at steady state after non-
intravenous administration (Vss/F), and total plasma clearance after oral administration (Cl/F). 
Central laboratories will be used for bioanalysis of oral rucaparib and its metabolites in human 
plasma.  Please refer to the laboratory manual for details on collection and processing of blood 
PK samples. 
9.10.2 AAG Measurement  
For all patients in Parts 2 & 3of the study, serum samples for AAG analysis will be collected pre-
dose on the same days as PK blood samples. 
9.10.3 Tumor Tissue Samples 
FFPE fresh and/or archival tumor tissue samples at screening and fresh biopsy at time of disease 
progression/treatment discontinuation will be optional for all patients in Part 1 of the study.  
Additional consent will be required. 
For patients in Part 2, an archival biopsy will be collected from all newly enrolled patients and 
from previously enrolled patients who provide appropriate consent.  The archival biopsy can be 
collected at any time during the study.  A biopsy sample at screening and/or time of disease 
progression/discontinuation of treatment is optional. 
For patients in Part 3, an archival biopsy will be confirmed as available at screening (mandatory 
for study entry) and subsequently submitted during the study as soon as possible after treatment 
begins.  An optional biopsy sample may be taken at time of disease progression/discontinuation 
of treatment. 
For fresh tissue, core needle biopsies should be collected from either primary tumor or an 
accessible lesion.  If a fresh tissue sample is not collected, an archival tumor tissue sample (most 
recent sample collected prior to treatment) should be provided.   Scrolls (for RNA extraction) 
and slides (for immunohistochemistry) will be prepared locally.  Information for tumor tissue 
collection and preparation will be provided in a laboratory manual. 
Analysis of the tumor tissue samples may include but not be limited to: 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 95 of 133 
Confidential 
• DNA extraction and sequencing in order to identify if a patient has a BRCA reversion or 
other mutation(s) that may be associated with response or resistance to rucaparib 
• Gene expression profiling on extracted RNA to potentially identify a signature associated 
with response to rucaparib  
• Immunohistochemistry analysis of tissue to determine if an immunohistochemistry assay 
can be developed to accurately identify homologous recombination repair deficiency in 
gBRCA patients 
9.10.4  
Safety Evaluations 
9.10.4.1  
Adverse Event Assessment 
The investigator has the responsibility for assessing the safety of the patients and for compliance 
with the protocol to ensure study integrity.  Patients will be monitored for AEs during study 
participation (beginning at the time informed consent is obtained) and until 28 days after the last 
dose of oral rucaparib.  Any ongoing SAEs will be followed until resolution or stabilization.  
AEs and laboratory abnormalities will be graded according to the NCI CTCAE2 grading system 
and recorded on the eCRF. 
Complete details for monitoring AEs, including the definition of drug-related AEs, are provided 
in Section 10. 
9.10.4.2  
Clinical Laboratory Investigations 
Certified local laboratories will perform study-related clinical laboratory tests according to 
institutional procedures, and the results will be reviewed by the investigator.  The panels of 
laboratory tests to be performed are shown below: 
Hematology:  Hemoglobin, hematocrit, WBC and differential (with ANC), and platelet count 
per the three schedules of evaluation at screening, during treatment, and at the end-of-study visit.  
Hematology results must be reviewed by the investigator prior to the start of treatment with oral 
rucaparib. 
Clinical Chemistry:  Total protein, albumin, creatinine, BUN or urea, total bilirubin, ALP, 
ALT, AST, lipid panel (total cholesterol, LDL, HDL, and triglycerides), glucose, sodium, 
potassium, chloride, CO2, calcium, and phosphorus per the three schedule of evaluations at 
screening, during treatment, and at the end-of-study visit.   
Urinalysis:  Performed on freshly voided clean sample by dipstick for protein, glucose, blood, 
pH, and ketones per the schedule of evaluations.  If dipstick findings are abnormal, then a 
microscopic evaluation will be performed to assess the abnormal findings.  Urinalysis will be 
performed at screening only (Parts 1 & 2). In Part 3, urinalysis is performed also at day 1 of each 
cycle and at EOT visit; microscopic evaluation shall be performed routinely.   
Serum ß-hCG Pregnancy Test:  Performed on women of childbearing potential ≤ 3 days before 
Day 1 Cycle 1, ≤ 3 days prior to Day1 of every cycle from Cycle 2 and beyond, and at the end-


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 96 of 133 
Confidential 
of-treatment visit.  A negative result must be confirmed by a physician before the first dose of 
oral rucaparib can be administered. 
Laboratory reports will be reviewed by the investigator or delegated physician who will then 
comment on out-of-range parameters and assess clinical significance.  Clinically significant 
abnormalities and associated panel results, as well as results of any additional tests performed as 
follow-up to the abnormalities, will be documented on the eCRF as an AE. 
9.10.4.3 Vital Signs 
Vital signs will include blood pressure, pulse, and body temperature.  All vital signs will be 
obtained after the patient has been resting for at least 5 min.  Vital signs will be performed at 
screening and at each study visit including the end-of-study visit.   
9.10.4.4 12-Lead Electrocardiograms 
For patients enrolled in Part 1, 12-lead ECGs (10 second ECG tracings collected in triplicate 
[>2 min apart]) will be taken at the following time points: 
• Screening (within 30 days prior to first rucaparib dose) 
• Day -8 prior to Cycle 1 (food-effect PK evaluation cohort[s] only): at a time point that 
will match estimated Tmax (2 h) following administration of oral rucaparib on Day -7 
• Day -7 prior to Cycle 1 (food-effect PK evaluation cohort[s] only: at the estimated Tmax 
(2 h) postdose, and at 7 h postdose 
• Day -1 prior to Cycle 1 (all Part 1 patients): at a time point that will match estimated Tmax 
(2 h) following administration of oral rucaparib on Day 1 
• Day 1 of Cycle 1 (all Part 1 patients): at the estimated Tmax (2 h) postdose, and at 7 h 
postdose 
• Day 15 of Cycle 1 (all Part 1 patients): at the estimated Tmax (2 h) postdose, and at 7 h 
postdose 
• Day 22 of Cycle 1 (all Part 1 patients): prior to dosing, if same date as Day 1 of Cycle 2. 
• Day 1 of Cycles 2 and beyond (all Part 1 patients): prior to dosing 
• End-of treatment 
In addition, patients in Part 1 receiving antiemetic medications known to produce QT 
prolongation will require additional ECG measurements at estimated Tmax.  ECGs should be 
performed approximately 2, 4, and 6-7 hours after dosing with rucaparib when the patient begins 
treatment with the antiemetic and again at the same timepoints 1 to 2 weeks later. 
ECGs should be performed after the patient has been resting for at least 5 min.  The 12-lead 
ECGs will be analyzed at a central ECG laboratory.  Details on recording ECGs and preparation 
for central interpretation will be included in the investigator’s file. The Sponsor will allow local 
ECG testing once sufficient centrally obtained data has been collected. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 97 of 133 
Confidential 
For patients enrolled in Part 2, 12-lead ECGs (10 second ECG tracings collected in triplicate 
[>2 min apart]) will be taken at the following time points: 
• Screening (within 30 days prior to first rucaparib dose) 
• Day 1 of Cycle 1 and Day 1 of Cycles 2 and beyond: prior to dosing (Part 2A only) 
• End-of treatment 
For patients enrolled in Part 3, 12-lead ECGs (10 second ECG tracings collected in triplicate 
[>2 min apart]) will be taken at the following time points: 
• Screening (within 30 days prior to first rucaparib dose) 
• End-of treatment 
9.10.4.5 Body Weight and Height 
Height will be measured during the screening visit only.  Weight will be measured at most clinic 
visits (the patient should be in light indoor clothes).   
9.10.4.6 Physical Examinations 
Physical examinations will include an assessment of all the major body systems.  Physical 
examinations will be performed at screening (complete) and at most study visits (limited as 
appropriate).  
9.10.4.7 ECOG Performance Status 
ECOG performance status (Appendix B) will be assessed at screening, on Day 1 of each cycle, 
and at the end-of-study visit.  ECOG performance status should be assessed by the same study 
personnel at each visit, if possible.  Care will be taken to accurately score performance status, 
especially during screening for study eligibility purposes.  Additional consideration should be 
given to borderline ECOG performance status to avoid enrolling patients with significant 
impairment. 
9.10.5 Efficacy Evaluations 
9.10.5.1 Tumor Assessments 
For Part 1 and Part 2, tumor assessments will be performed at screening, within 7 days prior to 
the start of Cycles 3, 5, and 7, within 7 days prior to the start of every three cycles thereafter, 
beginning with Cycle 10, and at the end-of-treatment visit. 
For Part 2B, tumor assessments will also be performed during the long-term follow-up period for 
any patient who discontinued from study treatment for reason other than disease progression or 
death, within 7 days prior to the start of every 9 weeks until radiologically confirmed disease 
progression, death, or initiation of subsequent treatment.  Patients who have been on study at 
least 18 months may decrease the frequency of tumor scans to every 16 weeks (±14 days). 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 98 of 133 
Confidential 
For Part 3, tumor scans will be performed at screening, within 7 days prior to the start of 
Cycles 3, 5, and 7, and within 7 days prior to the start of every three cycles thereafter, beginning 
with Cycle 10.   
If initial CR or PR is noted at Cycle 7 or beyond, confirmatory scans must be performed 4−6 
weeks later.  Tumor response will be interpreted using RECIST Version 1.1 (Appendix A). 
Tumor assessments should consist of clinical examination and appropriate imaging techniques 
(preferably CT scans of the chest, abdomen, and pelvis with appropriate slice thickness per 
RECIST); other studies (MRI, X-ray, PET, and ultrasound) may be performed if required.  The 
same methods used to detect lesions at baseline are to be used to follow the same lesions 
throughout the clinical study.  Investigators should perform scans of the anatomical sites that, in 
their judgment, are appropriate to assess based on each patient’s tumor status.  For patients in 
Part 2 and Part 3, tumor scans will be collected for possible evaluation by independent radiology 
review. 
9.10.5.2 Tumor Markers 
In Part 1, tumor markers are optional. 
In Part 2, CA-125 will be collected at screening, on Day 1 of every cycle, and at the end of 
treatment visit, performed by a certified local laboratory. 
In Part 3 tumor markers appropriate to the tumor type will be collected at screening, on Day 1 of 
every cycle, and at the end of treatment visit. Appropriate markers are those that are routinely 
collected to monitor progress of disease eg CA-125 in ovarian cancer; Carcinoembryonic 
Antigen (CEA) in colon cancer. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 99 of 133 
Confidential 
10 ADVERSE EVENT MANAGEMENT 
10.1 Definition of an Adverse Event 
An AE is defined as any untoward medical occurrence in a patient administered a medicinal 
product that does not necessarily have a causal relationship with this treatment.  An AE can, 
therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an investigational product, whether or 
not related to the investigational medicinal product.  This includes an exacerbation of 
pre-existing conditions or events, intercurrent illnesses, drug interaction, or the significant 
worsening of the indication under investigation that is not recorded elsewhere on the eCRF under 
specific efficacy assessments.  Anticipated fluctuations of pre-existing conditions, including the 
disease under study, that do not represent a clinically significant exacerbation or worsening are 
not considered AEs. 
For the purposes of this study, disease progression of the patient’s tumor with new or worsening 
symptoms must be documented as an AE.  However, disease progression documented solely by 
radiographic evidence with no new or worsening symptoms will not require reporting as an AE.   
It is the responsibility of the investigator to document all AEs that occur during the study.  AEs 
should be elicited by asking the patient a nonleading question (e.g., “Have you experienced any 
new or changed symptoms since we last asked/since your last visit?”).  AEs will be reported on 
the AE eCRF.  Symptoms reported spontaneously by the patient during the physical examination 
will also be documented on the AE eCRF (not on the physical examination eCRF, which is 
reserved for physical signs or findings). 
10.2 Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that occurs at any dose (including after informed 
consent is given and prior to dosing) that: 
• Results in death.  Death may occur as a result of the underlying disease process.  
Nevertheless, any event resulting in death during the reporting period must be treated as 
an SAE and reported as such.  All deaths occurring within 28 days of the last 
administration of oral rucaparib will be reported as SAEs.   
• Is life-threatening (patient is at immediate risk of death from the event as it occurred). 
• Requires in-patient hospitalization (formal admission to a hospital for medical reasons) or 
prolongation of existing hospitalization. 
• Results in persistent or significant disability/incapacity. 
• Results in a congenital anomaly/birth defect. 
Important medical events that may not result in death, are not life-threatening, or do not require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of such events include allergic bronchospasm 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 100 of 133 
Confidential 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or seizures that 
do not result in in-patient hospitalization, or the development of drug dependency or drug abuse. 
10.3 Definition of an Adverse Event of Special Interest (AESI) 
An AE of special interest (serious or nonserious) is one of scientific and medical concern 
specific to the sponsor’s product or program, for which ongoing monitoring and rapid 
communication by the investigator to the sponsor can be appropriate.  Such an event might 
warrant further investigation in order to characterize and understand it.  Depending on the nature 
of the event, rapid communication by the trial sponsor to other parties (e.g., health authorities or 
ethics committees) might also be warranted.  
Details on the sponsor’s currently agreed list of AESIs for rucaparib can be found in the current 
rucaparib Investigator’s Brochure.  These AESIs are to be reported to the sponsor expeditiously 
(see Section 10.9 for reporting instructions).  
10.4 Events or Outcomes Not Qualifying as Serious Adverse Events 
The following are not considered SAEs and therefore are not required to be reported to the 
Sponsor: 
• Pre-planned or elective hospitalization, including social and/or convenience situations (e.g., 
respite care). 
• Hospital visits of less than 24 hours duration (e.g., patient presents to the emergency room, 
but is not admitted to a ward).  
• Overdose of study drug or concomitant medication, unless there is an AE that meets SAE 
criteria (e.g., hospitalization), as a direct consequence of the overdose.  This should be 
entered as Overdose - followed by the appropriate AE/SAE term. 
• Events of disease progression of the patient’s underlying cancer as well as events clearly 
related to disease progression (i.e., signs and symptoms) should not be reported as a SAE 
unless the outcome is fatal and occurs during the safety reporting period.  If the event has a 
fatal outcome during the safety reporting period, then the event of Progression of Disease 
must be recorded as an AE/SAE with CTC Grade 5 (fatal outcome) indicated. 
• Diagnosis of progression of disease or hospitalization due to signs and symptoms of disease 
progression alone should not be reported as a SAE. 
10.5 Clinical Laboratory Assessments and Other Abnormal Assessments as 
Adverse Events and Serious Adverse Events 
A clinical laboratory abnormality should be documented as an AE if any one of the following 
conditions is met:  
• The abnormality is considered clinically significant by the investigator. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 101 of 133 
Confidential 
• The abnormality is of a degree that requires active management (change of dose, 
discontinuation of the drug, more frequent follow-up assessments, further diagnostic 
investigation, etc.). 
10.6 Pregnancy or Drug Exposure During Pregnancy 
Patients should be instructed to notify the investigator if pregnancy is discovered either during or 
within 6 months of completing treatment with rucaparib.  This also applies to male patients 
whose partners become pregnant in the same timeframe.  Women who become pregnant during 
the study will discontinue rucaparib immediately and the event will be reported on a specific 
Pregnancy Report Form in the same reporting timeframe as an SAE (Section 10.9).  The 
pregnancy will be followed to term, any premature terminations or obstetric complications 
reported, and the status of mother and child will be reported to the sponsor as soon as possible 
after delivery. 
10.7 Recording of Adverse Events, Serious Adverse Events, and Adverse Events of 
Special Interest 
Any AE that occurs after the first dose of study drug to 28 days after receiving the last dose of 
oral rucaparib will be recorded on the AE eCRF. In addition, any AE/SAE that occurs after 
informed consent is obtained and is deemed related to a screening procedure for the study should 
also be reported. In order to avoid vague, ambiguous, or colloquial expressions, the AE should 
be recorded in standard medical terminology rather than the patient’s own words.  Whenever 
possible, the investigator should combine signs and symptoms that constitute a single disease 
entity or syndrome.  For example, fever, headache, and nasal discharge may be reported as 
coryza, if that is a reasonable diagnosis. 
The existence of an AE may be concluded from a spontaneous report of the patient; from the 
physical examination; or from special tests such as the ECG, laboratory assessments, or other 
study-specified procedure (source of AE). 
Each AE is to be evaluated for duration, severity, seriousness, and causal relationship to the 
investigational drug.  The action taken and the outcome must also be recorded. 
SAEs that occur after informed consent or within 28 days after receiving the last dose of 
rucaparib, and all AESIs, whether or not related to rucaparib, must be reported to the sponsor’s 
SAE contact within 24 hours of knowledge of the event. After the 28-day window after treatment 
discontinuation, only SAEs assessed as related to study drug and all AESIs, irrespective of 
causality, should be reported.  This should be done by faxing or emailing the completed 
SAE/AESI report to the Sponsor/designee contact provided on the SAE/AESI report form.  
Information on the follow-up of AEs, SAEs, and AESIs is provided in Section 10.9. 
10.7.1 Intensity of Adverse Events 
The severity of the AE will be graded according to the NCI CTCAE Version 4.0 grading scale.2  
For AEs not covered by NCI CTCAE, the severity will be characterized as mild, moderate, 
severe, or life threatening according to the following definitions: 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 102 of 133 
Confidential 
• Mild events are usually transient and do not interfere with the patient’s daily activities. 
• Moderate events introduce a low level of inconvenience or concern to the patient and may 
interfere with daily activities. 
• Severe events interrupt the patient’s usual daily activities. 
• Life threatening events require urgent intervention to prevent potentially fatal 
consequences 
10.7.2 Relationship of Adverse Events to Investigational Medicinal Products 
The causal relationship between the study medication and the AE must be characterized as not 
related, unlikely, possible/probable, or definitely by the investigator.  The following definitions 
will help guide the cause-and-effect assessment. 
Not Related 
An AE that, after consideration, is clearly due to extraneous causes (diseases, 
environment, etc.), which should be specified, if known.   
Related 
An AE that follows a reasonable temporal relationship to administration of rucaparib. 
It follows a known response pattern to the suspected drug. 
It cannot be explained by alternative etiologies 
It is confirmed with a positive rechallenge or supporting laboratory data. 
 
10.7.3 Outcome and Action Taken 
The investigator will record the action taken and outcome for each AE according to the 
following criteria: 
Action Taken with Study Drug 
• None 
• Dose reduced/delayed 
• Rucaparib temporarily interrupted 
• Rucaparib permanently discontinued 
• Other (specify) 
Outcome 
• Recovered 
• Recovered with sequelae 
• Improved 
• Ongoing 
• Death 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 103 of 133 
Confidential 
• Lost to follow-up 
10.8 Follow-Up of Adverse Events, Serious Adverse Events, and Adverse Events of 
Special Interest 
All AEs occurring during the study are to be followed up in accordance with good medical 
practice until resolved; judged no longer clinically significant; or, if a chronic condition, until 
fully characterized through 28 days after the last dose of rucaparib.  All SAE/AESI should be 
followed until resolution or stabilization, or until patient is lost to follow-up. 
10.9 Regulatory Aspects of Adverse Event Reporting 
SAEs, AESIs, and pregnancy must be reported to the Sponsor’s SAE designee within 24 hours of 
knowledge of the event, according to the procedures below.  It is important that the investigator 
provide an assessment of relationship of the SAE to study treatment at the time of the initial 
report.  The Serious Adverse Event/Adverse Event of Special Interest (SAE/AESI) Report Form 
must be used for reporting SAEs and AESIs, and the Pregnancy Report Form must be used for 
reporting pregnancies.   
Additional information should be reported via facsimile to the number above.  Further details on 
SAE/pregnancy reporting can be found in the investigator’s file.   
Clovis Oncology, Inc. (Clovis Oncology), or its designee is responsible for submitting reports of 
AEs associated with the use of the drug that are both serious and unexpected to FDA, according 
to 21 Code of Federal Regulations (CFR) 312.32, to the European regulatory authorities 
according to the European Commission Clinical Trials Directive (2001/20/EC); and to other 
regulatory authorities, according to national law and/or local regulations.  All investigators 
participating in ongoing clinical studies with the study medication will receive copies of these 
reports for prompt submission to their Institutional Review Board (IRB) or Independent Ethics 
Committee (IEC).  In accordance with the European Commission Clinical Trials Directive 
(2001/20/EC), Clovis Oncology or its designee will notify the relevant ethics committees in 
concerned member states of applicable suspected unexpected serious adverse reactions 
(SUSARs) as individual notifications or through periodic line listings. 
Clovis Oncology or its designee will submit all safety updates and periodic reports to the 
regulatory authorities as required by applicable regulatory requirements. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 104 of 133 
Confidential 
11 STATISTICAL METHODS 
11.1 Analysis Populations 
The following analysis populations are defined for the study: 
PK-Evaluable Population (Parts 1 and 3 only)—all patients who have received at least one 
dose of rucaparib and have had adequate PK assessments drawn for determination of the PK 
profile.  Adequacy will be determined on a case-by-case basis and will be assessed prior to 
analysis of the blood samples. 
Food-Effect PK Evaluable Population (Parts 1 and 3 only)—all patients enrolled into a food 
effect PK evaluation cohort of the study who received rucaparib on both Day 7 and Day 1 (Cycle 
1) complied with the fed and fasted requirements, and have sufficient PK data for a comparison 
to be made between the fasted and fed state. 
ECG-Evaluable Population (Part 1 only)—all patients who have received at least one dose of 
rucaparib and have had adequate PK and ECG assessments performed for determination of the 
ECG effects in relationship to the PK of rucaparib. 
Safety Population—all patients who have received at least one dose of rucaparib. 
DLT-Evaluable Population (Part 1 only)—all patients enrolled into Part 1 of the study who 
received at least 17 complete days of rucaparib and completed Cycle 1 of treatment, or who 
experienced a DLT in Cycle 1. 
Efficacy-Evaluable Population—all patients who met eligibility criteria, received at least one 
dose of rucaparib, have measurable tumor lesions at baseline, and have at least one post-baseline 
disease assessment. 
11.2 Statistical Methods 
11.2.1 General Considerations 
The summary tables will be presented for all treated patients by each of the Parts of the study and 
by appropriate dose groups.   
Quantitative variables will be summarized using descriptive statistics (N, mean, standard 
deviation, median, minimum, and maximum) and/or frequency and percentages for medically 
relevant categories.  Categorical variables will be presented using frequencies and percentages.  
The Kaplan-Meier methodology will be used to summarize time-to-event variables.  If estimable, 
the 25th, 50th (median), and 75th percentiles will be presented along with the Kaplan-Meier 
estimates of 3, 6, 9, and 12 month PFS rates.  The number of patients with events and the number 
of censored patients will also be presented.   
Individual patient data listings will be provided to support summary tables.  All data will be used 
to their maximum possible extent but without any imputations for missing data. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 105 of 133 
Confidential 
A statistical analysis plan (SAP) will be available prior to the start of Part 2 of the study.  Any 
deviations from the statistical methods given in the study protocol will be described and justified 
in the SAP. 
All statistical analyses will be conducted with the SAS® System. 
11.2.2 Patient Disposition  
Patient disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency counts, and the corresponding 
percentages.   
11.2.3 Baseline Characteristics  
Baseline characteristics and demographic data will be summarized for the safety population. 
11.2.4 Efficacy Analyses  
The efficacy endpoints in each of the parts of the study will be evaluated using RECIST 
Version 1.1. 
11.2.4.1 Overall Response Rate - Primary Endpoint (Part 2) 
A primary efficacy endpoint in Part 2 of the study (ORR) is the best overall response recorded 
from the start of the treatment until disease progression or recurrence.  The ORR will be 
summarized for the tumor-evaluable population enrolled in Part 2 with frequencies and 
percentages.   
11.2.4.2 
Secondary Analyses and Endpoints in Part 2 and 3 
11.2.4.2.1 
ORR per RECIST v 1.1 and Gynecologic Cancer Intergroup (GCIG) CA-125 
Criteria (Part 2) 
The proportion of patients with the best response by RECIST v 1.127 of ‘Complete Response’ or 
‘Partial Response’ or response according to the GCIG CA-12528, 29 criteria will be summarized 
with number of patients and percent and for each response category.  
11.2.4.2.2 
Tumor Marker (CA-125) Response Rate Based on GCIG CA-125 Criteria 
(Part 2) 
Only patients with elevated level as baseline will be used for this analysis.  The incidence of 
patients with a response (i.e., at least 50% reduction from baseline which is confirmed at a 
second post-baseline value) in tumor marker CA-125 will be summarized.  The time to CA-125 
may also be summarized with Kaplan-Meier methodology where the time to CA-125 is defined 
as duration between the date of first study drug to the date of the first CA-125 response value (at 
least 50% reduction).  If the patient does not have a response they are censored at the last date of 
cancer antigen measurement.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 106 of 133 
Confidential 
11.2.4.2.3 
Progression-free Survival (PFS) (Part 2) 
PFS will be calculated as 1+ the number of days from the date of first dose of study drug to 
disease progression or death, due to any cause, whichever occurs first.  Patients without a 
documented event of progression will be censored on the date of their last adequate tumor 
assessment (i.e., radiologic assessment) or date of first dose of study drug if no tumor 
assessments have been performed.  PFS will be summarized using Kaplan-Meier methodology. 
11.2.4.2.4 
Duration of Response - Secondary Endpoint (Part 2) 
Duration of response for CR and PR, a secondary endpoint in Part 2, will be measured from the 
date that any of these best responses is first recorded until the first date that PD is objectively 
documented.  Duration of response will be summarized using descriptive statistics (N, mean, 
standard deviation, median, minimum, and maximum) as well as categorically. 
11.2.4.2.5 
Overall Survival (Part 2B) 
Overall survival is defined as the 1+ the number of days from the date of first dose of study drug 
to death, due to any cause. Patients without a documented event of death will be censored on the 
date of their last visit.  Overall survival will be summarized using Kaplan-Meier methodology 
time from randomization until death from any cause, and is measured in the intent-to-treat 
population. 
11.2.4.2.6 
Evaluation of Antitumor Activity – Secondary Endpoint (Parts 1 and 3) 
No formal statistical analysis of efficacy will be performed in Part 1.  For patients with 
measurable disease, response to treatment according to RECIST Version 1.1 will be reported via 
descriptive statistics by dose level. 
11.2.4.2.6.1 Changes in Tumor Markers Applicable to Patient’s Tumor Type (Part 1 and 3) 
Changes in tumor markers applicable to a patient’s tumor type will be summarized with 
summary statistics and may be analyzed in accordance to corresponding tumor marker responder 
criteria.  
11.2.4.3 
Exploratory Endpoints in Part 2  
11.2.4.3.1 
Explore the Association Between Genomic Alterations Identified in Tumor 
Tissue and Clinical Outcome (Part 2)  
The association between mutational status of BRCA1/2 and other homologous recombination 
genes, including genomic scarring/LOH assessment in tumor tissue will be evaluated for the 
response by RECIST v1.1 and/or CA-125.  This will be done by evaluating all the efficacy 
endpoints by mutational status for Part 2.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 107 of 133 
Confidential 
11.2.5 Pharmacokinetic Analyses 
As a primary endpoint in Part 1 and Part 3 of the study, PK parameters will be determined using 
noncompartmental methods.  AUC from Time 0 to the last observation will be calculated using 
the trapezoid rule.  The kel will be calculated using log-linear regression on the terminal part of 
the concentration time curve.  The terminal half-life and the AUC from the last observation to 
infinity will be calculated from the estimated kel.  Other parameters to be determined are Cmax, 
Tmax, Vss/F, and Cl/F.   
As a secondary endpoint, the effect of food on PK parameters including, but not limited to, Cmax 
and AUC, will be compared using linear mixed effect model. 
11.2.6 Exploratory Analysis - Relationship Between PK and QTc  
As an exploratory endpoint of the study, the relationship between the concentration of oral 
rucaparib (PK) and potential changes in QTc will be studied.  A linear and nonlinear mixed 
effect modeling approach will be used to quantify the relationship between the plasma 
concentration and the ΔΔQTc (time-matched, on-treatment to pretreatment difference in QTc 
interval, baseline-adjusted).  Plots of the mean QT/QTc versus drug concentrations and a 
concentration-QT variables correlation will be explored.   
11.2.7 Exploratory Analysis - Metabolite Profiling at the Recommended Phase 2 
Dose  
As an exploratory endpoint of the study, additional plasma samples will be collected on Day 15 
from three patients enrolled in the RP2D Expansion cohort.  Individual pooled plasma samples, 
one from each of these patients, will be prepared using the method proposed by Hamilton.7  The 
pooled plasma samples will be further processed before being analyzed by high-performance 
liquid chromatography coupled in-line with ultraviolet spectrophotometric and tandem mass 
spectrometric detection (HPLC-UV-MS/MS). 
11.2.8 Safety Analyses  
The safety analyses will be performed using the safety population (all patients who have received 
at least one dose of rucaparib).   
11.2.8.1 Extent of Exposure 
The following will be summarized by study part (i.e., Part 1, 2, and 3) and by dose group using 
descriptive statistics:  
• Number of patients receiving at least one dose  
• Number of patients at each dose group, average dose amount   
• Number of cycles initiated   
• Number of dose reductions/delays 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 108 of 133 
Confidential 
• Number of dose interruptions  
The number of patients at each dose group will be summarized with frequencies and percentages; 
the average dose will be summarized with descriptive statistics and frequency counts for relevant 
categories.  The number of cycles initiated will be investigated by summarizing the number of 
cycles started by each patient in each period.  The number of patients with at least one dose 
reduction/delay or interruption will be summarized with frequencies and percentages.    
11.2.8.2 Adverse Events 
The safety analyses will be performed using the safety population for each part of the study 
separately. 
AE coding will be performed using the Medical Dictionary for Drug Regulatory Activities.  The 
severity of the toxicities will be graded according to the NCI CTCAE whenever possible.  
Treatment-emergent AEs are defined as AEs with an onset date on or after the date of first dose 
of rucaparib until the date of the last rucaparib dose plus 28 days.  AEs will be considered 
treatment-emergent if all or part of the date of onset of the AE is missing and it cannot be 
determined if the AE meets the definition for treatment-emergent. 
The number and percentage of patients who experienced treatment-emergent AEs for each 
system organ class and preferred term will be presented by dose group.  Multiple instances of the 
treatment-emergent AEs in each system organ class and multiple occurrences of the same 
preferred term are counted only once per patient.  The number and percentage of patients with at 
least one treatment-emergent AE will also be summarized by dose group.   
Separate tables will present the following by dose group: 
• All treatment-emergent AEs 
• Treatment-emergent AEs by CTCAE grade 
• Grade 3 or greater treatment-emergent AEs 
• Treatment-related, treatment-emergent AEs 
• Dose-limiting toxicity AEs 
• Serious treatment-emergent AEs 
• Treatment-emergent AEs with an outcome of death 
• Treatment-emergent AEs leading to discontinuation of oral rucaparib 
• Treatment-emergent AEs resulting in interruption or reduction/delay of rucaparib 
The incidence of treatment-emergent AEs will be summarized by relationship to oral rucaparib 
using “treatment-related” and “not treatment-related” categories.  The category of treatment-
related is defined as a relationship of Possible/Probable, Definite, or Missing.  If a patient 
experiences multiple occurrences of the same AE with different relationship categories, the 
patient will be counted once as a relationship category of treatment-related.   


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 109 of 133 
Confidential 
If a patient experiences multiple occurrences of the same AE with different intensity toxicity 
grades, the patient will be counted once for the maximum (most severe) toxicity grade.  AEs with 
a missing intensity will be presented in the summary table with a toxicity grade of “Missing.”  
For each toxicity grade, the number and percentage of patients with at least one treatment-
emergent AE of the given grade will be summarized.    
Non-treatment-emergent AEs (pretreatment and post-treatment) will be presented in the by-
patient data listings.  
11.2.8.3 Clinical Laboratory Evaluations 
The clinical laboratory evaluations will be summarized using the safety population for each part 
of the study separately. 
Clinical laboratory evaluations include the continuous variables for hematology, serum 
chemistry, and urinalysis.  Laboratory values will be presented in Systeme International units.  
The baseline laboratory value will be defined as the last value prior to or on the day of the first 
dose of oral rucaparib.  The on-treatment period will be defined as the day after the first dose of 
oral rucaparib to 28 days after the last dose of rucaparib.  Laboratory values collected during the 
on-treatment period will be included in the summary tables.  The laboratory values collected 
after the on-treatment period will only be presented in the data listings.   
The summary of laboratory data will include descriptive statistics (N, mean, standard deviation, 
minimum, median, and maximum) of the maximum, minimum, and last value during the 
treatment period by dose group.  Summaries using descriptive statistics of the change from 
baseline to the maximum, minimum, and last value during the on-treatment period will also be 
given by dose group.  Supporting laboratory data including normal ranges and abnormal 
laboratory flags will be provided using by-patient listings.  Separate listings will be produced for 
clinically significant laboratory abnormalities (i.e., those that meet Grade 3 or 4 criteria 
according to CTCAE) by dose group.   
11.2.8.4 Vital Sign Measurements 
The vital signs measurements will be summarized using the safety population for each part of the 
study separately. 
The baseline vital sign measurement will be defined as the last value prior to or on the day of the 
first dose of rucaparib.  The on-treatment period will be defined as the day after the first dose of 
rucaparib to 28 days after the last dose of rucaparib.  Vital sign measurements collected during 
the on-treatment period will be included in the summary tables.  The vital sign measurements 
collected after the on-treatment period will only be presented in the data listings.   
The summary of vital sign data will include descriptive statistics (N, mean, standard deviation, 
minimum, median, and maximum) of the maximum, minimum, and last value during the 
on-treatment period by dose group.  Summaries using descriptive statistics of the change from 
baseline to the maximum, minimum, and last value during the on-treatment period will also be 
given by dose group.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 110 of 133 
Confidential 
11.2.8.5 12-Lead Electrocardiograms  
From ECGs conducted in Part 1 of the study, ECG intervals will be stratified into categories 
indicative of potential clinical significance.  Each patient’s maximum QT and QTc intervals from 
the pretreatment visit and treatment period visits will be classified as ≤450 msec, >450 to 
≤480 msec, >480 to ≤500 msec, and >500 msec.  For each patient’s maximum change from the 
pretreatment ECG visit for QT and QTc, intervals will be classified into <30 msec, ≥30 to 
<60 msec, and ≥60 msec.  The number and percentage of patients in each classified category will 
be presented.  Additional endpoints will include abnormal T waves and U waves and other ECG 
intervals and diagnostic parameters.  
Descriptive statistics will be used to summarize other ECG parameters of PR, QRS, QT, and RR 
interval, and the corresponding changes from pretreatment ECG visit at each time point.  Plots of 
the mean QT/QTc over time for Day 1 and Day 15 of Cycle 1/pretreatment ECG day 
measurements will be provided.   
11.2.8.6 Other Safety Measurements 
The body weight and ECOG will be summarized using the safety population for each part of the 
study separately. 
Body weight and ECOG performance status will be summarized with descriptive statistics (N, 
mean, standard deviation, median, minimum, and maximum).  Concomitant medications/ 
procedures will be tabulated and summarized. 
11.3 Interim Analysis 
No formal interim analyses will be performed. 
11.4 Sample Size Considerations 
The total patient enrollment planned for this study is approximately 140 patients:  56 patients 
were enrolled in Part 1.  Up to 41 evaluable patients with platinum-sensitive, relapsed, high-
grade serous or endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal 
associated with a gBRCA mutation will be enrolled in Part 2A.  Up to 40 evaluable patients with 
relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer with 
evidence of a deleterious BRCA mutation (germline or somatic) will be enrolled in Part 2B.  
Approximately 20 evaluable patients with an advanced solid tumor, inclusive of lymphoma, with 
evidence of a BRCA mutation (germline or somatic) will be enrolled into Part 3.   
Clinical trials of olaparib in recurrent ovarian cancer associated with a gBRCA mutation 
demonstrated ORRs of 13-41%.13, 25, 26  For the part of the study evaluating rucaparib in 
platinum-sensitive, relapsed, high-grade serous and endometrioid epithelial ovarian, fallopian 
tube, or primary peritoneal cancer associated with a gBRCA mutation, an ORR of 20% will be set 
as the target.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 111 of 133 
Confidential 
11.4.1 Sample Size Justification for Part 2A 
The study will use a Simon 2-stage design to evaluate the efficacy of rucaparib in Part 2 (Phase 
II portion).  Initially, 21 patients will be treated in Stage 1; if two or more patients in Stage 1 
have an objective response (CR or PR), then the remaining 20 patients will be treated in Stage 2.  
If fewer than two patients in Stage 1 have an objective response, then no further patients will be 
enrolled. 
Characteristics of the Simon 2-stage design include: 
• 5% probability of accepting a poor drug 
• 90% probability of accepting a good drug 
• ORR of 5% for a poor drug 
• ORR of 20% for a good drug 
• A promising drug will have five or more patients with an objective response (CR or PR) out 
of 41 patients at the end of Stage 2. 
The criteria for Stage 1 success were met in April 2014, and Stage 2 is ongoing with total 
enrollment of 41 evaluable patients completed in April 2015. 
11.4.2 Sample Size Justification for Part 2B 
The efficacy of rucaparib in ovarian cancer patients with a deleterious BRCA mutation (germline 
or somatic) who received ≥3 prior chemotherapy regimens and were treated with 600 mg BID 
rucaparib in Studies CO-338-017 (ARIEL2) and Part 2A of CO-338-010 has been evaluated.  In 
this group, which included both patients with platinum-sensitive and platinum-resistant disease, 
ORRs of 47% (RECIST) and 73% (RECIST & GCIG CA-125) have been observed, suggesting 
that rucaparib may be a suitable treatment alternative in this patient population with advanced 
disease and limited treatment options.   
The rationale for evaluating an additional BRCA-mutant OC cohort in this study is to better 
characterize the efficacy and safety in a heavily pre-treated patient population with a deleterious 
BRCA mutation (germline or somatic).  An ORR ≥20% in this population would be worthy of 
further exploration.  The table below provides 95% confidence intervals (CIs) for ORRs of 30% 
to 50% assuming a sample size of 40 patients.  
Confidence Intervals for Observed Response Rates 
ORR(%) 
[95% CI] 
30 
17,47 
40 
25, 57 
50 
34,66 
CI=Confidence intervals of ORR using Clopper-Pearson methodology.6 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 112 of 133 
Confidential 
Therefore with the sample size of 40 patients an observed ORR of 30% would show similar 
response as current treatment, however, an observed ORR of 40% or greater has a 95% CI which 
exceeds the 20%.  
11.4.3 Sample Size Justification for Part 3 
For Part 3, the study will be an initial randomized, two treatment, two period, crossover design, 
to explore food effect, with subsequent continuous BID dosing; it is estimated that enrolling 
approximately 20 evaluable patients will provide sufficient data for PK analysis. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 113 of 133 
Confidential 
12 
PATIENT DISPOSITION 
12.1 Patient Discontinuations 
A patient must be discontinued from protocol-prescribed therapy if any of the following apply: 
• Consent withdrawal at the patient’s own request or at the request of their legally 
authorized representative 
• Progression of patient’s underlying disease 
• Any event, adverse or otherwise, that, in the opinion of the investigator, would pose an 
unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the Investigator, would affect assessments of 
the clinical status to a significant degree and requires discontinuation of therapy 
• A positive pregnancy test at any time during the study 
• Increase in QT/QTc of >60 msec over baseline or QTc >500 msec 
In addition, the sponsor may discontinue the trial early for any of the reasons noted in 
Section 13.6. 
The sponsor (or designee) should be notified of all study terminations as soon as possible.  The 
date and reason for cessation of oral rucaparib must be documented in the eCRF and source 
documents.  To the extent possible, follow-up procedures should be performed on all patients 
who receive rucaparib.  The follow-up visit should occur 28 (±3) days following the last dose of 
rucaparib.  Patients will be followed for 28 days after the last dose of rucaparib for safety; those 
with ongoing SAEs will be followed until either resolution or stabilization has been determined.   
12.2 Study Stopping Rules 
If ≥33% of patients in the RP2D Expansion cohort experience a DLT, then enrollment into the 
RP2D Expansion arm will stop and a lower dose will be explored. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 114 of 133 
Confidential 
13  
STUDY ADMINISTRATION 
13.1 Regulatory and Ethical Considerations 
This study will be conducted in compliance with the protocol; Good Clinical Practices (GCPs), 
including ICH Technical Requirements for Registration of Pharmaceuticals for Human Use 
Guidelines; FDA regulatory requirements; and in accordance with the ethical principles of the 
Declaration of Helsinki.   
13.1.1 Regulatory Authority Approvals 
The sponsor or designee will submit the study protocol plus all relevant study documents to 
concerned regulatory agencies for approval prior to the study start.  No patient will be admitted 
to the study until appropriate regulatory approval of the study protocol has been received. 
Each investigator must complete a Form FDA 1572 and provide the completed form according to 
written instructions to the sponsor (or designee).  Each investigator must submit to the sponsor 
(or designee) financial disclosure information according to national law and/or local regulations. 
U.S.-generated data will be handled in accordance with the Health Information Portability and 
Accountability Act (HIPAA).  The trial will be registered at www.clinicaltrials.gov using the 
Protocol Registration System. 
13.1.2 Independent Ethics Committee/Institutional Review Board 
This protocol and any material to be provided to the patient (such as advertisements, patient 
information sheets, or descriptions of the study used to obtain informed consent) will be 
submitted by the investigator to an IEC/IRB.  This also applies to protocol amendments.   
Clovis Oncology will supply relevant data for the investigator to submit the study protocol and 
additional study documents to the IEC/IRB.  The principal investigator will submit the study 
protocol for review and approval by an IEC/IRB, according to national law and/or local 
regulations, and will provide the IEC/IRB with all appropriate materials.   
Verification of the IEC’s/IRB’s unconditional approval of the study protocol and the written 
informed consent form will be transmitted to Clovis Oncology.  This approval must refer to the 
study by exact study protocol title and number, identify the documents reviewed, and state the 
date of the review. 
No patient will be admitted to the study until appropriate IEC/IRB approval of the study protocol 
has been received, the investigator has obtained the signed and dated informed consent form, and 
the sponsor is notified.   
The principal investigator will submit appropriate reports on the progress of the study to the 
IEC/IRB at least annually in accordance with applicable national law and/or local regulations 
and in agreement with the policy established by the IEC/IRB and sponsor.   


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 115 of 133 
Confidential 
The IEC/IRB must be informed by the principal investigator of all subsequent study protocol 
amendments and of SAEs or SUSARs occurring during the study that are likely to affect the 
safety of the patients or the conduct of the study. 
13.2 Confidentiality of Information 
The investigator must assure that patients’ anonymity is strictly maintained and that their 
identities are protected from unauthorized parties.  Only patient initials and an identification code 
(i.e., not names) should be recorded on any form submitted to the sponsor and the IRB.  The 
investigator must keep logs on screened and enrolled patients.  In addition, the investigator must 
have a list where the identity of all treated patients can be found. 
The investigator agrees that all information received from Clovis Oncology, including, but not 
limited to, the Investigator’s Brochure, this protocol, eCRFs, the protocol-specified treatment, 
and any other study information, remain the sole and exclusive property of the sponsor during 
the conduct of the study and thereafter.  This information is not to be disclosed to any third party 
(except employees or agents directly involved in the conduct of the study or as required by law) 
without prior written consent from the sponsor.  The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by any employee or agent of the study center to 
any third party or otherwise into the public domain. 
13.3 Patient Informed Consent 
All information about the clinical study, including the patient information and the informed 
consent form, is prepared and used for the protection of the human rights of the patient according 
to ICH GCP guidelines and the Declaration of Helsinki. 
It is the responsibility of the investigator to obtain signed informed consent forms from each 
patient participating in this study after adequate explanation of the aims, methods, objectives, 
and potential hazards of the study and prior to undertaking any study-related procedures.   
The informed consent form, prepared by the investigator with the assistance of the sponsor, must 
be approved along with the study protocol by the IEC/IRB and be acceptable to the sponsor. 
The patient must be provided with the patient information and informed consent form consistent 
with the study protocol version used and approved by the relevant IEC/IRB.  The informed 
consent form must be in a language fully comprehensible to the prospective patient.  Patients 
(and/or relatives, guardians, or legal representatives, if necessary) must be given sufficient time 
and opportunity to inquire about the details of the study and to discuss and decide on their 
participation in the study with the investigator concerned.  The patient and the person explaining 
about the study and with whom they discuss the informed consent will sign and date the 
informed consent form.  A copy of the signed informed consent form will be retained by the 
patient and the original will be filed in the investigator file unless otherwise agreed.   


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 116 of 133 
Confidential 
13.4 Study Monitoring 
On behalf of Clovis Oncology, a CRO monitor will contact and visit the investigator at the study 
center prior to the entry of the first patient and at predetermined appropriate intervals during the 
study until after the last patient is completed.  The monitor will also perform a study closure 
visit.   
In accordance with ICH GCP guidelines, the investigator must ensure provision of sufficient 
time, reasonable space, and adequate qualified personnel for the monitoring visits.  The visits are 
for the purpose of verifying adherence to the study protocol and the completeness, consistency, 
and accuracy of data entered on the eCRF and other documents.   
The investigator will make all source data (i.e., the various study records, the eCRFs, laboratory 
test reports, other patient records, drug accountability forms, and other pertinent data) available 
for the monitor and allow access to them throughout the entire study period.  Monitoring is done 
by comparing the relevant site records of the patients with the entries on the eCRF (i.e., source 
data verification).  It is the monitor’s responsibility to verify the adherence to the study protocol 
and the completeness, consistency, and accuracy of the data recorded on the eCRFs.   
By agreeing to participate in the study, the investigator agrees to cooperate with the monitor to 
ensure that any problems detected in the course of the monitoring visits are resolved.  Contact 
information for the study monitor is located in the investigator file.  Representatives from Clovis 
Oncology may also contact and visit the investigators and monitor data during the study.   
13.5 Case Report Form 
The data will be collected using an electronic data capture (EDC) system by remote data entry on 
eCRFs.  Sites will receive training on the EDC system.  All users will be supplied with unique 
login credentials. 
Prior to study start, the investigator will prepare a list showing the signature and handwritten 
initials of all individuals authorized to make or change entries on eCRFs.  This “study center 
personnel and delegation list” must be kept current throughout the study. 
For each patient enrolled, an eCRF must be completed, reviewed, signed, and dated by the 
principal investigator or co-investigator within a reasonable time period (<3 weeks) after data 
collection.  This also applies to records for those patients who fail to complete the study.  If a 
patient withdraws from the study, the reason must be noted on the eCRF.  If a patient is 
withdrawn from the study because of a treatment-limiting AE, thorough efforts should be made 
to clearly document the outcome. 
All laboratory data and investigator observations on the results and any other clinically 
significant test results must be documented on eCRFs. 
Full information regarding electronic data capture and completing eCRFs is included in the 
investigator files.  All questions or comments related to electronic capture should be directed to 
the assigned monitor. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 117 of 133 
Confidential 
13.6 Study Termination and Site Closure 
Both the sponsor and the investigator reserve the right to terminate the study at any time.  Should 
this be necessary, both parties will arrange discontinuation procedures.  In terminating the study, 
Clovis Oncology and the investigator will assure that adequate consideration is given to the 
protection of the patients’ interests. 
Clovis Oncology reserves the right to discontinue the study at any time for medical or 
administrative reasons.  When feasible, a 30 day written notification will be given. 
The entire study will be stopped if: 
• The protocol-specified treatment is considered too toxic to continue the study. 
• Evidence has emerged that, in the opinion of the sponsor or the investigator(s), makes the 
continuation of the study unnecessary or unethical. 
• The stated objectives of the study are achieved. 
• The sponsor discontinues the development of oral rucaparib. 
Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow-up must be recorded on the eCRF.  All reasons for discontinuation of 
treatment must be documented.  In terminating the study, the investigator will ensure that 
adequate consideration is given to the protection of the patients’ interests. 
13.7 Modification of the Study Protocol 
Protocol amendments, except when necessary to eliminate an immediate hazard to patients, must 
be made only with the prior approval of Clovis Oncology.  Agreement from the investigator must 
be obtained for all protocol amendments and amendments to the informed consent document.  
The IEC/IRB must be informed of all amendments and give approval prior to their 
implementation.  The sponsor will submit any study protocol amendments to the concerned 
regulatory authorities for approval and keep the investigator(s) updated as detailed in the ICH 
GCP guidelines. 
13.8 Retention of Study Documents 
The study site will maintain a study file, which should contain, at minimum, the Investigator’s 
Brochure, the protocol and any amendments, drug accountability records, correspondence with 
the IEC/IRB and Clovis Oncology, and other study-related documents. 
The investigator agrees to keep records and those documents that include (but are not limited to) 
the identification of all participating patients, medical records, study-specific source documents, 
source worksheets, all original signed and dated informed consent forms, copies of all eCRFs, 
query responses, and detailed records of drug disposition to enable evaluations or audits from 
regulatory authorities and Clovis Oncology or its designees. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 118 of 133 
Confidential 
The investigator shall retain records required to be maintained for a period of 5 years following 
the date a marketing application in an ICH region is approved for the drug for the indication for 
which it is being investigated or, if no application is to be filed or if the application is not 
approved for such indication, until at least 5 years after the investigation is discontinued.  
However, these documents should be retained for a longer period if required by the applicable 
regulatory requirement(s) or if needed by Clovis Oncology.  In addition, the investigator must 
make provision for the patients’ medical records to be kept for the same period of time. 
No data should be destroyed without the agreement of Clovis Oncology.  Should the investigator 
wish to assign the study records to another party or move them to another location, Clovis 
Oncology must be notified in writing of the new responsible person and/or the new location.  
Clovis Oncology will inform the investigator, in writing, when the trial-related records are no 
longer needed. 
Patients’ medical records and other original data will be archived in accordance with the 
archiving regulations or facilities of the investigational site. 
13.9 Clinical Study Report 
A clinical study report will be prepared under the responsibility and supervision of Clovis 
Oncology and signed by the sponsor’s chief medical officer, thereby indicating their agreement 
with the analyses, results, and conclusions of the clinical study report.   
13.10 Study Publication 
All data generated from this study are the property of Clovis Oncology and shall be held in strict 
confidence along with all information furnished by Clovis Oncology.  Independent analysis 
and/or publication of these data by the investigator(s) or any member of their staff are not 
permitted without the prior written consent of Clovis Oncology.  Written permission to the 
investigator will be contingent on the review by Clovis Oncology of the statistical analysis and 
manuscript, and will provide for nondisclosure of Clovis Oncology confidential or proprietary 
information.  In all cases, the parties agree to submit all manuscripts or abstracts to all other 
parties 30 days prior to submission.  This will enable all parties to protect proprietary 
information and to provide comments based on information that may not yet be available to other 
parties. 
13.11 Quality Assurance Audits 
An audit visit to clinical centers may be conducted by a quality control auditor appointed by 
Clovis Oncology.  The purpose of an audit, which is independent of and separate from routine 
monitoring or quality control functions, is to evaluate trial conduct and compliance with the 
protocol, SOPs, ICH GCPs, and the applicable regulatory requirements.  The investigator and the 
sponsor may also be subject to an inspection by FDA, European Regulatory authorities, or other 
applicable regulatory authorities at any time.  The auditor and regulatory authorities will require 
authority from the investigator to have direct access to the patients’ medical records.  It is 
important that the investigator(s) and their staff cooperate with the auditor or regulatory 
authorities during this audit or inspection.  


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 119 of 133 
Confidential 
14 REFERENCES 
1. 
Garrett-Mayer E. Understanding the continual reassessment method for dose-finding 
studies: an overview for non-statisticians: Berkeley Electronic Press, Paper 74; 2005. 
http://www.bepress.com/jhubiostat/paper74. 
2. 
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), 
Version 4.0. 2009. 
3. 
Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic 
target in cancer. Clinical Cancer Research. 2010;16(18):4517-26. 
4. 
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the 
DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 
2005;434(7035):917-21. 
5. 
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing 
of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 
2005;434(7035):913-7. 
6. 
Clopper C. The use of confidence or fiducial limits illustrated in the case of the binomia. 
Biometrika. 1934;26:404-13. 
7. 
Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by 
assay of a single pooled sample. Clin Pharmacol Ther. 1981;29(3):408-13. 
8. 
Bischoff J, Ignatov A. The Role of Targeted Agents in the Treatment of Metastatic Breast 
Cancer. Breast Care. 2010;5(3):134-41. 
9. 
Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of Poly (ADP-
Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary 
Human Tumor Types. Genes Cancer. 2010;1(8):812-21. 
10. Pruthi S, Gostout BS, Lindor NM. Identification and Management of Women With BRCA 
Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc. 
2010;85(12):1111-20. 
11. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15. 
12. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral 
poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 
mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 
2010;376(9737):235-44. 
13. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. 
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 
mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 
2010;376(9737):245-51. 
14. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of 
poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 
2009;361(2):123-34. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 120 of 133 
Confidential 
15. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. 
Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) 
Polymerase-1 Inhibitor AG14361. J Natl Cancer Inst. 2004;96(1):56-67. 
16. Plummer E. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol. 
2006;6(4):364-8. 
17. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I Study of the 
Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide 
in Patients with Advanced Solid Tumors. Clin Cancer Res. 2008;14(23):7917-23. 
18. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical 
selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer 
Ther. 2007;6(3):945-56. 
19. Curtin NJ. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity 
to Temozolomide in Mismatch Repair-Deficient Cells. Clin Cancer Res. 2004;10(3):881-9. 
20. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PWB, et al. Selective 
Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin. 
Clin Cancer Res. 2008;14(12):3916-25. 
21. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, et al. 
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan 
activity against childhood neuroblastoma. Clin Cancer Res. 2009;15(4):1241-9. 
22. US Department of Health and Human Services, Food and Drug Administration, CDER. 
Draft Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, 
Implications for Dosing, and Labeling Recommendations February 2012. Available from: 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/
ucm292362.pdf. 
23. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, et al. Comparison of different 
algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in 
vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos. 
2009;37(8):1658-66. 
24. US Department of Health and Human Services, Food and Drug Administration, CDER, 
CBER. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation 
2009 [15 December 2014]. Available from: 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf. 
25. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. 
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian 
carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-
randomised study. Lancet Oncol. 2011;12(9):852-61. 
26. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, Open-
Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a 
Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 121 of 133 
Confidential 
With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer. J Clin Oncol. 
2012;30(4):372-9. 
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). 
European Journal of Cancer. 2009;45(2):228-47. 
28. Rustin GJS, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. New 
Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer). JNCI 
Journal of the National Cancer Institute. 2004;96(6):487-8. 
29. Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. 
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating 
RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J 
Gynecol Cancer. 2011;21(2):419-23. 
30. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and 
response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 
1982;5(6):649-55. 
31. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in 
Cancer. In: Macleod CM, editor. Evaluation of Chemotherapeutic Agents in Cancer. New 
York: Columbia University Press; 1949. p. 191-205. 
32. Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, Banerjee S, et al. 
Interconversion of three measures of performance status: an empirical analysis. European 
Journal of Cancer. 2010;46(18):3175-83. 
 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 122 of 133 
Confidential 
15 APPENDICES 
Appendix A. Response Evaluation Criteria in Solid Tumors Criteria 
Appendix B. Eastern Cooperative Oncology Group Performance Status Scale 
Appendix C. Examples of Concomitant Medications that can Prolong the QT Interval 
Appendix D. Examples of CYP Substrates with Narrow Therapeutic Range 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 123 of 133 
Confidential 
Appendix A 
Response Evaluation Criteria in Solid Tumors Criteria 
The RECIST guidelines (Version 1.1) are described in Eisenhauer (2009)27 and at 
http://www.eortc.be/Recist/Default.htm.  A short summary is given below. 
Measurable Disease: 
Tumor lesions:  measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) with the following: 
• A minimum size of 10 mm by CT scan (CT scan thickness no greater than 5 mm). 
• A minimum size of 10 mm caliper measurement by clinical exam (lesions that cannot be 
accurately measured with calipers should be recorded as nonmeasurable). 
• A minimum size of 20 mm by chest X-ray. 
All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters).  
Malignant lymph nodes:  to be considered pathologically enlarged and measurable, a lymph node 
must be ≥15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be not greater than 5 mm).  At baseline and in follow-up, only the short axis will be measured 
and followed.   
Nonmeasurable Disease: 
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or 
pathological lymph nodes with ≥10 to <15 mm short axis), as well as truly nonmeasurable 
lesions, are considered nonmeasurable disease.  Lesions considered truly nonmeasurable include 
leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, 
lymphangitic involvement of skin and lung, and abdominal masses/abdominal organomegaly 
identified by physical exam that is not measurable by reproducible imaging techniques.   
Bone Lesions 
Bone lesions, cystic lesion, and lesions previously treated with local therapy require particular 
comment.  Bone scan, PET scan, or plain films are not considered adequate imaging techniques 
to measure bone lesions.  However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
Lytic bone lesions or mixed lytic–blastic lesions with identifiable soft tissue components that can 
be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as 
measurable lesions if the soft tissue component meets the definition of measurability described 
above. 
Blastic bone lesions are nonmeasurable. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 124 of 133 
Confidential 
Cystic Lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor nonmeasurable) because they are, by definition, 
simple cysts. 
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions if 
they meet the definition of measurability described above.  However, if noncystic lesions are 
present in the same patient, these are preferred as target lesions. 
Lesions with Prior Local Treatment 
Tumor lesions situated in a previous irradiated area or in an area subjected to other locoregional 
therapy are usually not considered measurable unless there has been demonstrated progression in 
the lesion. 
Target Lesions 
All measurable lesions up to a maximum of two lesions per organ and five lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline.  Target lesions should be selected on the basis of their size (lesions with 
the longest diameter) and their suitability for accurate repeated measurements (either by imaging 
techniques or clinically).  A sum of the longest diameter (LD) for all target lesions will be 
calculated and reported as the baseline sum LD.  The baseline sum LD will be used as reference 
by which to characterize the objective tumor response.   
Nontarget Lesions 
RECIST criteria require unequivocal quantification of the changes in tumor size for adequate 
interpretation of the sum of target lesions.  Consequently, when the boundaries of the primary are 
difficult to delineate, this tumor should not be considered a target lesion. 
Guidelines for Evaluation of Measurable Disease 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up.  Imaging-based evaluation is 
preferred to evaluation by clinical examination when both methods have been used to assess the 
antitumor effect of a treatment. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 125 of 133 
Confidential 
Evaluation of Target Lesions 
Complete Response 
Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to <10 mm. 
Partial Response 
At least a 30% decrease in the sum of the LD of target lesions, taking as 
reference the baseline sum LD. 
Stable Disease 
Neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD since 
the treatment started. 
Progressive Disease 
At least a 20% increase in the sum of the LD of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is 
the smallest on study).  In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5 mm.  The 
appearance of one or more new lesions is also considered progression. 
 
Evaluation of Nontarget Lesions 
Complete Response 
Disappearance of all nontarget lesions and normalization of tumor marker 
level. 
Stable Disease/Incomplete 
Response 
Persistence of one or more nontarget lesion(s) or/and maintenance of tumor 
marker level above the normal limits. 
Progressive Disease 
Appearance of one or more new lesions and/or unequivocal progression of 
existing nontarget lesions. 
 
If tumor markers are initially above the institutional ULN, they must normalize for a patient to 
be considered a complete responder.   
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started).  The patient’s best response assignment will depend on the 
achievement of both measurement and confirmation criteria.   


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 126 of 133 
Confidential 
Evaluation of Best Overall Response (Patients with Target (+/–Non-target) Disease. 
Target Lesions 
Nontarget Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not 
evaluated 
No 
PR 
SD 
Non-PD or not 
evaluated 
No 
SD 
Not Evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
NE 
= 
Not evaluable. 
 
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as having 
symptomatic deterioration.  Every effort should be made to document the objective progression, 
even after discontinuation of treatment. 
In some circumstances, it may be difficult to distinguish residual disease from normal tissue.  
When the evaluation of CR depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspiration/biopsy) prior to confirming the CR status. 
Confirmatory Measurement/Duration of Response 
Confirmation 
CT scans are required within 7 days prior to the start of Cycles 3, 5, and 7, and then within 
7 days prior to the start of every third cycle of treatment thereafter, beginning with Cycle 10.  If 
an initial CR or PR is noted at Cycle 7 or beyond, confirmatory scans must be performed 
4-6 weeks later.  In the case of SD, follow-up measurements must have met the SD criteria at 
least once after study entry at a minimum interval of no less than 6–8 weeks.   
Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or PD is objectively 
documented (taking as reference for PD the smallest measurements recorded since the treatment 
started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 127 of 133 
Confidential 
Duration of Stable Disease 
SD is measured from the start of the treatment until the criteria for progression are met, taking as 
reference the smallest measurements recorded since the treatment started. 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 128 of 133 
Confidential 
Appendix B 
Eastern Cooperative Oncology Group Performance Status Scale 
ECOG Performance Status30 
0 
Fully active, able to carry on all predisease performance without restriction. 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature (e.g., light house work or office work). 
2 
Ambulatory and capable of all self care but unable to carry out any work activities.  Up and 
about more than 50% of waking hours. 
3 
Capable of only limited self care; confined to bed or chair more than 50% of waking hours. 
4 
Completely disabled.  Cannot carry on any self care.  Totally confined to bed or chair. 
5 
Dead. 
 
In the event performance status is assessed by the Karnofsky Performance Status31 scale, the 
following conversion chart applies.32 
 
Karnofsky Performance Status 
ECOG Performance 
Status 
General Description 
Score 
Specific Description 
Score 
Able to carry on 
normal activity and to 
work; no special care 
needed 
100 
Normal; no complaints; no 
evidence of disease 
0 
90 
Able to carry on normal activity; 
minor signs or symptoms of 
disease 
1 
80 
Normal activity with effort; some 
signs or symptoms of disease 
Unable to work; able 
to live at home and 
care for most personal 
needs; varying amount 
of assistance needed 
70 
Cares for self, unable to carry on 
normal activity or to do active 
work 
2 
60 
Requires occasional assistance, 
but is able to care for most of 
personal needs 
50 
Requires considerable assistance 
and frequent medical care 
3 
Unable to care for self; 
requires equivalent of 
institutional or hospital 
care; disease may be 
progressing rapidly 
40 
Disabled; requires special care 
and assistance 
30 
Severely disabled; hospital 
admission is indicated although 
death no imminent 
4 
20 
Very sick; hospital admission 
necessary; active supportive 
treatment necessary 
10 
Moribund; fatal processes 
progressing rapidly 
0 
Dead 
5 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 129 of 133 
Confidential 
Appendix C 
Examples of Concomitant Medications that can Prolong the QT Interval 
Generic Name 
Class/Clinical Use 
Comments 
Arsenic trioxide  
Anticancer/Leukemia 
 
Amitriptyline 
Tricyclic Antidepressant  
 
Bepridil  
Antianginal/heart pain 
Females > Males 
Chlorpromazine  
Antipsychotic/Antiemetic/ 
schizophrenia/nausea 
 
Cisapride 
GI stimulant/heartburn 
Restricted availability; Females > 
Males 
Clarithromycin 
Antibiotic/bacterial infection 
 
Clomipramine 
Tricyclic Antidepressant 
 
Desipramine 
Tricyclic Antidepressant 
 
Disopyramide  
Antiarrhythmic/abnormal heart 
rhythm 
Females > Males 
Dofetilide  
Antiarrhythmic/abnormal heart 
rhythm 
 
Dolasetron 
Antinausea/nausea, vomiting 
Requires additional ECG monitoring 
(Part 1) 
Domperidone 
Antinausea/nausea, vomiting; 
prokinetic; lactation stimulation 
Requires additional ECG monitoring 
(Part 1) 
Doxepin 
Tricyclic Antidepressant 
 
Droperidol  
Sedative; Antinausea/anesthesia 
adjunct, nausea 
Requires additional ECG monitoring 
(Part 1) 
Erythromycin  
Antibiotic; GI stimulant/bacterial 
infection; increase GI motility 
Females > Males 
Felbamate  
Anticonvulsant/seizure 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 130 of 133 
Confidential 
Generic Name 
Class/Clinical Use 
Comments 
Flecainide 
Antiarrhythmic/abnormal heart 
rhythm 
 
Fluoxetine  
Antidepressant/depression 
 
Foscarnet  
Antiviral/HIV infection 
 
Fosphenytoin 
Anticonvulsant/seizure 
 
Gatifloxacin 
Antibiotic/bacterial infection 
 
Halofantrine  
Antimalarial/malaria infection 
Females > Males 
Haloperidol  
Antipsychotic/schizophrenia, 
agitation 
When given intravenously or at 
higher-than-recommended doses, risk 
of sudden death, QT prolongation, 
and torsades increases 
Ibutilide 
Antiarrhythmic/abnormal heart 
rhythm 
Females > Males 
Indapamide 
Diuretic/stimulate urine and salt loss 
 
Isradipine 
Antihypertensive/high blood pressure 
 
Levofloxacin 
Antibiotic/bacterial infection 
 
Levomethadyl 
Opiate agonist/pain control, narcotic 
dependence 
 
Mesoridazine 
Antipsychotic/schizophrenia 
 
Methadone 
Opiate agonist/pain control, narcotic 
dependence 
 
Metoclopramide 
Antinausea/nausea, vomiting; diabetic 
gastroparesis; gastroesophageal reflux 
Requires additional ECG monitoring 
(Part 1) 
Moexipril/HCTZ  
Antihypertensive/high blood pressure 
 
Moxifloxacin  
Antibiotic/bacterial infection 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 131 of 133 
Confidential 
Generic Name 
Class/Clinical Use 
Comments 
Naratriptan 
Serotonin receptor agonist/Migraine 
treatment 
 
Nicardipine  
Antihypertensive/high blood pressure 
 
Octreotide  
Endocrine/acromegaly, carcinoid 
diarrhea 
 
Odansetron 
Antinausea/Antiemetic 
Requires additional ECG monitoring 
(Part 1) 
Paroxetine 
Antidepressant/depression 
 
Pentamidine  
Anti-infective/pneumocystis 
pneumonia 
Females > Males 
Pimozide 
Antipsychotic/Tourette’s tics 
Females > Males 
Procainamide  
Antiarrhythmic/abnormal heart 
rhythm 
 
Quetiapine  
Antipsychotic/schizophrenia 
 
Quinidine 
Antiarrhythmic/abnormal heart 
rhythm 
Females > Males 
Ranolazine 
Chronic angina 
 
Risperidone 
Antipsychotic/schizophrenia 
 
Roxithromycin 
Antibiotic/bacterial infection 
 
Salmeterol  
Sympathomimetic/asthma, COPD 
 
Sertraline 
Antidepressant/depression 
 
Sotalol  
Antiarrhythmic/abnormal heart 
rhythm 
Females > Males 
Sparfloxacin  
Antibiotic/bacterial infection 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 132 of 133 
Confidential 
Generic Name 
Class/Clinical Use 
Comments 
Sumatriptan 
Serotonin receptor agonist/Migraine 
treatment 
 
Tacrolimus  
Immunosuppressant/Immune 
suppression 
 
Tamoxifen  
Anticancer/breast cancer 
 
Thioridazine 
Antipsychotic/schizophrenia 
 
Tizanidine  
Muscle relaxant 
 
Venlafaxine  
Antidepressant/depression 
 
Ziprasidone 
Antipsychotic/schizophrenia 
 
Zolmitriptan 
Migraine treatment 
 
Refer to https://crediblemeds.org/. 
 


Clovis Oncology, Inc. 
 
Clinical Protocol 
Oral rucaparib (CO-338) 
CO-338-010 
 
29 June 2016 
 
 
 
Page 133 of 133 
Confidential 
Appendix D 
Examples of CYP Substrates with Narrow Therapeutic Range 
CYP Enzyme 
Substrates with Narrow 
Therapeutic Rangea 
 
CYP2C9 
Warfarin, phenytoin  
 
CYP2C19 
S-mephenytoin  
 
CYP3A 
Alfentanil, astemizole, cisapride, cyclosporine, 
dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, 
sirolimus, tacrolimus, terfenadine 
The table is based on the Draft FDA Guidance on Drug Interaction Studies — Study Design, Data Analysis, 
Implications for Dosing, and Labeling Recommendations, 2012.22  
 
a CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that 
small increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety 
concerns (eg, Torsades de Pointes). 
 

SAP_001.pdf: